<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523421003743</prism:url><dc:identifier>doi:10.1016/j.ejmech.2021.113525</dc:identifier><eid>1-s2.0-S0223523421003743</eid><prism:doi>10.1016/j.ejmech.2021.113525</prism:doi><pii>S0223-5234(21)00374-3</pii><dc:title>Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3) </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>221</prism:volume><prism:startingPage>113525</prism:startingpage><prism:pageRange>113525</prism:pagerange><articleNumber>113525</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2021-10-05</prism:coverdate><prism:coverDisplayDate>5 October 2021</prism:coverdisplaydate><prism:copyright>Â© 2021 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Huang, Qiuyao</dc:creator><dc:creator>Zhong, Yan</dc:creator><dc:creator>Li, Bingbing</dc:creator><dc:creator>Ouyang, Shumin</dc:creator><dc:creator>Deng, Lin</dc:creator><dc:creator>Mo, Jianshan</dc:creator><dc:creator>Shi, Shuo</dc:creator><dc:creator>Lv, Nan</dc:creator><dc:creator>Wu, Ruibo</dc:creator><dc:creator>Liu, Peiqing</dc:creator><dc:creator>Hu, Wenhao</dc:creator><dc:creator>Zhang, Xiaolei</dc:creator><dc:creator>Wang, Yuanxiang</dc:creator><dc:description>
                  STAT3 has been validated as an attractive anticancer target due to its important roles in cancer initiation and progression. However, discovery of potent and selective STAT3 small-molecule inhibitors with druglike properties is still challenging. In this study, two series of substituted 2-phenylquinolines and 2-arylimidazo[1,2-a]pyridines were designed through structure-based drug discovery approach by condensing the privileged structures of STX-119 and SH4-54. Our study has resulted in the discovery of a number of highly potent and selective STAT3 inhibitors, exemplified by compound 39 with the privileged structure of 2-phenylimidazo[1,2-a]pyridine, which selectively inhibits phosphorylation of STAT3 and suppresses subsequent signaling pathway. Moreover, 39 inhibits cell growth, migration and invasion of human triple negative breast cancer (TNBC) cells lines. Consistently, it achieves significant and dose-dependent tumor growth inhibition in both cell line-derived and patient-derived xenograft tumor models in mice. These results clearly indicate that 39 is a highly potent and selective STAT3 inhibitor.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>Structure-based drug discovery</dcterms:subject><dcterms:subject>Privileged structures</dcterms:subject><dcterms:subject>STAT3</dcterms:subject><dcterms:subject>Small-molecule inhibitors</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523421003743" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523421003743" rel="scidir"/></link></coredata><objects><object ref="fx19" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="90" height="119" size="3616">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx19.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="535" height="288" size="28647">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="535" height="618" size="55980">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="66" height="27" size="1125">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx23" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="40" height="25" size="852">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx23.jpg?httpAccept=%2A%2F%2A</object><object ref="fx40" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="62" height="25" size="952">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx40.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="145" height="90" size="3629">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="535" height="260" size="43984">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr9.jpg?httpAccept=%2A%2F%2A</object><object ref="fx36" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="68" height="25" size="1102">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx36.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="55" height="40" size="1210">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx9.jpg?httpAccept=%2A%2F%2A</object><object ref="fx35" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="68" height="25" size="1087">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx35.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="580" height="621" size="133595">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx39" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="61" height="32" size="1296">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx39.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="43" height="27" size="966">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr13" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="802" height="446" size="131118">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr13.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="558" height="234" size="24851">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx20" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="40" height="25" size="854">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx20.jpg?httpAccept=%2A%2F%2A</object><object ref="gr14" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="802" height="445" size="125271">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr14.jpg?httpAccept=%2A%2F%2A</object><object ref="fx26" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="40" height="25" size="852">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx26.jpg?httpAccept=%2A%2F%2A</object><object ref="fx34" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="61" height="25" size="1009">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx34.jpg?httpAccept=%2A%2F%2A</object><object ref="fx41" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="68" height="25" size="1107">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx41.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="558" height="202" size="23916">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-sc2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx29" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="40" height="25" size="852">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx29.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="42" height="32" size="1007">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx8.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="90" height="27" size="1530">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx14.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="153" height="114" size="3990">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="535" height="616" size="53587">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="sc5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="558" height="275" size="54259">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-sc5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="535" height="186" size="25414">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="fx25" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="40" height="25" size="852">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx25.jpg?httpAccept=%2A%2F%2A</object><object ref="fx18" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="66" height="41" size="1579">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx18.jpg?httpAccept=%2A%2F%2A</object><object ref="ga1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="500" height="150" size="31748">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-ga1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="67" height="27" size="1248">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="114" height="81" size="2733">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx13.jpg?httpAccept=%2A%2F%2A</object><object ref="gr12" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="580" height="520" size="109064">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr12.jpg?httpAccept=%2A%2F%2A</object><object ref="fx32" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="54" height="32" size="1127">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx32.jpg?httpAccept=%2A%2F%2A</object><object ref="fx15" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="89" height="27" size="1469">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx15.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="380" height="200" size="25964">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx24" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="40" height="25" size="852">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx24.jpg?httpAccept=%2A%2F%2A</object><object ref="fx17" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="82" height="33" size="1573">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx17.jpg?httpAccept=%2A%2F%2A</object><object ref="fx37" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="68" height="31" size="1333">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx37.jpg?httpAccept=%2A%2F%2A</object><object ref="fx43" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="62" height="25" size="951">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx43.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="713" height="185" size="39735">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr10.jpg?httpAccept=%2A%2F%2A</object><object ref="fx38" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="39" height="30" size="867">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx38.jpg?httpAccept=%2A%2F%2A</object><object ref="fx31" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="40" height="25" size="854">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx31.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="380" height="317" size="23011">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="fx45" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="76" height="25" size="1173">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx45.jpg?httpAccept=%2A%2F%2A</object><object ref="fx16" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="90" height="27" size="1559">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx16.jpg?httpAccept=%2A%2F%2A</object><object ref="fx30" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="62" height="25" size="1023">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx30.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="713" height="472" size="86815">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr11.jpg?httpAccept=%2A%2F%2A</object><object ref="fx27" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="40" height="25" size="854">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx27.jpg?httpAccept=%2A%2F%2A</object><object ref="fx21" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="40" height="25" size="854">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx21.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="66" height="49" size="1741">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx12.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="42" height="32" size="1028">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx10.jpg?httpAccept=%2A%2F%2A</object><object ref="fx28" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="40" height="25" size="853">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx28.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="67" height="27" size="1186">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx6.jpg?httpAccept=%2A%2F%2A</object><object ref="sc4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="580" height="151" size="18671">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-sc4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="66" height="34" size="1495">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx11.jpg?httpAccept=%2A%2F%2A</object><object ref="fx42" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="68" height="25" size="1087">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx42.jpg?httpAccept=%2A%2F%2A</object><object ref="fx22" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="40" height="25" size="854">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx22.jpg?httpAccept=%2A%2F%2A</object><object ref="sc3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="713" height="93" size="14788">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-sc3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="802" height="172" size="40522">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="67" height="27" size="1193">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx7.jpg?httpAccept=%2A%2F%2A</object><object ref="fx44" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="76" height="31" size="1489">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx44.jpg?httpAccept=%2A%2F%2A</object><object ref="fx33" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="40" height="25" size="852">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx33.jpg?httpAccept=%2A%2F%2A</object><object ref="fx19" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="123" height="163" size="2797">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx19.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="118" size="4783">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="142" height="164" size="6747">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="fx5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="89" size="2145">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx5.sml?httpAccept=%2A%2F%2A</object><object ref="fx23" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="178" height="111" size="2646">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx23.sml?httpAccept=%2A%2F%2A</object><object ref="fx40" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="88" size="2220">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx40.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="135" size="3030">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="gr9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="106" size="13622">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr9.sml?httpAccept=%2A%2F%2A</object><object ref="fx36" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="80" size="2381">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx36.sml?httpAccept=%2A%2F%2A</object><object ref="fx9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="157" size="3275">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx9.sml?httpAccept=%2A%2F%2A</object><object ref="fx35" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="80" size="2311">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx35.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="153" height="164" size="17751">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="fx39" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="115" size="3485">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx39.sml?httpAccept=%2A%2F%2A</object><object ref="fx3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="191" height="119" size="2667">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx3.sml?httpAccept=%2A%2F%2A</object><object ref="gr13" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="122" size="14249">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr13.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="92" size="3968">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="fx20" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="178" height="111" size="2632">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx20.sml?httpAccept=%2A%2F%2A</object><object ref="gr14" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="122" size="14195">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr14.sml?httpAccept=%2A%2F%2A</object><object ref="fx26" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="178" height="111" size="2751">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx26.sml?httpAccept=%2A%2F%2A</object><object ref="fx34" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="89" size="2377">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx34.sml?httpAccept=%2A%2F%2A</object><object ref="fx41" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="80" size="2426">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx41.sml?httpAccept=%2A%2F%2A</object><object ref="sc2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="79" size="4084">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-sc2.sml?httpAccept=%2A%2F%2A</object><object ref="fx29" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="178" height="111" size="2783">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx29.sml?httpAccept=%2A%2F%2A</object><object ref="fx8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="189" height="145" size="3727">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx8.sml?httpAccept=%2A%2F%2A</object><object ref="fx14" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="66" size="1922">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx14.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="163" size="2919">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="142" height="163" size="7379">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="sc5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="108" size="7785">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-sc5.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="76" size="2947">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="fx25" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="178" height="111" size="2617">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx25.sml?httpAccept=%2A%2F%2A</object><object ref="fx18" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="137" size="4161">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx18.sml?httpAccept=%2A%2F%2A</object><object ref="ga1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="66" size="5503">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-ga1.sml?httpAccept=%2A%2F%2A</object><object ref="fx4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="88" size="2447">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx4.sml?httpAccept=%2A%2F%2A</object><object ref="fx13" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="156" size="3450">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx13.sml?httpAccept=%2A%2F%2A</object><object ref="gr12" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="183" height="164" size="16854">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr12.sml?httpAccept=%2A%2F%2A</object><object ref="fx32" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="130" size="3500">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx32.sml?httpAccept=%2A%2F%2A</object><object ref="fx15" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="66" size="1913">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx15.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="115" size="6418">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="fx24" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="178" height="111" size="2643">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx24.sml?httpAccept=%2A%2F%2A</object><object ref="fx17" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="88" size="2797">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx17.sml?httpAccept=%2A%2F%2A</object><object ref="fx37" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="99" size="3021">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx37.sml?httpAccept=%2A%2F%2A</object><object ref="fx43" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="88" size="2208">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx43.sml?httpAccept=%2A%2F%2A</object><object ref="gr10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="57" size="5573">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr10.sml?httpAccept=%2A%2F%2A</object><object ref="fx38" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="175" height="135" size="3251">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx38.sml?httpAccept=%2A%2F%2A</object><object ref="fx31" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="178" height="111" size="2558">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx31.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="196" height="164" size="7362">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="fx45" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="72" size="2197">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx45.sml?httpAccept=%2A%2F%2A</object><object ref="fx16" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="66" size="2098">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx16.sml?httpAccept=%2A%2F%2A</object><object ref="fx30" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="88" size="2540">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx30.sml?httpAccept=%2A%2F%2A</object><object ref="gr11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="145" size="9877">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr11.sml?httpAccept=%2A%2F%2A</object><object ref="fx27" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="178" height="111" size="2793">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx27.sml?httpAccept=%2A%2F%2A</object><object ref="fx21" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="178" height="111" size="2647">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx21.sml?httpAccept=%2A%2F%2A</object><object ref="fx12" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="163" size="4299">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx12.sml?httpAccept=%2A%2F%2A</object><object ref="fx10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="188" height="145" size="3733">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx10.sml?httpAccept=%2A%2F%2A</object><object ref="fx28" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="178" height="111" size="2776">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx28.sml?httpAccept=%2A%2F%2A</object><object ref="fx6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="88" size="2543">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx6.sml?httpAccept=%2A%2F%2A</object><object ref="sc4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="57" size="3102">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-sc4.sml?httpAccept=%2A%2F%2A</object><object ref="fx11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="112" size="3790">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx11.sml?httpAccept=%2A%2F%2A</object><object ref="fx42" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="81" size="2297">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx42.sml?httpAccept=%2A%2F%2A</object><object ref="fx22" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="178" height="111" size="2771">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx22.sml?httpAccept=%2A%2F%2A</object><object ref="sc3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="29" size="2178">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-sc3.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="47" size="5672">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="fx7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="88" size="2434">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx7.sml?httpAccept=%2A%2F%2A</object><object ref="fx44" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="90" size="2769">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx44.sml?httpAccept=%2A%2F%2A</object><object ref="fx33" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="178" height="111" size="2646">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx33.sml?httpAccept=%2A%2F%2A</object><object ref="fx19" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="402" height="533" size="25806">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx19_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2370" height="1274" size="215784">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-sc1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2370" height="2736" size="382122">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="294" height="120" size="6070">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx23" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="178" height="111" size="4793">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx23_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx40" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="276" height="111" size="5715">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx40_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="643" height="397" size="24985">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2370" height="1152" size="356499">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx36" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="305" height="111" size="6683">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx36_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="245" height="176" size="6666">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx35" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="305" height="111" size="6545">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx35_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2568" height="2750" size="1015512">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx39" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="274" height="144" size="8266">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx39_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="191" height="119" size="4926">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr13" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3551" height="1973" size="1071838">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr13_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2470" height="1038" size="192079">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx20" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="178" height="111" size="4811">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx20_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr14" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3551" height="1972" size="1031049">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr14_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx26" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="178" height="111" size="4798">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx26_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx34" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="273" height="111" size="5744">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx34_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx41" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="302" height="111" size="6622">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx41_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2470" height="894" size="190790">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-sc2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx29" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="178" height="111" size="4807">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx29_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="189" height="145" size="6295">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="399" height="120" size="7956">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx14_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="679" height="505" size="27784">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2370" height="2728" size="389676">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2470" height="1216" size="372205">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-sc5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2370" height="822" size="208558">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx25" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="178" height="111" size="4802">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx25_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx18" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="295" height="184" size="10646">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx18_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="ga1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2213" height="663" size="194539">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-ga1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="298" height="120" size="6664">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="506" height="361" size="19261">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx13_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr12" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2568" height="2302" size="1135012">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr12_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx32" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="240" height="143" size="6932">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx32_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx15" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="398" height="120" size="7808">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx15_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1682" height="886" size="142761">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx24" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="178" height="111" size="4796">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx24_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx17" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="367" height="147" size="9644">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx17_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx37" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="305" height="138" size="8674">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx37_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx43" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="276" height="111" size="5711">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx43_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3158" height="818" size="265682">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx38" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="175" height="135" size="5506">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx38_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx31" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="178" height="111" size="4807">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx31_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1682" height="1404" size="152486">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx45" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="337" height="111" size="7353">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx45_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx16" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="399" height="120" size="9084">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx16_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx30" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="276" height="111" size="6045">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx30_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3158" height="2092" size="681574">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx27" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="178" height="111" size="4802">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx27_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx21" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="178" height="111" size="4792">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx21_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="295" height="220" size="11362">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx12_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="188" height="145" size="6233">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx28" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="178" height="111" size="4811">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx28_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="298" height="120" size="6653">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2568" height="668" size="138448">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-sc4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="296" height="151" size="9811">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx42" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="301" height="111" size="6660">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx42_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx22" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="178" height="111" size="4800">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx22_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3158" height="414" size="109507">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-sc3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3552" height="760" size="298248">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="298" height="120" size="6784">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx44" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="337" height="138" size="9254">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx44_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx33" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="178" height="111" size="4802">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-fx33_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Microsoft Word file" mimetype="application/word" size="8258439">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-mmc1.docx?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="2705698">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421003743-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85105559908</scopus-id><scopus-eid>2-s2.0-85105559908</scopus-eid><pubmed-id>34000483</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85105559908" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20210507">2021-05-07</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20210507">2021-05-07</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20210514">2021-05-14</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20210514">2021-05-14</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2021-06-11T16:42:51</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523421003743</xocs:eid>
      <xocs:pii-formatted>S0223-5234(21)00374-3</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523421003743</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2021.113525</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523421X00104</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20210611">2021-06-11T22:33:10.897369Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20211005</xocs:date-search-begin>
      <xocs:year-nav>2021</xocs:year-nav>
      <xocs:indexeddate epoch="1620352302">2021-05-07T01:51:42.125777Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast footnotes grantnumber grantsponsor grantsponsorid highlightsabst orcid otherkwds primabst ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>221</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>221</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 221</xocs:vol-iss-suppl-text>
      <xocs:sort-order>28</xocs:sort-order>
      <xocs:first-fp>113525</xocs:first-fp>
      <xocs:article-number>113525</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>113525</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20211005</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>5 October 2021</xocs:cover-date-text>
      <xocs:cover-date-start>2021-10-05</xocs:cover-date-start>
      <xocs:cover-date-year>2021</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Full papers</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>Â© 2021 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>STRUCTUREBASEDDISCOVERYPOTENTSELECTIVESMALLMOLECULEINHIBITORSTARGETINGSIGNALTRANSDUCERACTIVATORTRANSCRIPTION3STAT3</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>HUANG</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>Q</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusions</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Experimental section</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>DEBNATH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>6645</xocs:ref-first-fp>
            <xocs:ref-last-lp>6668</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>111922</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>ALZAIDSIDDIQUEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>254</xocs:ref-first-fp>
            <xocs:ref-last-lp>267</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>SANSONE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1005</xocs:ref-first-fp>
            <xocs:ref-last-lp>1014</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>MIKLOSSY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>611</xocs:ref-first-fp>
            <xocs:ref-last-lp>629</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>JOHNSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>234</xocs:ref-first-fp>
            <xocs:ref-last-lp>248</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>BEEBE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>74</xocs:ref-first-fp>
            <xocs:ref-last-lp>91</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>736</xocs:ref-first-fp>
            <xocs:ref-last-lp>746</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>MA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>9178</xocs:ref-first-fp>
            <xocs:ref-last-lp>9182</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>LASALA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>4115</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>ZHAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>47</xocs:ref-first-fp>
            <xocs:ref-last-lp>61</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>207</xocs:ref-first-fp>
            <xocs:ref-last-lp>221</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>SPITZNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1986</xocs:ref-first-fp>
            <xocs:ref-last-lp>2011</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>PAVLINOV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>8174</xocs:ref-first-fp>
            <xocs:ref-last-lp>8182</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>MCAULAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>10358</xocs:ref-first-fp>
            <xocs:ref-last-lp>10372</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>48</xocs:ref-first-fp>
            <xocs:ref-last-lp>54</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>117</xocs:ref-first-fp>
            <xocs:ref-last-lp>128</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>KARAKASHEVA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>4957</xocs:ref-first-fp>
            <xocs:ref-last-lp>4970</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>KITAMURA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1947</xocs:ref-first-fp>
            <xocs:ref-last-lp>1952</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>SONGTL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1146</xocs:ref-first-fp>
            <xocs:ref-last-lp>1158</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>ATSAVES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1633</xocs:ref-first-fp>
            <xocs:ref-last-lp>1637</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>1544</xocs:ref-first-fp>
            <xocs:ref-last-lp>1563</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>MATSUNO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>371</xocs:ref-first-fp>
            <xocs:ref-last-lp>375</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>PAGE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>5605</xocs:ref-first-fp>
            <xocs:ref-last-lp>5609</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>HAFTCHENARY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1102</xocs:ref-first-fp>
            <xocs:ref-last-lp>1107</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>HUISONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>KARAKASHEVA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>4957</xocs:ref-first-fp>
            <xocs:ref-last-lp>4970</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>BAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>498</xocs:ref-first-fp>
            <xocs:ref-last-lp>511 e417</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>ZHOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>11280</xocs:ref-first-fp>
            <xocs:ref-last-lp>11300</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>BECKERS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>145</xocs:ref-first-fp>
            <xocs:ref-last-lp>151</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>MUSHARRAFIEH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>4074</xocs:ref-first-fp>
            <xocs:ref-last-lp>4090</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>FELICETTI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>7827</xocs:ref-first-fp>
            <xocs:ref-last-lp>7848</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>KRAPF</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>5449</xocs:ref-first-fp>
            <xocs:ref-last-lp>5461</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>CUSHING</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>480</xocs:ref-first-fp>
            <xocs:ref-last-lp>511</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>SABATINI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>4975</xocs:ref-first-fp>
            <xocs:ref-last-lp>4989</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>MADAK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>5162</xocs:ref-first-fp>
            <xocs:ref-last-lp>5186</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>FOX</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>3464</xocs:ref-first-fp>
            <xocs:ref-last-lp>3483</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>MOHAMMAD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1609</xocs:ref-first-fp>
            <xocs:ref-last-lp>1615</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>KODRAJT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>5387</xocs:ref-first-fp>
            <xocs:ref-last-lp>5396</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>LAUJ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>113</xocs:ref-first-fp>
            <xocs:ref-last-lp>128</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>YAKOUB</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1951</xocs:ref-first-fp>
            <xocs:ref-last-lp>1968</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>MA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>2513</xocs:ref-first-fp>
            <xocs:ref-last-lp>2529</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>DENORAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>6876</xocs:ref-first-fp>
            <xocs:ref-last-lp>6888</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>CAIL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>148</xocs:ref-first-fp>
            <xocs:ref-last-lp>158</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>TRAPANIG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>292</xocs:ref-first-fp>
            <xocs:ref-last-lp>305</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>SCHUST</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>1235</xocs:ref-first-fp>
            <xocs:ref-last-lp>1242</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>498</xocs:ref-first-fp>
            <xocs:ref-last-lp>507</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>195</xocs:ref-first-fp>
            <xocs:ref-last-lp>203</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>538</xocs:ref-first-fp>
            <xocs:ref-last-lp>550</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref50">
            <xocs:ref-normalized-surname>JI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1010</xocs:ref-first-fp>
            <xocs:ref-last-lp>1014</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref51">
            <xocs:ref-normalized-surname>WU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>275</xocs:ref-first-fp>
            <xocs:ref-last-lp>279</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref52">
            <xocs:ref-normalized-surname>HSU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>385</xocs:ref-first-fp>
            <xocs:ref-last-lp>395</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref53">
            <xocs:ref-normalized-surname>WU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1021</xocs:ref-first-fp>
            <xocs:ref-last-lp>1027</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref54">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>999</xocs:ref-first-fp>
            <xocs:ref-last-lp>1014</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref55">
            <xocs:ref-normalized-surname>NISHANTH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>502</xocs:ref-first-fp>
            <xocs:ref-last-lp>516</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref56">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>76</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>HUANGX2021X113525</xocs:refkey3>
         <xocs:refkey4ai>HUANGX2021X113525XQ</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2023-05-14T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2023-05-14T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">Â© 2021 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2021-05-01T15:37:57.713Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency>Fundamental Research Funds for the Central Universities</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100013804</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency>Guangzhou Municipal Science and Technology Project</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100010256</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency-acronym>NSFC</xocs:funding-agency-acronym>
            <xocs:funding-agency>National Natural Science Foundation of China</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100001809</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991</xocs:funding-agency-country>
         </xocs:funding>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(21)00374-3</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523421003743</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523421003743</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2021.113525</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2021-06-11T22:33:10.897369Z</xocs:timestamp>
         <xocs:cover-date-start>2021-10-05</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/MAIN/application/pdf/c57de325ec2b50ad15f198616e73b93d/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>7206011</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>25</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523421003743-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/PREVIEW/image/png/c2c844d6cb15a838ed38e1c91b5e7e18/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>61083</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx19.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx19/DOWNSAMPLED/image/jpeg/9909a675aeb12f4dd113a5bfc9523d56/fx19.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3616</xocs:filesize>
               <xocs:pixel-height>119</xocs:pixel-height>
               <xocs:pixel-width>90</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/sc1/DOWNSAMPLED/image/jpeg/32a3eaa748602bc6f48fb6743af3275c/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>28647</xocs:filesize>
               <xocs:pixel-height>288</xocs:pixel-height>
               <xocs:pixel-width>535</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr6/DOWNSAMPLED/image/jpeg/6c167e8f786135c1232f6db154217f10/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>55980</xocs:filesize>
               <xocs:pixel-height>618</xocs:pixel-height>
               <xocs:pixel-width>535</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx5/DOWNSAMPLED/image/jpeg/871645db7cc21d637855af472a3cc9fb/fx5.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1125</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>66</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx23.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx23/DOWNSAMPLED/image/jpeg/c266ade6cd41c99e693942004e93ce4c/fx23.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx23</xocs:file-basename>
               <xocs:filename>fx23.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>852</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>40</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx40.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx40/DOWNSAMPLED/image/jpeg/621de3bcb0a359adb83b21a67ac4a747/fx40.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx40</xocs:file-basename>
               <xocs:filename>fx40.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>952</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>62</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx2/DOWNSAMPLED/image/jpeg/102e19b0091166a1d71a50e8033a9038/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3629</xocs:filesize>
               <xocs:pixel-height>90</xocs:pixel-height>
               <xocs:pixel-width>145</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr9/DOWNSAMPLED/image/jpeg/335520d3be08137de212ba102dd1fe6c/gr9.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>43984</xocs:filesize>
               <xocs:pixel-height>260</xocs:pixel-height>
               <xocs:pixel-width>535</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx36.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx36/DOWNSAMPLED/image/jpeg/99deb16b39d5605ce556f113dfadc880/fx36.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx36</xocs:file-basename>
               <xocs:filename>fx36.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1102</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>68</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx9/DOWNSAMPLED/image/jpeg/a8f509dd4187240e3c06ce37c922a465/fx9.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1210</xocs:filesize>
               <xocs:pixel-height>40</xocs:pixel-height>
               <xocs:pixel-width>55</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx35.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx35/DOWNSAMPLED/image/jpeg/21b1851ba4797d0a4d4a5fdc6be9e004/fx35.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx35</xocs:file-basename>
               <xocs:filename>fx35.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1087</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>68</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr2/DOWNSAMPLED/image/jpeg/f9fb85fbb3d74d3765124397e8647dd9/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>133595</xocs:filesize>
               <xocs:pixel-height>621</xocs:pixel-height>
               <xocs:pixel-width>580</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx39.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx39/DOWNSAMPLED/image/jpeg/ba16e6fc19e25ad56fec47da64cafe59/fx39.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx39</xocs:file-basename>
               <xocs:filename>fx39.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1296</xocs:filesize>
               <xocs:pixel-height>32</xocs:pixel-height>
               <xocs:pixel-width>61</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx3/DOWNSAMPLED/image/jpeg/d917a29b6e7db955684387fcbe35d52b/fx3.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>966</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>43</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr13.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr13/DOWNSAMPLED/image/jpeg/26f1ba6c50455ec165d53de5303a3954/gr13.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr13</xocs:file-basename>
               <xocs:filename>gr13.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>131118</xocs:filesize>
               <xocs:pixel-height>446</xocs:pixel-height>
               <xocs:pixel-width>802</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr1/DOWNSAMPLED/image/jpeg/a819f48071e822f4707525bad3ed1e22/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>24851</xocs:filesize>
               <xocs:pixel-height>234</xocs:pixel-height>
               <xocs:pixel-width>558</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx20.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx20/DOWNSAMPLED/image/jpeg/1558954df24d4967bb599f85764a6c8b/fx20.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>854</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>40</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr14.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr14/DOWNSAMPLED/image/jpeg/9f855c41e9b1584df1f792c1f89d2b07/gr14.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr14</xocs:file-basename>
               <xocs:filename>gr14.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>125271</xocs:filesize>
               <xocs:pixel-height>445</xocs:pixel-height>
               <xocs:pixel-width>802</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx26.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx26/DOWNSAMPLED/image/jpeg/fdf6c0140be0788363780be5db69283f/fx26.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx26</xocs:file-basename>
               <xocs:filename>fx26.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>852</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>40</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx34.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx34/DOWNSAMPLED/image/jpeg/21678c90b8ea4dfd32d07bf27cdc67ca/fx34.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx34</xocs:file-basename>
               <xocs:filename>fx34.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1009</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>61</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx41.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx41/DOWNSAMPLED/image/jpeg/dd02effeada98d9ef57d65e5f7f42faa/fx41.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx41</xocs:file-basename>
               <xocs:filename>fx41.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1107</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>68</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-sc2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/sc2/DOWNSAMPLED/image/jpeg/6b5924d27a2c61c6c6caf4da72727a9b/sc2.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>23916</xocs:filesize>
               <xocs:pixel-height>202</xocs:pixel-height>
               <xocs:pixel-width>558</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx29.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx29/DOWNSAMPLED/image/jpeg/cab958129f0113162b512019a7a9bc65/fx29.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx29</xocs:file-basename>
               <xocs:filename>fx29.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>852</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>40</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx8/DOWNSAMPLED/image/jpeg/89c269a089da0efe9af79b289a4215ea/fx8.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1007</xocs:filesize>
               <xocs:pixel-height>32</xocs:pixel-height>
               <xocs:pixel-width>42</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx14.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx14/DOWNSAMPLED/image/jpeg/321a8423277edbf12772e8773e9ebbd8/fx14.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1530</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>90</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx1/DOWNSAMPLED/image/jpeg/1866daa893928daebdfcc937d8c6ccfd/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3990</xocs:filesize>
               <xocs:pixel-height>114</xocs:pixel-height>
               <xocs:pixel-width>153</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr7/DOWNSAMPLED/image/jpeg/2a70cc13bfdd73089c06d98ad1d90912/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>53587</xocs:filesize>
               <xocs:pixel-height>616</xocs:pixel-height>
               <xocs:pixel-width>535</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-sc5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/sc5/DOWNSAMPLED/image/jpeg/f41eb81d938b1ce7b3798a04d22cfd3b/sc5.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc5</xocs:file-basename>
               <xocs:filename>sc5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>54259</xocs:filesize>
               <xocs:pixel-height>275</xocs:pixel-height>
               <xocs:pixel-width>558</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr3/DOWNSAMPLED/image/jpeg/de917bc6e6566219a9a2d1a3179bfda5/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>25414</xocs:filesize>
               <xocs:pixel-height>186</xocs:pixel-height>
               <xocs:pixel-width>535</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx25.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx25/DOWNSAMPLED/image/jpeg/cae972cada17c626ab235a54754ca0f6/fx25.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx25</xocs:file-basename>
               <xocs:filename>fx25.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>852</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>40</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx18.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx18/DOWNSAMPLED/image/jpeg/a31e89678572415f375b91d65d09f04a/fx18.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1579</xocs:filesize>
               <xocs:pixel-height>41</xocs:pixel-height>
               <xocs:pixel-width>66</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-ga1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/ga1/DOWNSAMPLED/image/jpeg/d9192fbf4a45129eadf79fdadf38f854/ga1.jpg</xocs:ucs-locator>
               <xocs:file-basename>ga1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>ga1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>31748</xocs:filesize>
               <xocs:pixel-height>150</xocs:pixel-height>
               <xocs:pixel-width>500</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx4/DOWNSAMPLED/image/jpeg/7f14bc5ff2a1788bb7e4058929899887/fx4.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1248</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>67</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx13.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx13/DOWNSAMPLED/image/jpeg/6cc884efb151a5ba9432f7a54a8aba04/fx13.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2733</xocs:filesize>
               <xocs:pixel-height>81</xocs:pixel-height>
               <xocs:pixel-width>114</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr12.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr12/DOWNSAMPLED/image/jpeg/4979768abd493f12ed426aa436e34dfe/gr12.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>109064</xocs:filesize>
               <xocs:pixel-height>520</xocs:pixel-height>
               <xocs:pixel-width>580</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx32.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx32/DOWNSAMPLED/image/jpeg/bea794444effc041715e6c57ef0f8d8e/fx32.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx32</xocs:file-basename>
               <xocs:filename>fx32.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1127</xocs:filesize>
               <xocs:pixel-height>32</xocs:pixel-height>
               <xocs:pixel-width>54</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx15.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx15/DOWNSAMPLED/image/jpeg/2cf8185e911a21126916f89865df8fd5/fx15.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1469</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>89</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr4/DOWNSAMPLED/image/jpeg/6ab6ce8cc4b76cae0c558807fd27b8bb/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>25964</xocs:filesize>
               <xocs:pixel-height>200</xocs:pixel-height>
               <xocs:pixel-width>380</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx24.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx24/DOWNSAMPLED/image/jpeg/dfed1f2a5a143ea1da25bf245c9bac27/fx24.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx24</xocs:file-basename>
               <xocs:filename>fx24.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>852</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>40</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx17.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx17/DOWNSAMPLED/image/jpeg/83aa938c46634d7d0a41ca8d910c7823/fx17.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1573</xocs:filesize>
               <xocs:pixel-height>33</xocs:pixel-height>
               <xocs:pixel-width>82</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx37.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx37/DOWNSAMPLED/image/jpeg/a8336be39e3816bc831852b4fd8e923d/fx37.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx37</xocs:file-basename>
               <xocs:filename>fx37.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1333</xocs:filesize>
               <xocs:pixel-height>31</xocs:pixel-height>
               <xocs:pixel-width>68</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx43.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx43/DOWNSAMPLED/image/jpeg/7a748b999e848ddb1b816f131be04abc/fx43.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx43</xocs:file-basename>
               <xocs:filename>fx43.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>951</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>62</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr10/DOWNSAMPLED/image/jpeg/053cd54fdd61555ae4827f233ca7ad89/gr10.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>39735</xocs:filesize>
               <xocs:pixel-height>185</xocs:pixel-height>
               <xocs:pixel-width>713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx38.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx38/DOWNSAMPLED/image/jpeg/17e52af213b18682f8430b82d07cfc1a/fx38.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx38</xocs:file-basename>
               <xocs:filename>fx38.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>867</xocs:filesize>
               <xocs:pixel-height>30</xocs:pixel-height>
               <xocs:pixel-width>39</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx31.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx31/DOWNSAMPLED/image/jpeg/3692b66bf71eb85d626c6fa06ee487b5/fx31.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx31</xocs:file-basename>
               <xocs:filename>fx31.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>854</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>40</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr8/DOWNSAMPLED/image/jpeg/454b8733cd0b916cab08f9624d4c597d/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>23011</xocs:filesize>
               <xocs:pixel-height>317</xocs:pixel-height>
               <xocs:pixel-width>380</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx45.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx45/DOWNSAMPLED/image/jpeg/99375b993f7e2e5e370500303a65f253/fx45.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx45</xocs:file-basename>
               <xocs:filename>fx45.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1173</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>76</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx16.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx16/DOWNSAMPLED/image/jpeg/31c29379edeff2378002c9851ff967b2/fx16.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1559</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>90</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx30.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx30/DOWNSAMPLED/image/jpeg/c21b11594cad77993e997b8877c0b07b/fx30.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx30</xocs:file-basename>
               <xocs:filename>fx30.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1023</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>62</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr11/DOWNSAMPLED/image/jpeg/2da31e3ab407695c4ca58b852b998f4c/gr11.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>86815</xocs:filesize>
               <xocs:pixel-height>472</xocs:pixel-height>
               <xocs:pixel-width>713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx27.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx27/DOWNSAMPLED/image/jpeg/038e884c65f2502a1de486045ed8cade/fx27.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx27</xocs:file-basename>
               <xocs:filename>fx27.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>854</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>40</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx21.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx21/DOWNSAMPLED/image/jpeg/d437f2175091d7193db0723ea4483cb1/fx21.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>854</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>40</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx12.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx12/DOWNSAMPLED/image/jpeg/e0b056c06f483696291670c21a0cf685/fx12.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1741</xocs:filesize>
               <xocs:pixel-height>49</xocs:pixel-height>
               <xocs:pixel-width>66</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx10/DOWNSAMPLED/image/jpeg/8b2b940dc16020f9f84ecbaf7090ab44/fx10.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1028</xocs:filesize>
               <xocs:pixel-height>32</xocs:pixel-height>
               <xocs:pixel-width>42</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx28.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx28/DOWNSAMPLED/image/jpeg/c62e3259ebf9b0215766b130bf02009e/fx28.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx28</xocs:file-basename>
               <xocs:filename>fx28.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>853</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>40</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx6/DOWNSAMPLED/image/jpeg/62946fbe82d89cc3a4fd40b70395f87b/fx6.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1186</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>67</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-sc4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/sc4/DOWNSAMPLED/image/jpeg/927aa16540c837e7f7f69860308819d4/sc4.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc4</xocs:file-basename>
               <xocs:filename>sc4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>18671</xocs:filesize>
               <xocs:pixel-height>151</xocs:pixel-height>
               <xocs:pixel-width>580</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx11/DOWNSAMPLED/image/jpeg/e9dd5e10a5c463fa4aab6589dfac185b/fx11.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1495</xocs:filesize>
               <xocs:pixel-height>34</xocs:pixel-height>
               <xocs:pixel-width>66</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx42.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx42/DOWNSAMPLED/image/jpeg/ac8f3415c5537e0335460391ada79155/fx42.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx42</xocs:file-basename>
               <xocs:filename>fx42.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1087</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>68</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx22.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx22/DOWNSAMPLED/image/jpeg/18dabe66fa8bad11157126d40c806d57/fx22.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>854</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>40</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-sc3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/sc3/DOWNSAMPLED/image/jpeg/68d1fb48b4739b4da2bb4c32bfcfe83a/sc3.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>14788</xocs:filesize>
               <xocs:pixel-height>93</xocs:pixel-height>
               <xocs:pixel-width>713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr5/DOWNSAMPLED/image/jpeg/6896261c18117a33577e20c0a49e136a/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>40522</xocs:filesize>
               <xocs:pixel-height>172</xocs:pixel-height>
               <xocs:pixel-width>802</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx7/DOWNSAMPLED/image/jpeg/ee745c00c8bcbc9b1561b40ce7ddeb47/fx7.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1193</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>67</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx44.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx44/DOWNSAMPLED/image/jpeg/b86b7c57afd71f3dec652f8464cb5781/fx44.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx44</xocs:file-basename>
               <xocs:filename>fx44.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1489</xocs:filesize>
               <xocs:pixel-height>31</xocs:pixel-height>
               <xocs:pixel-width>76</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx33.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx33/DOWNSAMPLED/image/jpeg/a57ce581dfe6b2818b01f66f0e0ce988/fx33.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx33</xocs:file-basename>
               <xocs:filename>fx33.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>852</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>40</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx19.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx19/THUMBNAIL/image/gif/6af0f5416ab6ffca999570791cec558c/fx19.sml</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2797</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>123</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/sc1/THUMBNAIL/image/gif/f14a3053a3b064af5d7f67b0ea36de5c/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4783</xocs:filesize>
               <xocs:pixel-height>118</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr6/THUMBNAIL/image/gif/8cb665cfb583c26404dfc8a9eefc2cac/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6747</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>142</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx5/THUMBNAIL/image/gif/6576c9cc01ec5ef57bd1eff6bc618602/fx5.sml</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2145</xocs:filesize>
               <xocs:pixel-height>89</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx23.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx23/THUMBNAIL/image/gif/0fd4899260985c20f9e426eba8368367/fx23.sml</xocs:ucs-locator>
               <xocs:file-basename>fx23</xocs:file-basename>
               <xocs:filename>fx23.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2646</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx40.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx40/THUMBNAIL/image/gif/bf305962bebc632e672eb74658db1a90/fx40.sml</xocs:ucs-locator>
               <xocs:file-basename>fx40</xocs:file-basename>
               <xocs:filename>fx40.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2220</xocs:filesize>
               <xocs:pixel-height>88</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx2/THUMBNAIL/image/gif/f2f5a16ba6463fac88445a1248aea8c3/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3030</xocs:filesize>
               <xocs:pixel-height>135</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr9/THUMBNAIL/image/gif/e042b1ce1d0b8eca7388c735dbc96cc2/gr9.sml</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13622</xocs:filesize>
               <xocs:pixel-height>106</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx36.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx36/THUMBNAIL/image/gif/8b8d8342eff8cdf22d29ea20d7529dba/fx36.sml</xocs:ucs-locator>
               <xocs:file-basename>fx36</xocs:file-basename>
               <xocs:filename>fx36.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2381</xocs:filesize>
               <xocs:pixel-height>80</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx9/THUMBNAIL/image/gif/ae3ceefdf95703e24331f89156b5ee14/fx9.sml</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3275</xocs:filesize>
               <xocs:pixel-height>157</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx35.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx35/THUMBNAIL/image/gif/03220a9c80f72e3ce59dc89a3a9049f2/fx35.sml</xocs:ucs-locator>
               <xocs:file-basename>fx35</xocs:file-basename>
               <xocs:filename>fx35.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2311</xocs:filesize>
               <xocs:pixel-height>80</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr2/THUMBNAIL/image/gif/0820ccdce8f8f954ba3e169420571a64/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>17751</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>153</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx39.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx39/THUMBNAIL/image/gif/65afb3a61a65d21b7fe3b7fe9686257f/fx39.sml</xocs:ucs-locator>
               <xocs:file-basename>fx39</xocs:file-basename>
               <xocs:filename>fx39.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3485</xocs:filesize>
               <xocs:pixel-height>115</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx3/THUMBNAIL/image/gif/e6f02097c18f6ae0b5363b0e7d591e18/fx3.sml</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2667</xocs:filesize>
               <xocs:pixel-height>119</xocs:pixel-height>
               <xocs:pixel-width>191</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr13.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr13/THUMBNAIL/image/gif/8648bc93f9fd259473e8e27bd8b9bad2/gr13.sml</xocs:ucs-locator>
               <xocs:file-basename>gr13</xocs:file-basename>
               <xocs:filename>gr13.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>14249</xocs:filesize>
               <xocs:pixel-height>122</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr1/THUMBNAIL/image/gif/ff6ed87e90256e0ac7297b22708d5fa0/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3968</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx20.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx20/THUMBNAIL/image/gif/2768f7437d1d34ff1848da3a9f97e454/fx20.sml</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2632</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr14.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr14/THUMBNAIL/image/gif/7380afd69d51d42b786afe8155fedda2/gr14.sml</xocs:ucs-locator>
               <xocs:file-basename>gr14</xocs:file-basename>
               <xocs:filename>gr14.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>14195</xocs:filesize>
               <xocs:pixel-height>122</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx26.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx26/THUMBNAIL/image/gif/875853c06cd557ffa026abb04312135d/fx26.sml</xocs:ucs-locator>
               <xocs:file-basename>fx26</xocs:file-basename>
               <xocs:filename>fx26.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2751</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx34.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx34/THUMBNAIL/image/gif/de007e55c0558be45ca117f3c5ed8330/fx34.sml</xocs:ucs-locator>
               <xocs:file-basename>fx34</xocs:file-basename>
               <xocs:filename>fx34.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2377</xocs:filesize>
               <xocs:pixel-height>89</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx41.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx41/THUMBNAIL/image/gif/bfe44ca298e0ec66aacd236d079751ce/fx41.sml</xocs:ucs-locator>
               <xocs:file-basename>fx41</xocs:file-basename>
               <xocs:filename>fx41.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2426</xocs:filesize>
               <xocs:pixel-height>80</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-sc2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/sc2/THUMBNAIL/image/gif/eb0e33cc4636aaf494c5272449ca0a98/sc2.sml</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4084</xocs:filesize>
               <xocs:pixel-height>79</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx29.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx29/THUMBNAIL/image/gif/93022688a42334b9dabafb86fda483d5/fx29.sml</xocs:ucs-locator>
               <xocs:file-basename>fx29</xocs:file-basename>
               <xocs:filename>fx29.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2783</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx8/THUMBNAIL/image/gif/81a14ef4da577148ee1bc103815caf19/fx8.sml</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3727</xocs:filesize>
               <xocs:pixel-height>145</xocs:pixel-height>
               <xocs:pixel-width>189</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx14.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx14/THUMBNAIL/image/gif/49561b86d509701eca2594396c01a659/fx14.sml</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1922</xocs:filesize>
               <xocs:pixel-height>66</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx1/THUMBNAIL/image/gif/29a9cff622485cd10ae9f7611a40536d/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2919</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr7/THUMBNAIL/image/gif/70294542f2f40047679dfba53452e689/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7379</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>142</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-sc5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/sc5/THUMBNAIL/image/gif/f12cba67dbf8222c0536073b60a65c57/sc5.sml</xocs:ucs-locator>
               <xocs:file-basename>sc5</xocs:file-basename>
               <xocs:filename>sc5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7785</xocs:filesize>
               <xocs:pixel-height>108</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr3/THUMBNAIL/image/gif/cc688eb50b724f6c67bab1d65201ecde/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2947</xocs:filesize>
               <xocs:pixel-height>76</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx25.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx25/THUMBNAIL/image/gif/310279b3466f413751da0f35b1536dae/fx25.sml</xocs:ucs-locator>
               <xocs:file-basename>fx25</xocs:file-basename>
               <xocs:filename>fx25.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2617</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx18.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx18/THUMBNAIL/image/gif/2b95b72c5c6ddb99a760601ca8898859/fx18.sml</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4161</xocs:filesize>
               <xocs:pixel-height>137</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-ga1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/ga1/THUMBNAIL/image/gif/98df584a8c64a3d8eb20911aacc81c3d/ga1.sml</xocs:ucs-locator>
               <xocs:file-basename>ga1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>ga1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5503</xocs:filesize>
               <xocs:pixel-height>66</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx4/THUMBNAIL/image/gif/ccb305d9efade8bc6ebe8cd533c0a69e/fx4.sml</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2447</xocs:filesize>
               <xocs:pixel-height>88</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx13.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx13/THUMBNAIL/image/gif/656aefab2932b05f3effdca8a95e2d46/fx13.sml</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3450</xocs:filesize>
               <xocs:pixel-height>156</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr12.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr12/THUMBNAIL/image/gif/47a75f2086a78f59d081b25f9ab71f83/gr12.sml</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>16854</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>183</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx32.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx32/THUMBNAIL/image/gif/1ba00acd1d358a2994d2d8c57e8b17fe/fx32.sml</xocs:ucs-locator>
               <xocs:file-basename>fx32</xocs:file-basename>
               <xocs:filename>fx32.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3500</xocs:filesize>
               <xocs:pixel-height>130</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx15.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx15/THUMBNAIL/image/gif/312faa078a5f8298202275b656b5f9bd/fx15.sml</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1913</xocs:filesize>
               <xocs:pixel-height>66</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr4/THUMBNAIL/image/gif/015209d59cb759a5927728cf1f98bc3d/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6418</xocs:filesize>
               <xocs:pixel-height>115</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx24.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx24/THUMBNAIL/image/gif/0a060d2d2d141c33ebca26c5216c3422/fx24.sml</xocs:ucs-locator>
               <xocs:file-basename>fx24</xocs:file-basename>
               <xocs:filename>fx24.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2643</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx17.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx17/THUMBNAIL/image/gif/79d0c58954a195963a3e4e2205d34cf2/fx17.sml</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2797</xocs:filesize>
               <xocs:pixel-height>88</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx37.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx37/THUMBNAIL/image/gif/62c9d8110bcb3f83f59d87ca0a63e9cc/fx37.sml</xocs:ucs-locator>
               <xocs:file-basename>fx37</xocs:file-basename>
               <xocs:filename>fx37.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3021</xocs:filesize>
               <xocs:pixel-height>99</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx43.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx43/THUMBNAIL/image/gif/b8836418f30ba93a8867f530ed0aad96/fx43.sml</xocs:ucs-locator>
               <xocs:file-basename>fx43</xocs:file-basename>
               <xocs:filename>fx43.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2208</xocs:filesize>
               <xocs:pixel-height>88</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr10/THUMBNAIL/image/gif/1f388a9f1bb839f2a0fd3b9c4940040b/gr10.sml</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5573</xocs:filesize>
               <xocs:pixel-height>57</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx38.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx38/THUMBNAIL/image/gif/b35ed3310e37a88f2e55f1d03958023b/fx38.sml</xocs:ucs-locator>
               <xocs:file-basename>fx38</xocs:file-basename>
               <xocs:filename>fx38.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3251</xocs:filesize>
               <xocs:pixel-height>135</xocs:pixel-height>
               <xocs:pixel-width>175</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx31.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx31/THUMBNAIL/image/gif/7d277c89bfd8bb96bc13a58c8623116a/fx31.sml</xocs:ucs-locator>
               <xocs:file-basename>fx31</xocs:file-basename>
               <xocs:filename>fx31.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2558</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr8/THUMBNAIL/image/gif/93a15cfe517f85f745d807407419a8f8/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7362</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>196</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx45.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx45/THUMBNAIL/image/gif/266f8d7e867b2a8937ef446e373398fb/fx45.sml</xocs:ucs-locator>
               <xocs:file-basename>fx45</xocs:file-basename>
               <xocs:filename>fx45.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2197</xocs:filesize>
               <xocs:pixel-height>72</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx16.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx16/THUMBNAIL/image/gif/823a3d886d4a54a86d2c4be24e6e122b/fx16.sml</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2098</xocs:filesize>
               <xocs:pixel-height>66</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx30.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx30/THUMBNAIL/image/gif/e9bd572821fdb74334b29f93edd150f5/fx30.sml</xocs:ucs-locator>
               <xocs:file-basename>fx30</xocs:file-basename>
               <xocs:filename>fx30.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2540</xocs:filesize>
               <xocs:pixel-height>88</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr11/THUMBNAIL/image/gif/cd76f3d77122a96455d311c950e5b4d2/gr11.sml</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9877</xocs:filesize>
               <xocs:pixel-height>145</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx27.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx27/THUMBNAIL/image/gif/26e5e4494d69799f5579aa840c28b9df/fx27.sml</xocs:ucs-locator>
               <xocs:file-basename>fx27</xocs:file-basename>
               <xocs:filename>fx27.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2793</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx21.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx21/THUMBNAIL/image/gif/edced9b646370441549f0deb2b0ef25e/fx21.sml</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2647</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx12.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx12/THUMBNAIL/image/gif/414384718a69f3dec49702ac6d0b71ef/fx12.sml</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4299</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx10/THUMBNAIL/image/gif/29760b04b1ffe2133c2ecba6f2738f8d/fx10.sml</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3733</xocs:filesize>
               <xocs:pixel-height>145</xocs:pixel-height>
               <xocs:pixel-width>188</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx28.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx28/THUMBNAIL/image/gif/37a27ed4ee5d05ac04879bb224a7a92f/fx28.sml</xocs:ucs-locator>
               <xocs:file-basename>fx28</xocs:file-basename>
               <xocs:filename>fx28.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2776</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx6/THUMBNAIL/image/gif/8e0e9f07d7ff4c13da6d941407f2e046/fx6.sml</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2543</xocs:filesize>
               <xocs:pixel-height>88</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-sc4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/sc4/THUMBNAIL/image/gif/2eca7ef0cdda7d19102d37c871be1264/sc4.sml</xocs:ucs-locator>
               <xocs:file-basename>sc4</xocs:file-basename>
               <xocs:filename>sc4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3102</xocs:filesize>
               <xocs:pixel-height>57</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx11/THUMBNAIL/image/gif/670222d6e60909953700151fa8ea2a84/fx11.sml</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3790</xocs:filesize>
               <xocs:pixel-height>112</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx42.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx42/THUMBNAIL/image/gif/dd3f02983f5585738044485e68077718/fx42.sml</xocs:ucs-locator>
               <xocs:file-basename>fx42</xocs:file-basename>
               <xocs:filename>fx42.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2297</xocs:filesize>
               <xocs:pixel-height>81</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx22.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx22/THUMBNAIL/image/gif/91d677cb1aeee9adf182ad1dd464ba54/fx22.sml</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2771</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-sc3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/sc3/THUMBNAIL/image/gif/57649a12be2862a7e47d2f2395b6ddee/sc3.sml</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2178</xocs:filesize>
               <xocs:pixel-height>29</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr5/THUMBNAIL/image/gif/df14a66a8a8fd88edeb7ed156280eb66/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5672</xocs:filesize>
               <xocs:pixel-height>47</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx7/THUMBNAIL/image/gif/5fcd5dc25337c37d2e63147fc2181dfd/fx7.sml</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2434</xocs:filesize>
               <xocs:pixel-height>88</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx44.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx44/THUMBNAIL/image/gif/db29109358bbbd820373ed298d5fe0c6/fx44.sml</xocs:ucs-locator>
               <xocs:file-basename>fx44</xocs:file-basename>
               <xocs:filename>fx44.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2769</xocs:filesize>
               <xocs:pixel-height>90</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx33.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx33/THUMBNAIL/image/gif/211bd0bd4e64154d09b6665f8cfabb11/fx33.sml</xocs:ucs-locator>
               <xocs:file-basename>fx33</xocs:file-basename>
               <xocs:filename>fx33.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2646</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx19_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx19/HIGHRES/image/jpeg/ccb248c2a160b5850d2c042ce65db576/fx19_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>25806</xocs:filesize>
               <xocs:pixel-height>533</xocs:pixel-height>
               <xocs:pixel-width>402</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-sc1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/sc1/HIGHRES/image/jpeg/e16aa0fb9a2d24bdd490b78c66c81f2b/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>215784</xocs:filesize>
               <xocs:pixel-height>1274</xocs:pixel-height>
               <xocs:pixel-width>2370</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr6/HIGHRES/image/jpeg/fcd3311dde83ac17f23941e8a790ed82/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>382122</xocs:filesize>
               <xocs:pixel-height>2736</xocs:pixel-height>
               <xocs:pixel-width>2370</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx5/HIGHRES/image/jpeg/4fe19164c305f99485d9edd253974850/fx5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6070</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>294</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx23_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx23/HIGHRES/image/jpeg/863f4dec83ebaae4bb76094d452937d0/fx23_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx23</xocs:file-basename>
               <xocs:filename>fx23_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4793</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx40_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx40/HIGHRES/image/jpeg/beb5b2e9e8297983b826166bf40ee746/fx40_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx40</xocs:file-basename>
               <xocs:filename>fx40_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5715</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>276</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx2/HIGHRES/image/jpeg/ffcab4956963400bbbcac76632201999/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>24985</xocs:filesize>
               <xocs:pixel-height>397</xocs:pixel-height>
               <xocs:pixel-width>643</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr9/HIGHRES/image/jpeg/3f77a4d03b2ca41f09ba8a324aac8ce9/gr9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>356499</xocs:filesize>
               <xocs:pixel-height>1152</xocs:pixel-height>
               <xocs:pixel-width>2370</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx36_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx36/HIGHRES/image/jpeg/697760bbf4129f419d0b2998bef93e34/fx36_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx36</xocs:file-basename>
               <xocs:filename>fx36_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6683</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>305</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx9/HIGHRES/image/jpeg/59127d19129947860c915277e921fb43/fx9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6666</xocs:filesize>
               <xocs:pixel-height>176</xocs:pixel-height>
               <xocs:pixel-width>245</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx35_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx35/HIGHRES/image/jpeg/0ce5573f3cb0d133849cf206758550bf/fx35_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx35</xocs:file-basename>
               <xocs:filename>fx35_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6545</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>305</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr2/HIGHRES/image/jpeg/948b3733e6306b99d1249f9ca59788a1/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1015512</xocs:filesize>
               <xocs:pixel-height>2750</xocs:pixel-height>
               <xocs:pixel-width>2568</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx39_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx39/HIGHRES/image/jpeg/a66151cddf3c67b82dea371d2b019034/fx39_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx39</xocs:file-basename>
               <xocs:filename>fx39_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>8266</xocs:filesize>
               <xocs:pixel-height>144</xocs:pixel-height>
               <xocs:pixel-width>274</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx3/HIGHRES/image/jpeg/6f81cf36108487c5ea90839993325120/fx3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4926</xocs:filesize>
               <xocs:pixel-height>119</xocs:pixel-height>
               <xocs:pixel-width>191</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr13_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr13/HIGHRES/image/jpeg/d9ffa67d6e5438ce24a2585b850d7961/gr13_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr13</xocs:file-basename>
               <xocs:filename>gr13_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1071838</xocs:filesize>
               <xocs:pixel-height>1973</xocs:pixel-height>
               <xocs:pixel-width>3551</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr1/HIGHRES/image/jpeg/2c2c7564241f2dfc4b596434a68285a0/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>192079</xocs:filesize>
               <xocs:pixel-height>1038</xocs:pixel-height>
               <xocs:pixel-width>2470</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx20_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx20/HIGHRES/image/jpeg/d3e462e104db1029704443941e46203f/fx20_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4811</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr14_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr14/HIGHRES/image/jpeg/2fabe3d102b2be1ae71a78238d6ab326/gr14_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr14</xocs:file-basename>
               <xocs:filename>gr14_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1031049</xocs:filesize>
               <xocs:pixel-height>1972</xocs:pixel-height>
               <xocs:pixel-width>3551</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx26_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx26/HIGHRES/image/jpeg/3edfca519c2edadb8339d6eba5600881/fx26_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx26</xocs:file-basename>
               <xocs:filename>fx26_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4798</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx34_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx34/HIGHRES/image/jpeg/8348ccd502d494ef533a5a21b4ecf74e/fx34_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx34</xocs:file-basename>
               <xocs:filename>fx34_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5744</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>273</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx41_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx41/HIGHRES/image/jpeg/0a832443ddfef1796022ea40663e206b/fx41_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx41</xocs:file-basename>
               <xocs:filename>fx41_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6622</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>302</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-sc2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/sc2/HIGHRES/image/jpeg/9ad0cef2dd04a0308a3ab4f60d302aa5/sc2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>190790</xocs:filesize>
               <xocs:pixel-height>894</xocs:pixel-height>
               <xocs:pixel-width>2470</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx29_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx29/HIGHRES/image/jpeg/0fa93547ec98f72591761f3fd4fe2790/fx29_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx29</xocs:file-basename>
               <xocs:filename>fx29_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4807</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx8/HIGHRES/image/jpeg/e1dc82638650a5f08f831059b133b67d/fx8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6295</xocs:filesize>
               <xocs:pixel-height>145</xocs:pixel-height>
               <xocs:pixel-width>189</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx14_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx14/HIGHRES/image/jpeg/ab0c505d28b9f2c0ad10cfc6144756af/fx14_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>7956</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>399</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx1/HIGHRES/image/jpeg/93f485c7a9c3587c2836452c121851f8/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>27784</xocs:filesize>
               <xocs:pixel-height>505</xocs:pixel-height>
               <xocs:pixel-width>679</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr7/HIGHRES/image/jpeg/4bf497a47fe828257f966530d8620de4/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>389676</xocs:filesize>
               <xocs:pixel-height>2728</xocs:pixel-height>
               <xocs:pixel-width>2370</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-sc5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/sc5/HIGHRES/image/jpeg/cfb25201a37d7a3884c26b5b48908e50/sc5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc5</xocs:file-basename>
               <xocs:filename>sc5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>372205</xocs:filesize>
               <xocs:pixel-height>1216</xocs:pixel-height>
               <xocs:pixel-width>2470</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr3/HIGHRES/image/jpeg/b40c425554f4b49483643c27f79fec74/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>208558</xocs:filesize>
               <xocs:pixel-height>822</xocs:pixel-height>
               <xocs:pixel-width>2370</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx25_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx25/HIGHRES/image/jpeg/a778d3ca162dec00d7dcc358bfb88df0/fx25_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx25</xocs:file-basename>
               <xocs:filename>fx25_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4802</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx18_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx18/HIGHRES/image/jpeg/c67c8f2910ad6bf9f496ed00922b1063/fx18_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>10646</xocs:filesize>
               <xocs:pixel-height>184</xocs:pixel-height>
               <xocs:pixel-width>295</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-ga1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/ga1/HIGHRES/image/jpeg/a0ed768cdd4d9bb1aca3fa2abec54970/ga1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>ga1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>ga1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>194539</xocs:filesize>
               <xocs:pixel-height>663</xocs:pixel-height>
               <xocs:pixel-width>2213</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx4/HIGHRES/image/jpeg/45acf708d5a534cdc2fda990d8558b32/fx4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6664</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>298</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx13_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx13/HIGHRES/image/jpeg/2047a35d51bc64d5edcb44a6348bca45/fx13_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>19261</xocs:filesize>
               <xocs:pixel-height>361</xocs:pixel-height>
               <xocs:pixel-width>506</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr12_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr12/HIGHRES/image/jpeg/3d405b2c19240b818aa733c28212d95e/gr12_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1135012</xocs:filesize>
               <xocs:pixel-height>2302</xocs:pixel-height>
               <xocs:pixel-width>2568</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx32_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx32/HIGHRES/image/jpeg/2b76648593c4ad546504c6004794e4c3/fx32_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx32</xocs:file-basename>
               <xocs:filename>fx32_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6932</xocs:filesize>
               <xocs:pixel-height>143</xocs:pixel-height>
               <xocs:pixel-width>240</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx15_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx15/HIGHRES/image/jpeg/870efc4ce66611599b4e6f75c427ae5d/fx15_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>7808</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>398</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr4/HIGHRES/image/jpeg/f779bb846264abb337a3dae4c99d85b6/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>142761</xocs:filesize>
               <xocs:pixel-height>886</xocs:pixel-height>
               <xocs:pixel-width>1682</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx24_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx24/HIGHRES/image/jpeg/0078be65b228835eab8ef3edb09e2355/fx24_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx24</xocs:file-basename>
               <xocs:filename>fx24_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4796</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx17_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx17/HIGHRES/image/jpeg/f5154dd7aceca7703e76fff832c8e158/fx17_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>9644</xocs:filesize>
               <xocs:pixel-height>147</xocs:pixel-height>
               <xocs:pixel-width>367</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx37_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx37/HIGHRES/image/jpeg/d5c3bb2c761459ff2dcda7bf0828afe6/fx37_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx37</xocs:file-basename>
               <xocs:filename>fx37_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>8674</xocs:filesize>
               <xocs:pixel-height>138</xocs:pixel-height>
               <xocs:pixel-width>305</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx43_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx43/HIGHRES/image/jpeg/f1f1435950d53a34df5eb02bf5e67bdb/fx43_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx43</xocs:file-basename>
               <xocs:filename>fx43_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5711</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>276</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr10/HIGHRES/image/jpeg/d562a57d6944cc012fdc60ab8decfb71/gr10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>265682</xocs:filesize>
               <xocs:pixel-height>818</xocs:pixel-height>
               <xocs:pixel-width>3158</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx38_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx38/HIGHRES/image/jpeg/9f5071fe290d3197fd22ceb2ca34cf68/fx38_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx38</xocs:file-basename>
               <xocs:filename>fx38_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5506</xocs:filesize>
               <xocs:pixel-height>135</xocs:pixel-height>
               <xocs:pixel-width>175</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx31_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx31/HIGHRES/image/jpeg/188767cbd879420bc125f2be0d00b580/fx31_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx31</xocs:file-basename>
               <xocs:filename>fx31_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4807</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr8/HIGHRES/image/jpeg/85abc19ca07789461d5745c0a7d03d9d/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>152486</xocs:filesize>
               <xocs:pixel-height>1404</xocs:pixel-height>
               <xocs:pixel-width>1682</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx45_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx45/HIGHRES/image/jpeg/fa18c226f65f58d2fe374e92fa4c2176/fx45_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx45</xocs:file-basename>
               <xocs:filename>fx45_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>7353</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>337</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx16_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx16/HIGHRES/image/jpeg/d89ea25b1ec1dc152df00e560ebc80d6/fx16_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>9084</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>399</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx30_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx30/HIGHRES/image/jpeg/398d687b76f7934da9a70624a9b32113/fx30_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx30</xocs:file-basename>
               <xocs:filename>fx30_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6045</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>276</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr11/HIGHRES/image/jpeg/6564aec079149da9a7b6656de6ea05c9/gr11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>681574</xocs:filesize>
               <xocs:pixel-height>2092</xocs:pixel-height>
               <xocs:pixel-width>3158</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx27_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx27/HIGHRES/image/jpeg/d645ca0b538d1981f7fe3504924f3da5/fx27_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx27</xocs:file-basename>
               <xocs:filename>fx27_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4802</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx21_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx21/HIGHRES/image/jpeg/cdb7ebf99299cfebfd72afaa636b12df/fx21_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4792</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx12_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx12/HIGHRES/image/jpeg/284375167e51a3fa8cd157aaea9a234a/fx12_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>11362</xocs:filesize>
               <xocs:pixel-height>220</xocs:pixel-height>
               <xocs:pixel-width>295</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx10/HIGHRES/image/jpeg/3a62dfc794b418ce1674ca07aeb61bfb/fx10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6233</xocs:filesize>
               <xocs:pixel-height>145</xocs:pixel-height>
               <xocs:pixel-width>188</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx28_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx28/HIGHRES/image/jpeg/1f9caf6e21f902abe85ccea145e9298e/fx28_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx28</xocs:file-basename>
               <xocs:filename>fx28_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4811</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx6/HIGHRES/image/jpeg/51a6233c2be142809415b6a8b6f47775/fx6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6653</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>298</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-sc4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/sc4/HIGHRES/image/jpeg/251a2f4628e175705d8d36e7110c889f/sc4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc4</xocs:file-basename>
               <xocs:filename>sc4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>138448</xocs:filesize>
               <xocs:pixel-height>668</xocs:pixel-height>
               <xocs:pixel-width>2568</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx11/HIGHRES/image/jpeg/4f2bab857602fd00a8d65389578fd04e/fx11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>9811</xocs:filesize>
               <xocs:pixel-height>151</xocs:pixel-height>
               <xocs:pixel-width>296</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx42_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx42/HIGHRES/image/jpeg/789eeae5c028afe67449f022de1f101c/fx42_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx42</xocs:file-basename>
               <xocs:filename>fx42_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6660</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>301</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx22_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx22/HIGHRES/image/jpeg/a0056f6f7dabee46285ada13c1a32019/fx22_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4800</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-sc3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/sc3/HIGHRES/image/jpeg/e94679187bf9ddf68f39c4772c30c6b9/sc3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>109507</xocs:filesize>
               <xocs:pixel-height>414</xocs:pixel-height>
               <xocs:pixel-width>3158</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/gr5/HIGHRES/image/jpeg/4b9640000665520680446c74737ba9df/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>298248</xocs:filesize>
               <xocs:pixel-height>760</xocs:pixel-height>
               <xocs:pixel-width>3552</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx7/HIGHRES/image/jpeg/68e16cec9cacc966cf94d803c5c11cb1/fx7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6784</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>298</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx44_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx44/HIGHRES/image/jpeg/bd7b50d56df2db8a1fc725926a4fbdee/fx44_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx44</xocs:file-basename>
               <xocs:filename>fx44_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>9254</xocs:filesize>
               <xocs:pixel-height>138</xocs:pixel-height>
               <xocs:pixel-width>337</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-fx33_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/fx33/HIGHRES/image/jpeg/040ce117bd694eff5568cbfd5f9a1fcc/fx33_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx33</xocs:file-basename>
               <xocs:filename>fx33_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4802</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-mmc1.docx</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421003743/mmc1/MAIN/application/vnd.openxmlformats-officedocument.wordprocessingml.document/6cdc0a103ca520c902bae10cd1493029/mmc1.docx</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.docx</xocs:filename>
               <xocs:extension>docx</xocs:extension>
               <xocs:filesize>8258439</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421003743-am.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10XM7VXDC11/MAIN/application/pdf/03e1c54b4077594fb0c3f9dc1d1e92cb/am.pdf</xocs:ucs-locator>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>false</xocs:pdf-optimized>
               <xocs:filesize>2705698</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>113525</aid>
            <ce:article-number>113525</ce:article-number>
            <ce:pii>S0223-5234(21)00374-3</ce:pii>
            <ce:doi>10.1016/j.ejmech.2021.113525</ce:doi>
            <ce:copyright type="full-transfer" year="2021">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig.Â 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Chemical structures of previously reported STAT3 inhibitors (<ce:bold>1-5</ce:bold>) and degrader (<ce:bold>6</ce:bold>).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0020" role="short">Fig.Â 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S0223523421003743/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig.Â 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">(A) Three pockets within STAT3 SH2 domain (PDB ID: <ce:inter-ref id="intref0025" xlink:href="pdb:1BG1" xlink:type="simple">1BG1</ce:inter-ref>). (B) Binding mode of compound <ce:bold>1</ce:bold>. (C) Binding mode of compound <ce:bold>3</ce:bold>. (D) Binding mode of compound <ce:bold>8</ce:bold>. (E) Our design of new STAT3 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0025" role="short">Fig.Â 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S0223523421003743/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig.Â 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">Design of imidazo[1, 2-a]pyridine-based STAT3 inhibitor.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0030" role="short">Fig.Â 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S0223523421003743/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig.Â 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">SPR analysis of compound <ce:bold>39</ce:bold> binding to STAT3 protein. Representative data from three independent experiments are shown.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0035" role="short">Fig.Â 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S0223523421003743/gr4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig.Â 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">Effects of compound <ce:bold>39</ce:bold> on phosphorylation of STAT3 (A), STAT1 and STAT5 (B) analyzed by western blotting. Representative images from three independent experiments are shown.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0040" role="short">Fig.Â 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S0223523421003743/gr5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig.Â 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">Effects of compound <ce:bold>39</ce:bold> on STAT3 dimerization. (A) colocalization study of compound <ce:bold>39</ce:bold> in HEK-293T cells with HA-STAT3 (green) and FLAG-STAT3 (red). DAPI nuclear was stained in blue. (B) Coimmunoprecipitation assay of compound <ce:bold>39</ce:bold> in HEK-293T cells. Representative images from three independent experiments are shown.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0045" role="short">Fig.Â 6</ce:alt-text>
               <ce:link locator="gr6" xlink:href="pii:S0223523421003743/gr6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig.Â 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">Effects of compound <ce:bold>39</ce:bold> on nuclear translocation of phosphorylated STAT3 in MDA-MB-231Â cell line. Representative images from three independent experiments are shown.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0050" role="short">Fig.Â 7</ce:alt-text>
               <ce:link locator="gr7" xlink:href="pii:S0223523421003743/gr7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig8">
               <ce:label>Fig.Â 8</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">Effects of compound <ce:bold>39</ce:bold> on STAT3 DNA-binding and STAT3-dependent transcriptional activation. (A) EMSA analysis of STAT3 or STAT5 DNA-binding activity in nuclear extracts prepared from MDA-MB-231 and MDA-MB-468Â cells after treatment of compound <ce:bold>39</ce:bold>. (B) Luciferase reporter assay of compound <ce:bold>39</ce:bold> in HEK-293T cells. Representative images from three independent experiments are shown. (âââ) pÂ <Â 0.001; (ââââ) pÂ <Â 0.0001.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0055" role="short">Fig.Â 8</ce:alt-text>
               <ce:link locator="gr8" xlink:href="pii:S0223523421003743/gr8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig9">
               <ce:label>Fig.Â 9</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0050" view="all">Western blotting analysis was used to examine the phosphorylation of STAT3 and expression of STAT3-regulated genes in TNBC cells treated with different doses of compound <ce:bold>39</ce:bold> for 24Â h. Representative data from three independent experiments are shown.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0060" role="short">Fig.Â 9</ce:alt-text>
               <ce:link locator="gr9" xlink:href="pii:S0223523421003743/gr9" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig10">
               <ce:label>Fig.Â 10</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="fspara0055" view="all">Effects of compound <ce:bold>39</ce:bold> on proliferation and colony formation of TNBC cells. (A) Cell viability of cancer cell lines treated with compound <ce:bold>39</ce:bold> using the MTT assay. (B) Inhibitory effects of compound <ce:bold>39</ce:bold> on colony formation of TNBC cells. Representative data from three independent experiments are shown. (â) pÂ <Â 0.05; (ââ) pÂ <Â 0.01; (âââ) pÂ <Â 0.001; (ââââ) pÂ <Â 0.0001.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0065" role="short">Fig.Â 10</ce:alt-text>
               <ce:link locator="gr10" xlink:href="pii:S0223523421003743/gr10" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig11">
               <ce:label>Fig.Â 11</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="fspara0060" view="all">Effects of compound <ce:bold>39</ce:bold> on inducing apoptosis and cleavage of PARP and caspase 7 in breast cancer cells. (A) Apoptosis induced by compound <ce:bold>39</ce:bold>Â at different concentrations was examined by a annexin V-FITC/PI-staining based flow cytometry. (ââ) pÂ <Â 0.01; (âââ) pÂ <Â 0.001; (ââââ) pÂ <Â 0.0001. (B) Western blot analysis of the effect of compound <ce:bold>39</ce:bold> on cleaved- PARP and cleaved-caspase7. Î²-Action was used as the loading control. Representative data from three independent experiments are shown.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0070" role="short">Fig.Â 11</ce:alt-text>
               <ce:link locator="gr11" xlink:href="pii:S0223523421003743/gr11" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig12">
               <ce:label>Fig.Â 12</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="fspara0065" view="all">Effects of compound <ce:bold>39</ce:bold> on cell migration and invasion. (A) Inhibition of cell migration by compound <ce:bold>39</ce:bold> in wound healing assay. (B) Inhibition of cell invasion by compound <ce:bold>39</ce:bold> in transwell assays. Representative images from three independent experiments are shown. (âââ) PÂ <Â 0.001, (ââââ) pÂ <Â 0.0001.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0075" role="short">Fig.Â 12</ce:alt-text>
               <ce:link locator="gr12" xlink:href="pii:S0223523421003743/gr12" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig13">
               <ce:label>Fig.Â 13</ce:label>
               <ce:caption id="cap0070">
                  <ce:simple-para id="fspara0070" view="all">Antitumor activity of compound <ce:bold>39</ce:bold> in MDA-MB--231-4175 xenograft model in mice. Tumor volume (A), body weight (B), and tumor weight (C) of the mice with the indicated treatment of compound <ce:bold>39</ce:bold>. (D) Tumor proliferation biomarker Ki67 detection of tumor tissues by immunohistochemistry after treatment with compound <ce:bold>39</ce:bold>. (E) pY705-STAT3, STAT3, Bcl-xL and Mcl-1 immunoblot in tumor tissue lysates. (F) Morphological images of heart, liver, spleen, lung and kidney tissues from treated mice. Values, meanÂ Â±Â SEM, nÂ =Â 6. (â) PÂ <Â 0.05.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0080" role="short">Fig.Â 13</ce:alt-text>
               <ce:link locator="gr13" xlink:href="pii:S0223523421003743/gr13" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig14">
               <ce:label>Fig.Â 14</ce:label>
               <ce:caption id="cap0075">
                  <ce:simple-para id="fspara0075" view="all">Antitumor activity of compound <ce:bold>39</ce:bold> in breast cancer PDX model in mice. Tumor volume (A), body weight (B), and tumor weight (C) of the mice with the indicated treatment of compound <ce:bold>39</ce:bold>. (D) Tumor proliferation biomarker Ki67 detection of tumor tissues after treatment with compound <ce:bold>39</ce:bold>. (E) pY705-STAT3, STAT3, Bcl-xL and Mcl-1 immunoblot in tumor tissue lysates. (F) Morphological images of heart, liver, spleen, lung and kidney tissues from treated mice. Values, meanÂ Â±Â SEM, nÂ =Â 6. (â) PÂ <Â 0.05.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0085" role="short">Fig.Â 14</ce:alt-text>
               <ce:link locator="gr14" xlink:href="pii:S0223523421003743/gr14" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:caption id="cap0080">
                  <ce:simple-para id="fspara0080" view="all">Synthesis of compounds 7-16<ce:sup loc="post">a</ce:sup>. <ce:sup loc="post">a</ce:sup> Reagents and conditions: (a) HOAt, EDC, DIPEA, DMF, rt, 4Â h, 80%; (b) ethyl 2-bromoacetate, Cs<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, DMF, rt, 6Â h, 76%; (c) LiOH<ce:sup loc="post">.</ce:sup>H<ce:inf loc="post">2</ce:inf>O, MeOH-H<ce:inf loc="post">2</ce:inf>O (2:3), rt, 1Â h, 88%.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0090" role="short">Scheme 1</ce:alt-text>
               <ce:link locator="sc1" xlink:href="pii:S0223523421003743/sc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch2">
               <ce:label>Scheme 2</ce:label>
               <ce:caption id="cap0085">
                  <ce:simple-para id="fspara0085" view="all">Synthesis of compounds 17-33<ce:sup loc="post">a</ce:sup>. <ce:sup loc="post">a</ce:sup> Reagents and conditions: (a) HOAt, EDC, DIPEA, DMF, rt, 4Â h, 60â80%; (b) suitable arylboronic acid, Pd(PPh<ce:inf loc="post">3</ce:inf>)<ce:inf loc="post">4</ce:inf>, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, 1,4-dioxane-H<ce:inf loc="post">2</ce:inf>O (4:1), reflux, overnight, 75â79%.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0095" role="short">Scheme 2</ce:alt-text>
               <ce:link locator="sc2" xlink:href="pii:S0223523421003743/sc2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch3">
               <ce:label>Scheme 3</ce:label>
               <ce:caption id="cap0090">
                  <ce:simple-para id="fspara0090" view="all">Synthesis of compound 34<ce:sup loc="post">a</ce:sup>. <ce:sup loc="post">a</ce:sup> Reagents and conditions: (a) CBr<ce:inf loc="post">4</ce:inf>, CH<ce:inf loc="post">3</ce:inf>CN, 80Â Â°C, 4Â h, 85%; (b) LiOH<ce:sup loc="post">.</ce:sup>H<ce:inf loc="post">2</ce:inf>O, MeOH-H<ce:inf loc="post">2</ce:inf>O (2:3), rt, 1Â h, 92%; (c) <ce:bold>63a</ce:bold>, HATU, DIPEA, DMF, 0<ce:sup loc="post">o</ce:sup>C-rt, 5Â h, 85%.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0100" role="short">Scheme 3</ce:alt-text>
               <ce:link locator="sc3" xlink:href="pii:S0223523421003743/sc3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch4">
               <ce:label>Scheme 4</ce:label>
               <ce:caption id="cap0095">
                  <ce:simple-para id="fspara0095" view="all">Synthesis of compounds 35-38<ce:sup loc="post">a</ce:sup>. <ce:sup loc="post">a</ce:sup> Reagents and conditions: (a) ethyl diazoacetate, Rh<ce:inf loc="post">2</ce:inf>(oct)<ce:inf loc="post">4</ce:inf>, CHCl<ce:inf loc="post">3</ce:inf>, rt, 4Â h, 85%; (b) LiOH<ce:sup loc="post">.</ce:sup>H<ce:inf loc="post">2</ce:inf>O, MeOH-H<ce:inf loc="post">2</ce:inf>O (2:3), rt, 1Â h, 80%; (c) HOAt, EDC, DIPEA, DMF, rt, 4Â h, 65â75%.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0105" role="short">Scheme 4</ce:alt-text>
               <ce:link locator="sc4" xlink:href="pii:S0223523421003743/sc4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch5">
               <ce:label>Scheme 5</ce:label>
               <ce:caption id="cap0100">
                  <ce:simple-para id="fspara0100" view="all">Synthesis of compounds 39-61<ce:sup loc="post">a</ce:sup>. <ce:sup loc="post">a</ce:sup> Reagents and conditions: (a) ethyl diazoacetate, Rh<ce:inf loc="post">2</ce:inf>(oct)<ce:inf loc="post">4</ce:inf>, CHCl<ce:inf loc="post">3</ce:inf>, rt, 4Â h, 70â95%; (b) LiOH<ce:sup loc="post">.</ce:sup>H<ce:inf loc="post">2</ce:inf>O, MeOH-H<ce:inf loc="post">2</ce:inf>O (2:3), rt, 1Â h, 82â95%; (c) HOAt, EDC, DIPEA, DMF, rt, 4Â h, 65â80%.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0110" role="short">Scheme 5</ce:alt-text>
               <ce:link locator="sc5" xlink:href="pii:S0223523421003743/sc5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl1" rowsep="0">
               <ce:label>TableÂ 1</ce:label>
               <ce:caption id="cap0105">
                  <ce:simple-para id="tspara0010" view="all">Antiproliferative activity of quinoline derivatives <ce:bold>7-16</ce:bold> against human cancer cell lines.<ce:cross-ref id="crosref0445" refid="tbl1fna">
                        <ce:sup loc="post">a</ce:sup>
                     </ce:cross-ref>
                  </ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0115" role="short">TableÂ 1</ce:alt-text>
               <ce:link locator="fx1" xlink:href="pii:S0223523421003743/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="6">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Compd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">n</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col6" namest="col4" role="colgroup">IC<inf loc="post">50</inf> (Î¼M)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MGC-803</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">A549</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.0Â Â±Â 2.03</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.9Â Â±Â 0.58</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.8Â Â±Â 0.72</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.9Â Â±Â 0.68</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.9Â Â±Â 0.69</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.9Â Â±Â 1.12</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>9</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>10</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OCH<inf loc="post">2</inf>CO<inf loc="post">2</inf>Et</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OCH<inf loc="post">2</inf>CO<inf loc="post">2</inf>H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>12</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">20.1Â Â±Â 3.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>13</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>14</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">50Â Â±Â 5.16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">14.6Â Â±Â 2.28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">16.6Â Â±Â 1.15</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OCH<inf loc="post">2</inf>CO<inf loc="post">2</inf>Et</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>16</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OCH<inf loc="post">2</inf>CO<inf loc="post">2</inf>H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>SH4-54</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.0Â Â±Â 0.24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.6Â Â±Â 0.14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.0Â Â±Â 0.15</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>STX-119</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">18.25Â Â±Â 3.09</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7.43Â Â±Â 1.74</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">11.59Â Â±Â 3.09</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl1fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0015" view="all">Data are calculated based on three independent experiments.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl2" rowsep="0">
               <ce:label>TableÂ 2</ce:label>
               <ce:caption id="cap0110">
                  <ce:simple-para id="tspara0015" view="all">Antiproliferative activity of quinoline derivatives <ce:bold>17-33</ce:bold> against human cancer cell lines.<ce:cross-ref id="crosref0450" refid="tbl2fna">
                        <ce:sup loc="post">a</ce:sup>
                     </ce:cross-ref>
                  </ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0120" role="short">TableÂ 2</ce:alt-text>
               <ce:link locator="fx2" xlink:href="pii:S0223523421003743/fx2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="5">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Compd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col5" namest="col3" role="colgroup">IC<inf loc="post">50</inf> (Î¼M)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MGC-803</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">A549</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>17</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Br</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">25.5Â Â±Â 2.48</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15.5Â Â±Â 2.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">21.4Â Â±Â 2.10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>18</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>19</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">50.4Â Â±Â 4.71</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>20</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>21</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>22</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>-Butyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">39.6Â Â±Â 4.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">40.9Â Â±Â 6.68</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>23</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>iso-</italic>Propyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>24</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx3" xlink:href="pii:S0223523421003743/fx3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0125" role="short">Image 3</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.3Â Â±Â 0.28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.6Â Â±Â 0.90</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.0Â Â±Â 0.32</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>25</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:href="pii:S0223523421003743/fx4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0130" role="short">Image 4</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>26</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx5" xlink:href="pii:S0223523421003743/fx5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0135" role="short">Image 5</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">11.2Â Â±Â 2.66</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">40.4Â Â±Â 3.18</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">29.9Â Â±Â 4.16</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>27</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx6" xlink:href="pii:S0223523421003743/fx6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0140" role="short">Image 6</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">21.0Â Â±Â 4.32</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.8Â Â±Â 0.54</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.9Â Â±Â 0.43</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>28</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx7" xlink:href="pii:S0223523421003743/fx7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0145" role="short">Image 7</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">20.2Â Â±Â 2.24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15.6Â Â±Â 3.42</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15.6Â Â±Â 4.14</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>29</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx8" xlink:href="pii:S0223523421003743/fx8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0150" role="short">Image 8</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.8Â Â±Â 1.46</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15.0Â Â±Â 0.98</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15.0Â Â±Â 2.13</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>30</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx9" xlink:href="pii:S0223523421003743/fx9" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0155" role="short">Image 9</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">64.8Â Â±Â 5.78</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>31</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx10" xlink:href="pii:S0223523421003743/fx10" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0160" role="short">Image 10</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.3Â Â±Â 1.26</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.1Â Â±Â 0.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.5Â Â±Â 0.57</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>32</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx11" xlink:href="pii:S0223523421003743/fx11" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0165" role="short">Image 11</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.3Â Â±Â 0.45</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.8Â Â±Â 0.84</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.3Â Â±Â 0.75</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>33</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx12" xlink:href="pii:S0223523421003743/fx12" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0170" role="short">Image 12</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>SH4-54</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.0Â Â±Â 0.24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.6Â Â±Â 0.14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.0Â Â±Â 0.15</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl2fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0020" view="all">Data are calculated based on three independent experiments.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl3" rowsep="0">
               <ce:label>TableÂ 3</ce:label>
               <ce:caption id="cap0115">
                  <ce:simple-para id="tspara0020" view="all">Antiproliferative activity of imidazo[1, 2-a]pyridine derivatives <ce:bold>34</ce:bold>-<ce:bold>38</ce:bold> against human cancer cell lines.<ce:cross-ref id="crosref0455" refid="tbl3fna">
                        <ce:sup loc="post">a</ce:sup>
                     </ce:cross-ref>
                  </ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0180" role="short">TableÂ 3</ce:alt-text>
               <ce:link locator="fx13" xlink:href="pii:S0223523421003743/fx13" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="6">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Compd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">N</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col6" namest="col4" role="colgroup">IC<inf loc="post">50</inf> (Î¼M)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MGC-803</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">A549</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>34</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx14" xlink:href="pii:S0223523421003743/fx14" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0185" role="short">Image 14</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>35</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx15" xlink:href="pii:S0223523421003743/fx15" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0190" role="short">Image 15</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.4Â Â±Â 0.45</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.7Â Â±Â 0.32</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.6Â Â±Â 0.51</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>36</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx16" xlink:href="pii:S0223523421003743/fx16" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0195" role="short">Image 16</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.5Â Â±Â 1.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.5Â Â±Â 0.23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.2Â Â±Â 0.24</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>37</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx17" xlink:href="pii:S0223523421003743/fx17" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0200" role="short">Image 17</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10Â Â±Â 0.87</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.5Â Â±Â 0.35</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.6Â Â±Â 0.54</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>38</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx18" xlink:href="pii:S0223523421003743/fx18" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0205" role="short">Image 18</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.2Â Â±Â 0.29</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.0Â Â±Â 0.17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.6Â Â±Â 0.14</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>SH4-54</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.0Â Â±Â 0.24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.6Â Â±Â 0.14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.0Â Â±Â 0.15</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl3fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0025" view="all">Data are calculated based on three independent experiments.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl4" rowsep="0">
               <ce:label>TableÂ 4</ce:label>
               <ce:caption id="cap0120">
                  <ce:simple-para id="tspara0025" view="all">Antiproliferative activity of imidazo[1, 2-a]pyridine derivative <ce:bold>38-61</ce:bold> against human cancer cell lines.<ce:cross-ref id="crosref0460" refid="tbl4fna">
                        <ce:sup loc="post">a</ce:sup>
                     </ce:cross-ref>
                  </ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0215" role="short">TableÂ 4</ce:alt-text>
               <ce:link locator="fx19" xlink:href="pii:S0223523421003743/fx19" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="8">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <colspec colname="col8" colnum="8"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Compd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<inf loc="post">1</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<inf loc="post">4</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col8" namest="col6" role="colgroup">IC<inf loc="post">50</inf> (Î¼M)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MGC-803</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">A549</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>38</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx20" xlink:href="pii:S0223523421003743/fx20" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0220" role="short">Image 20</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.2Â Â±Â 0.29</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.0Â Â±Â 0.17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.6Â Â±Â 0.14</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>39</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx21" xlink:href="pii:S0223523421003743/fx21" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0225" role="short">Image 21</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.2Â Â±Â 0.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.6Â Â±Â 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.1Â Â±Â 0.11</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>40</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx22" xlink:href="pii:S0223523421003743/fx22" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0230" role="short">Image 22</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.1Â Â±Â 0.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.3Â Â±Â 0.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.7Â Â±Â 0.05</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>41</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Br</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx23" xlink:href="pii:S0223523421003743/fx23" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0235" role="short">Image 23</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.9Â Â±Â 0.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.9Â Â±Â 0.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.8Â Â±Â 0.06</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>42</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx24" xlink:href="pii:S0223523421003743/fx24" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0240" role="short">Image 24</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.6Â Â±Â 0.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.0Â Â±Â 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.7Â Â±Â 0.07</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>43</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx25" xlink:href="pii:S0223523421003743/fx25" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0245" role="short">Image 25</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.2Â Â±Â 0.17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.7Â Â±Â 0.22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.0Â Â±Â 0.05</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>44</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx26" xlink:href="pii:S0223523421003743/fx26" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0250" role="short">Image 26</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.1Â Â±Â 0.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.7Â Â±Â 0.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.2Â Â±Â 0.08</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>45</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Br</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx27" xlink:href="pii:S0223523421003743/fx27" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0255" role="short">Image 27</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.0Â Â±Â 0.42</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.5Â Â±Â 0.24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.8Â Â±Â 0.06</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>46</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx28" xlink:href="pii:S0223523421003743/fx28" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0260" role="short">Image 28</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx29" xlink:href="pii:S0223523421003743/fx29" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0265" role="short">Image 29</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.4Â Â±Â 0.34</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.7Â Â±Â 0.26</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.1Â Â±Â 0.06</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>47</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx30" xlink:href="pii:S0223523421003743/fx30" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0270" role="short">Image 30</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx31" xlink:href="pii:S0223523421003743/fx31" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0275" role="short">Image 31</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.0Â Â±Â 0.04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.5Â Â±Â 0.09</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.7Â Â±Â 0.11</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>48</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx32" xlink:href="pii:S0223523421003743/fx32" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0280" role="short">Image 32</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx33" xlink:href="pii:S0223523421003743/fx33" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0285" role="short">Image 33</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.4Â Â±Â 0.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.7Â Â±Â 0.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.8Â Â±Â 0.08</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>49</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx34" xlink:href="pii:S0223523421003743/fx34" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0290" role="short">Image 34</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.1Â Â±Â 0.56</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.9Â Â±Â 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.3Â Â±Â 0.16</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>50</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx35" xlink:href="pii:S0223523421003743/fx35" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0295" role="short">Image 35</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.7Â Â±Â 0.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.4Â Â±Â 0.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.4Â Â±Â 0.10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>51</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx36" xlink:href="pii:S0223523421003743/fx36" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0300" role="short">Image 36</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.4Â Â±Â 0.32</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.6Â Â±Â 0.14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.7Â Â±Â 0.11</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>52</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx37" xlink:href="pii:S0223523421003743/fx37" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0305" role="short">Image 37</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.8Â Â±Â 0.78</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.4Â Â±Â 0.34</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.8Â Â±Â 0.48</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>53</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx38" xlink:href="pii:S0223523421003743/fx38" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0310" role="short">Image 38</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.4Â Â±Â 0.04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.3Â Â±Â 0.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.1Â Â±Â 0.06</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>54</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx39" xlink:href="pii:S0223523421003743/fx39" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0315" role="short">Image 39</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.4Â Â±Â 0.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.5Â Â±Â 0.24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.0Â Â±Â 0.15</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>55</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx40" xlink:href="pii:S0223523421003743/fx40" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0320" role="short">Image 40</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.1Â Â±Â 0.45</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.8Â Â±Â 0.22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.9Â Â±Â 0.05</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>56</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx41" xlink:href="pii:S0223523421003743/fx41" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0325" role="short">Image 41</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.0Â Â±Â 0.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.4Â Â±Â 0.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.5Â Â±Â 0.07</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>57</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx42" xlink:href="pii:S0223523421003743/fx42" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0330" role="short">Image 42</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.0Â Â±Â 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.6Â Â±Â 0.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.2Â Â±Â 0.06</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>58</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx43" xlink:href="pii:S0223523421003743/fx43" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0335" role="short">Image 43</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.1Â Â±Â 0.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.7Â Â±Â 0.10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.5Â Â±Â 0.23</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>59</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx44" xlink:href="pii:S0223523421003743/fx44" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0340" role="short">Image 44</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.4Â Â±Â 0.32</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.9Â Â±Â 0.42</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7.5Â Â±Â 1.12</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>60</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx45" xlink:href="pii:S0223523421003743/fx45" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0345" role="short">Image 45</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.5Â Â±Â 0.83</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.2Â Â±Â 0.36</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.4Â Â±Â 0.87</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>61</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">20.2Â Â±Â 2.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">22.5Â Â±Â 1.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">23.4Â Â±Â 2.28</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl4fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0030" view="all">Data are calculated based on three independent experiments.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl5" rowsep="0">
               <ce:label>TableÂ 5</ce:label>
               <ce:caption id="cap0125">
                  <ce:simple-para id="tspara0030" view="all">
                     <ce:italic>InÂ vitro</ce:italic> metabolic stability in human liver microsomes.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0350" role="short">TableÂ 5</ce:alt-text>
               <tgroup cols="3">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col3" namest="col2" role="colgroup">HLM</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Compd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">clearance (mL/min/g)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <italic>T</italic>
                           <inf loc="post">1/2</inf> (min)</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>38</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">208.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.1</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>39</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">87.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">24.2</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>50</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">478.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.4</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl6" rowsep="0">
               <ce:label>TableÂ 6</ce:label>
               <ce:caption id="cap0130">
                  <ce:simple-para id="tspara0035" view="all">
                     <ce:italic>InÂ vivo</ce:italic> PK Parameters for compound 39.<ce:cross-ref id="crosref0465" refid="tbl6fna">
                        <ce:sup loc="post">a</ce:sup>
                     </ce:cross-ref>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0355" role="short">TableÂ 6</ce:alt-text>
               <tgroup cols="5">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <italic>T</italic>
                           <inf loc="post">1/2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <italic>T</italic>
                           <inf loc="post">max</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <italic>C</italic>
                           <inf loc="post">max</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">AUC<inf loc="post">0-last</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">AUC<inf loc="post">0-inf</inf>
                        </entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">(h)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">(h)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">(ng/mL)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">(hâng/mL)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">(hâng/mL)</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.46</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.67</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">23.8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">54.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">56.1</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl6fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0035" view="all">Values are the average of three runs. Vehicle: DMSO/0.5% HPMC (5/95, v/v/). T<ce:inf loc="post">1/2</ce:inf>, half-life; T<ce:inf loc="post">max</ce:inf>, time of maximum concentration; C<ce:inf loc="post">max</ce:inf>, maximum concentration; AUC, area under the plasma concentration-time curve.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
         </ce:floats>
         <head>
            <ce:title id="title0010">Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3)</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523421003743-ad6dcc97e995f64fad756b46736b96ef">
                  <ce:given-name>Qiuyao</ce:given-name>
                  <ce:surname>Huang</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0015" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523421003743-43ce6d1d4a6b51adb34dee8ef2876748">
                  <ce:given-name>Yan</ce:given-name>
                  <ce:surname>Zhong</ce:surname>
                  <ce:cross-ref id="crosref0020" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0025" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523421003743-70e6809c87f0acc045515267f91a6f80">
                  <ce:given-name>Bingbing</ce:given-name>
                  <ce:surname>Li</ce:surname>
                  <ce:cross-ref id="crosref0030" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0035" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523421003743-0af8c4681602da42a8ea35d24b284068">
                  <ce:given-name>Shumin</ce:given-name>
                  <ce:surname>Ouyang</ce:surname>
                  <ce:cross-ref id="crosref0040" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au5" author-id="S0223523421003743-7db26e5290d643f535b08cc60490d052">
                  <ce:given-name>Lin</ce:given-name>
                  <ce:surname>Deng</ce:surname>
                  <ce:cross-ref id="crosref0045" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au6" author-id="S0223523421003743-978f3a830b6b99ac0ff0df22a5415362">
                  <ce:given-name>Jianshan</ce:given-name>
                  <ce:surname>Mo</ce:surname>
                  <ce:cross-ref id="crosref0050" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au7" author-id="S0223523421003743-40f6aed47a8d178822d7b4b8d0d1aecf">
                  <ce:given-name>Shuo</ce:given-name>
                  <ce:surname>Shi</ce:surname>
                  <ce:cross-ref id="crosref0055" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au8" author-id="S0223523421003743-ec72f7e8e74f6b79063791dc9265564d">
                  <ce:given-name>Nan</ce:given-name>
                  <ce:surname>Lv</ce:surname>
                  <ce:cross-ref id="crosref0060" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au9" author-id="S0223523421003743-2d088cdafdc374b8df54716f3bbcecbd">
                  <ce:given-name>Ruibo</ce:given-name>
                  <ce:surname>Wu</ce:surname>
                  <ce:cross-ref id="crosref0065" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au10" author-id="S0223523421003743-f4901aad62d1e5dde43c1bbf4d263c4c">
                  <ce:given-name>Peiqing</ce:given-name>
                  <ce:surname>Liu</ce:surname>
                  <ce:cross-ref id="crosref0070" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au11" author-id="S0223523421003743-6ec166574fb71482370fe3bb67afbb72">
                  <ce:given-name>Wenhao</ce:given-name>
                  <ce:surname>Hu</ce:surname>
                  <ce:cross-ref id="crosref0075" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au12" author-id="S0223523421003743-621f02de492ac727d20a4ff7daeb084c">
                  <ce:given-name>Xiaolei</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
                  <ce:cross-ref id="crosref0080" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0085" refid="cor2">
                     <ce:sup loc="post">ââ</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au13" orcid="0000-0001-5650-4396" author-id="S0223523421003743-5b4c8c93ea521dfadd3c3468180e80bc">
                  <ce:given-name>Yuanxiang</ce:given-name>
                  <ce:surname>Wang</ce:surname>
                  <ce:cross-ref id="crosref0090" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0095" refid="cor1">
                     <ce:sup loc="post">â</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523421003743-ee0c5afe0c95bbae2700a7478b445051">
                  <ce:label>a</ce:label>
                  <ce:textfn>Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Guangdong Key Laboratory of Chiral Molecule and Drug Discovery</sa:organization>
                     <sa:organization>School of Pharmaceutical Sciences</sa:organization>
                     <sa:organization>Sun Yat-Sen University</sa:organization>
                     <sa:city>Guangzhou</sa:city>
                     <sa:postal-code>510006</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S0223523421003743-21b56bd54e49c36272e4aa770d66c8db">
                  <ce:label>b</ce:label>
                  <ce:textfn>Guangdong Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Guangdong Key Laboratory of New Drug Design and Evaluation</sa:organization>
                     <sa:organization>School of Pharmaceutical Sciences</sa:organization>
                     <sa:organization>Sun Yat-Sen University</sa:organization>
                     <sa:city>Guangzhou</sa:city>
                     <sa:postal-code>510006</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">Guangdong Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>â</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>ââ</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para id="ntpara0010" view="all">These authors contributed equally.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:date-received day="2" month="3" year="2021"/></ce:date-received>
            <ce:date-revised day="11" month="4" year="2021"/></ce:date-revised>
            <ce:date-accepted day="23" month="4" year="2021"/></ce:date-accepted>
            <ce:abstract id="abs0010" xml:lang="en" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">STAT3 has been validated as an attractive anticancer target due to its important roles in cancer initiation and progression. However, discovery of potent and selective STAT3 small-molecule inhibitors with druglike properties is still challenging. In this study, two series of substituted 2-phenylquinolines and 2-arylimidazo[1,2-a]pyridines were designed through structure-based drug discovery approach by condensing the privileged structures of <ce:bold>STX-119</ce:bold> and <ce:bold>SH4-54</ce:bold>. Our study has resulted in the discovery of a number of highly potent and selective STAT3 inhibitors, exemplified by compound <ce:bold>39</ce:bold> with the privileged structure of 2-phenylimidazo[1,2-a]pyridine, which selectively inhibits phosphorylation of STAT3 and suppresses subsequent signaling pathway. Moreover, <ce:bold>39</ce:bold> inhibits cell growth, migration and invasion of human triple negative breast cancer (TNBC) cells lines. Consistently, it achieves significant and dose-dependent tumor growth inhibition in both cell line-derived and patient-derived xenograft tumor models in mice. These results clearly indicate that <ce:bold>39</ce:bold> is a highly potent and selective STAT3 inhibitor.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text id="alttext0010" role="short">Image 1</ce:alt-text>
                           <ce:link locator="ga1" xlink:href="pii:S0223523421003743/ga1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords id="kwrds0010" xml:lang="en" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>Structure-based drug discovery</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Privileged structures</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>STAT3</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Small-molecule inhibitors</ce:text>
               </ce:keyword>
            </ce:keywords>
            <ce:keywords class="abr" id="kwrds0015" xml:lang="en" view="all">
               <ce:section-title id="sectitle0030">Abbreviations</ce:section-title>
               <ce:keyword id="kwrd0030">
                  <ce:text>STAT3</ce:text>
                  <ce:keyword id="kwrd0035">
                     <ce:text>signal transducer and activator of transcription 3</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0040">
                  <ce:text>pY705</ce:text>
                  <ce:keyword id="kwrd0045">
                     <ce:text>phosphorylated Tyr705</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0050">
                  <ce:text>pSTAT3</ce:text>
                  <ce:keyword id="kwrd0055">
                     <ce:text>phosphorylated STAT3</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0060">
                  <ce:text>PROTAC</ce:text>
                  <ce:keyword id="kwrd0065">
                     <ce:text>proteolysis targeting chimera</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0070">
                  <ce:text>HLM</ce:text>
                  <ce:keyword id="kwrd0075">
                     <ce:text>human liver microsome</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0080">
                  <ce:text>EMSA</ce:text>
                  <ce:keyword id="kwrd0085">
                     <ce:text>Electrophoretic mobility shift assay</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0090">
                  <ce:text>TNBC</ce:text>
                  <ce:keyword id="kwrd0095">
                     <ce:text>triple negative breast cancer</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0100">
                  <ce:text>PI</ce:text>
                  <ce:keyword id="kwrd0105">
                     <ce:text>propidium iodide</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0110">
                  <ce:text>TGI</ce:text>
                  <ce:keyword id="kwrd0115">
                     <ce:text>tumor growth inhibition</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0120">
                  <ce:text>PDX</ce:text>
                  <ce:keyword id="kwrd0125">
                     <ce:text>patient-derived xenograft</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0130">
                  <ce:text>FITC</ce:text>
                  <ce:keyword id="kwrd0135">
                     <ce:text>fluorescein isothiocyanate</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0140">
                  <ce:text>HOAt</ce:text>
                  <ce:keyword id="kwrd0145">
                     <ce:text>1-hydroxy-7-azabenzotriazole</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0150">
                  <ce:text>EDC</ce:text>
                  <ce:keyword id="kwrd0155">
                     <ce:text>N-Ethyl-Nâ²-(3-dimethylaminopropyl)carbodiimide</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0160">
                  <ce:text>DIPEA</ce:text>
                  <ce:keyword id="kwrd0165">
                     <ce:text>N,N-Diisopropylethylamine</ce:text>
                  </ce:keyword>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0035">Introduction</ce:section-title>
                  <ce:para id="p0025" view="all">As a transcription factor, STAT3 transduces extracellular signals to the nucleus and then activates transcription of target genes. Under physiological conditions, it mediates cell proliferation, differentiation, apoptosis, survival, and other important cellular processes in response to stimulation of a large number of cytokines and growth factors [<ce:cross-ref id="crosref0100" refid="bib1">1</ce:cross-ref>,<ce:cross-ref id="crosref0105" refid="bib2">2</ce:cross-ref>]. However, constitutive STAT3 activation has been detected in almost 70% of human solid and hematological tumors, and is generally associated with poor clinical prognosis [<ce:cross-ref id="crosref0110" refid="bib3">3</ce:cross-ref>,<ce:cross-ref id="crosref0115" refid="bib4">4</ce:cross-ref>]. In view of its critical roles in cancer initiation and progression, STAT3 has attracted considerable interest as a potential target in cancer therapy [<ce:cross-refs id="crosrefs0010" refid="bib5 bib6 bib7 bib8 bib9 bib10">5â10</ce:cross-refs>]. On the other hand, aberrant STAT3 activation has been reported to mediate acquired resistance to a broad spectrum of chemotherapies, radiotherapies and targeted therapies, by up-regulating the expression of antiapoptotic proteins and surviving protein (such as Bcl-2, survivin, c-Myc, cyclin-D1, and Mcl-1) and down-regulating tumor suppressor gene (such as p53) [<ce:cross-refs id="crosrefs0015" refid="bib11 bib12 bib13 bib14 bib15">11â15</ce:cross-refs>]. Therefore, inhibition of STAT3 represents a new advance to reverse STAT3-addicted cancer cell resistance. Furthermore, constitutively activated STAT3 is also reported to play critical roles in modulation of tumor microenvironment and immune response through up-regulation of immunosuppressive factors and down-regulation of immune activation factors [<ce:cross-refs id="crosrefs0020" refid="bib16 bib17 bib18">16â18</ce:cross-refs>]. It has been validated that the combination of immune checkpoint inhibitors and STAT3 specific inhibitors can enhance the efficacy of cancer immunotherapy and demonstrates a synergistic antitumor effect [<ce:cross-refs id="crosrefs0025" refid="bib19 bib20 bib21 bib22">19â22</ce:cross-refs>]. Accordingly, the development of potent and selective STAT3 inhibitors has multifaceted applications in cancer therapy and is highly desirable.</ce:para>
                  <ce:para id="p0030" view="all">In the canonical STAT3 signaling pathway, STAT3 is activated by phosphorylation of tyrosine residue 705 (Tyr705) within its Src homology 2 (SH2) domain, followed by forming a homodimer via reciprocal interaction between the phosphorylated Tyr705 (pY705) within one monomer and the SH2 domain of the other. Activated STAT3 homodimers then translocate from the cytoplasm to the nucleus, where they bind to STAT3-specific DNA-response elements and regulate the expression of target genes. As the SH2 domain plays a pivotal role in STAT3 signaling cascade, significant efforts have been made to discover STAT3 inhibitors targeting the SH2 domain. These STAT3 SH2 domain inhibitors consist of small peptidomimetics, natural products and synthetic nonpeptidic small-molecules [<ce:cross-refs id="crosrefs0030" refid="bib1 bib2 bib3 bib4">1â4</ce:cross-refs>]. However, most of these inhibitors suffer from unfavorable cell permeability and druglike properties, or weak to modest binding affinity, highlighting the challenge in developing potent and selective small-molecule STAT3 SH2 domain inhibitors.<ce:sup loc="post">1,2</ce:sup> For instance, the previously discovered peptidomimetic STAT3 SH2 domain inhibitors usually demonstrate high binding affinities to STAT3 in biochemical assays, but display undesired cell permeability and druglike properties [<ce:cross-ref id="crosref0120" refid="bib1">1</ce:cross-ref>]. On the other hand, synthetic nonpeptidic STAT3 SH2 inhibitors as exemplified by the compounds <ce:bold>1</ce:bold>-<ce:bold>5</ce:bold> [<ce:cross-refs id="crosrefs0035" refid="bib23 bib24 bib25 bib26 bib27">23â27</ce:cross-refs>] in <ce:cross-ref id="crosref0125" refid="fig1">Fig.Â 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>, which possess good cell permeability compared to peptidomimetic inhibitors, usually exhibit weak to moderate binding affinities to STAT3.</ce:para>
                  <ce:para id="p0035" view="all">Recently, Wang and coworkers discovered a potent STAT3 degrader <ce:bold>SD-36</ce:bold> (<ce:bold>6</ce:bold>) based upon the proteolysis targeting chimera (PROTAC) concept, by employing a ligand for cereblon/cullin 4A E3 ligase and a peptidomimetic STAT3 SH2 domain inhibitor [<ce:cross-ref id="crosref0130" refid="bib28">28</ce:cross-ref>,<ce:cross-ref id="crosref0135" refid="bib29">29</ce:cross-ref>]. The degrader <ce:bold>SD-36</ce:bold> is capable of effectively and selectively degrading STAT3 protein and exhibits highly potent anticancer activities. However, developing selective and potent nonpeptidic STAT3 SH2 inhibitors which serve as the starting point for discovering STAT3 degraders, may provide more promising clinical candidates with desirable druglike properties.</ce:para>
                  <ce:para id="p0040" view="all">In this context, we performed structure-based drug design approach to facilitate the discovery of highly potent and selective STAT3 small-molecule inhibitors. Two series of novel STAT3 small-molecule inhibitors were designed and synthesized with the privileged structures of 2-phenylquinoline and 2-arylimidazo[1,2-<ce:italic>a</ce:italic>]pyridine, respectively. Further optimization led to the identification of compound <ce:bold>39</ce:bold> as the most promising STAT3 small-molecule inhibitor. Our data demonstrated that compound <ce:bold>39</ce:bold> selectively bound to STAT3 SH2 domain, inhibited STAT3 activation and subsequent signaling pathway, and ultimately suppressed cell growth, migration and invasion of human cancer cell lines. Moreover, compound <ce:bold>39</ce:bold> demonstrated significant and dose-dependent tumor growth inhibition in both cell line-derived and patient derived xenograft tumor models in mice.</ce:para>
               </ce:section>
               <ce:section id="sec2" role="results" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0040">Results and discussion</ce:section-title>
                  <ce:para id="p0045" view="all">
                     <ce:bold>2-Phenylquinoline-based STAT3 inhibitor</ce:bold>. Our drug discovery campaign initiated with two previously reported STAT3 inhibitors, <ce:bold>STX-119</ce:bold> [<ce:cross-ref id="crosref0140" refid="bib23">23</ce:cross-ref>] and <ce:bold>SH4-54</ce:bold> [<ce:cross-ref id="crosref0145" refid="bib25">25</ce:cross-ref>], both of which are selective STAT3 inhibitors and have similar binding mode with the SH2 domain revealed by molecular modeling. Analysis of the X-ray structure of STAT3 SH2 domain (PDB ID: <ce:inter-ref id="intref0010" xlink:href="pdb:1BG1" xlink:type="simple">1BG1</ce:inter-ref>) [<ce:cross-ref id="crosref0150" refid="bib30">30</ce:cross-ref>] suggested that there are three important sub-pockets within the SH2 domain, including pY705 binding site, Leu706 binding site and a side pocket (<ce:cross-ref id="crosref0155" refid="fig2">Fig.Â 2</ce:cross-ref>
                     <ce:float-anchor refid="fig2"/></ce:float-anchor>A). The molecule docking of <ce:bold>STX-119</ce:bold> with STAT3 SH2 domain revealed that 2-phenylquinoline bound to the pY705 binding site alongside the side pocket, and 5-(furan-2-yl)-1,3,4-oxadiazol targeted to the Leu706 sub-pocket (<ce:cross-ref id="crosref0160" refid="fig2">Fig.Â 2</ce:cross-ref>B). Molecule modeling studies on <ce:bold>SH4-54</ce:bold> showed that the salicylic acid group and tosylamide moiety accessed to the pY705 sub-pocket and side pocket, respectively, and cyclohexylphenyl occupied to the Leu706 sub-pocket (<ce:cross-ref id="crosref0165" refid="fig2">Fig.Â 2</ce:cross-ref>C). While these two compounds display modest inhibitory activity against human cancer cell lines [<ce:cross-ref id="crosref0170" refid="bib23">23</ce:cross-ref>,<ce:cross-ref id="crosref0175" refid="bib25">25</ce:cross-ref>], the privileged structures embedded in them attracted our attentions, such as 2-phenylquinoline in <ce:bold>STX-119</ce:bold> and cyclohexylbenzene in <ce:bold>SH4-54</ce:bold>. 2-Phenylquinoline is a well-known privileged structure and has been found to be the core structure of many bioactive substances [<ce:cross-refs id="crosrefs0040" refid="bib31 bib32 bib33 bib34 bib35">31â35</ce:cross-refs>]. Cyclohexylbenzene is also claimed to be a privileged structure due to its common presence in various bioactive compounds [<ce:cross-refs id="crosrefs0045" refid="bib36 bib37 bib38 bib39 bib40">36â40</ce:cross-refs>]. Since cyclohexylphenyl of <ce:bold>SH4-54</ce:bold> was shown to occupy an essentially similar binding pocket as compared to 5-(furan-2-yl)-1,3,4-oxadiazol of <ce:bold>STX-119</ce:bold>, we surmised that fusing cyclohexylphenyl of <ce:bold>SH4-54</ce:bold> with 2-phenylquinoline of <ce:bold>STX-119</ce:bold> would result in identification of novel STAT3 inhibitors with privileged structures and improved potencies. It is important to note that C2-phenyl of <ce:bold>STX-119</ce:bold> bound to the side pocket (<ce:cross-ref id="crosref0180" refid="fig2">Fig.Â 2</ce:cross-ref>B), a specific site for STAT3 over other STAT members which provides structure basis for the high selectivity of <ce:bold>STX-119</ce:bold>. Novel inhibitors derive from 2-phenylquinoline may also display high selectivity for STAT3. Therefore, the initial series of compounds were designed by condensing 4-cyclohexylaniline or (4-cyclohexylphenyl)methanamine with 2-phenylquinoline-4-carboxylic acid and several hydrophilic groups were also incorporated into the C7-positon of quinoline core to modulate their physicochemical characteristics.</ce:para>
                  <ce:para id="p0050" view="all">As an initial screening, the 10 hybrid compounds were evaluated for their cell growth inhibitory activities in the cell viability assays against cancer cell lines which express constitutively active STAT3, including MDA-MB-231 (breast cancer cell line), MGC-803 (gastric cancer cell line) and A549 (non-small cell lung cancer cell line). <ce:bold>SH4-54</ce:bold> and <ce:bold>STX-0119</ce:bold> were included as positive controls and the data are summarized in <ce:cross-ref id="crosref0190" refid="tbl1">TableÂ 1</ce:cross-ref>
                     <ce:float-anchor refid="tbl1"/></ce:float-anchor>, which were comparable to the reported values. Compound <ce:bold>7</ce:bold> was obtained by fusing 4-cyclohexylaniline and 2-phenylquinoline-4-carboxylic acid together, and showed slightly decreased inhibitory activities with IC<ce:inf loc="post">50</ce:inf> values of 10Â Î¼M, 5.9Â Î¼M and 5.8Â Î¼M for MDA-MB-231, MGC-803 and A549, respectively. With the aim of improving the physicochemical characteristics of compound <ce:bold>7</ce:bold>, methoxy group was incorporated at the C7-postion of the quinoline ring and afforded compound <ce:bold>8</ce:bold>, which displayed enhanced potency with IC<ce:inf loc="post">50</ce:inf> values of 5.9Â Î¼M, 4.9Â Î¼M and 4.8Â Î¼M against the three tested cancer cells, respectively. However, incorporation of other hydrophilic groups, including hydroxy (<ce:bold>9</ce:bold>), 2-ethoxy-2-oxoethoxy (<ce:bold>10</ce:bold>) and carboxymethoxy (<ce:bold>11</ce:bold>), at the quinoline C7-postion of compound <ce:bold>7</ce:bold> was not well tolerated and led to completely abolished cell growth inhibitory activity. On the other hand, it seems that the design concept of condensation of (4-cyclohexylphenyl)methanamine with 2-phenylquinoline scaffold was unsuccessful, and the hybrid compounds <ce:bold>12</ce:bold>, <ce:bold>13</ce:bold>, <ce:bold>15</ce:bold> and <ce:bold>16</ce:bold> were found to be completely inactive with IC<ce:inf loc="post">50</ce:inf> values greater than 100Â Î¼M, even though hydroxy substituted quinoline derivative <ce:bold>14</ce:bold> displayed weak cancer cell growth inhibition. It is interesting to note that the structural differences between <ce:bold>13</ce:bold> and <ce:bold>8</ce:bold> are the groups that were designed to access to the Leu706 pocket, 4-cyclohexylbenzylamine for <ce:bold>13</ce:bold> and 4-cyclohexylaniline for <ce:bold>8</ce:bold>. The huge difference in the cellular activity of <ce:bold>13</ce:bold> and <ce:bold>8</ce:bold> revealed that 4-cyclohexylphenylamines is preferred than 4-cyclohexylbenzylamine when 2-phenylquinoline is used as the core structure.</ce:para>
                  <ce:para id="p0055" view="all">Upon the basis of its potent cell growth inhibitory activity and privileged chemical structure, compound <ce:bold>8</ce:bold> was selected as a starting point for further optimization. Before the next round of optimization, compound <ce:bold>8</ce:bold> was first docked to the three hot spots within the SH2 domain to determine whether it has the binding modes as we predicted. The docking result confirmed our proposal and demonstrated that cyclohexylphenyl fragment of compound <ce:bold>8</ce:bold> occupied to the Leu706 sub-pocket (<ce:cross-ref id="crosref0195" refid="fig2">Fig.Â 2</ce:cross-ref>D). Therefore, in an effort to explore the structure-activity relationship (SAR) on this position and to identify more potent STAT3 inhibitors, cyclohexyl of compound <ce:bold>8</ce:bold> was replaced by a diverse of groups, including halogen (<ce:bold>17-19</ce:bold>), alkyl (<ce:bold>20, 22, 23</ce:bold>), alkoxy (<ce:bold>21</ce:bold>), aryl (<ce:bold>24-28</ce:bold>) and heteroaryl (<ce:bold>29-33</ce:bold>).</ce:para>
                  <ce:para id="p0060" view="all">As shown in <ce:cross-ref id="crosref0200" refid="tbl2">TableÂ 2</ce:cross-ref>
                     <ce:float-anchor refid="tbl2"/></ce:float-anchor>, replacement of cyclohexyl group of compound <ce:bold>8</ce:bold> with halogen atoms led to compounds <ce:bold>17</ce:bold>-<ce:bold>19</ce:bold> with significantly decreased potency against the three test cancer lines. Compound <ce:bold>17</ce:bold> displayed very weak inhibitory activity with the IC<ce:inf loc="post">50</ce:inf> values ranging from 15.5Â Î¼M to 25.5Â Î¼M and compounds <ce:bold>18</ce:bold>, <ce:bold>19</ce:bold> were found to be completely inactive with IC<ce:inf loc="post">50</ce:inf> values greater than 50Â Î¼M. The similar tendency was also observed in the series of simple alkyl and alkoxy derivatives <ce:bold>20</ce:bold>-<ce:bold>23</ce:bold>, indicating that the size of the substitution has a significant effect on inhibitory potency. In the series of aryl substituted compounds <ce:bold>24-28</ce:bold>, significant discrepancy in the cellular inhibitory potency was observed. Interestingly, replacement of the cyclohexyl group of <ce:bold>8</ce:bold> with phenyl led to the compound <ce:bold>24</ce:bold>, which exhibited enhanced inhibitory effects with IC<ce:inf loc="post">50</ce:inf> values of 5.3Â Î¼M, 2.6Â Î¼M and 3.0Â Î¼M against the three tested cancer cells, respectively. In contrast, <ce:italic>para</ce:italic>-isopropylphenyl derivative <ce:bold>25</ce:bold> did not show any antiproliferative effects in the three type cancer cells. <ce:italic>Para</ce:italic>-fluorophenyl derivative <ce:bold>26</ce:bold> and <ce:italic>para</ce:italic>-methylthiophenyl derivative <ce:bold>28</ce:bold> displayed slight inhibitory activity against the proliferation of the three tested cancer cells. <ce:italic>Para</ce:italic>-methoxyphenyl derivative <ce:bold>27</ce:bold> exhibited moderate inhibitory activity against MGC-803 and A549Â cells with the IC<ce:inf loc="post">50</ce:inf> values of 5.8 and 4.9Â Î¼M, respectively, but displayed much weaker activity against MDA-MB-231Â cells with the IC<ce:inf loc="post">50</ce:inf> value greater than 20Â Î¼M. In addition to aryl group, compounds with various heteroaryl groups (<ce:bold>29-33</ce:bold>) were also examined. While thiophenyl (<ce:bold>29</ce:bold>), pyridinyl (<ce:bold>30</ce:bold>), and indolyl (<ce:bold>33</ce:bold>), decreased the inhibitory potency, furanyl derivative <ce:bold>31</ce:bold> showed more potent antiproliferative effects against MGC-803Â cells with an IC<ce:inf loc="post">50</ce:inf> value of 2.1Â Î¼M when compared to <ce:bold>8</ce:bold>.</ce:para>
                  <ce:para id="p0065" view="all">Compound <ce:bold>31</ce:bold> also retained the antiproliferative potency against A549Â cells, but exhibited decreased inhibitory activity against the growth of MDA-MB-231Â cells, with IC<ce:inf loc="post">50</ce:inf> values of 5.5Â Î¼M and 10.3Â Î¼M, respectively. Benzofuranyl derivative <ce:bold>32</ce:bold> showed antiproliferative activity comparable to compound <ce:bold>8</ce:bold> against the three tested cancer cell lines with the IC<ce:inf loc="post">50</ce:inf> values of around 5.0Â Î¼M. These results indicate that cyclohexyl group of compound <ce:bold>8</ce:bold> can also be replaced by phenyl, furanyl, or benzofuranyl.</ce:para>
                  <ce:para id="p0070" view="all">
                     <ce:bold>Imidazo[1, 2-<ce:italic>a</ce:italic>]pyridine-based STAT3 inhibitor</ce:bold>. In an effort to identify more potent STAT3 inhibitors with privileged structure, we turned our attention to optimize the 2-phenylquinoline moiety. Further exploration the binding mode of compound <ce:bold>8</ce:bold> in a complex with the STAT3 SH2 domain suggested that the 2-phenylquinoline occupied both the Tyr705 and side pocket as we predicted (<ce:cross-ref id="crosref0205" refid="fig2">Fig.Â 2</ce:cross-ref>D). However, the C2-phenyl group of <ce:bold>8</ce:bold> just located on the threshold of the side pocket, not in the deep of the pocket mainly due to longer distance between C2-phenyl and C4-carbamoyl of quinoline than that between side pocket and Leu706 pocket. We surmised that shortening the distance between C2-phenyl and C4-carbamoyl may enhance the binding affinity with SH2 domain and translate to increased cell growth inhibitory activity. To test this hypothesis, compound <ce:bold>34</ce:bold> was designed and synthesized by replacing the 2-phenylquinoline with 2-phenylimidazo[1,2-<ce:italic>a</ce:italic>]pyridine, which is also defined as a privileged structure and represents one of the most important structural fragments for new drug discovery (<ce:cross-ref id="optqKbTXrcj7S" refid="fig3">Fig.Â 3</ce:cross-ref>
                     <ce:float-anchor refid="fig3"/></ce:float-anchor>) [<ce:cross-refs id="crosrefs0050" refid="bib41 bib42 bib43 bib44 bib45">41â45</ce:cross-refs>]. Unfortunately, compound <ce:bold>34</ce:bold> showed no inhibitory activity on cancer cell proliferation. We hypothesized that the abolished activity of compound <ce:bold>34</ce:bold> could be largely attributed to its torsion force derived from a repulsive interaction between the oxygen of C3- carbamoyl and the hydrogen at the C-2â position of C2-phenyl. To address this issue, compound <ce:bold>35</ce:bold> was prepared by adding a methylene linker between 3-carbamoyl and the imidazo[1,2-<ce:italic>a</ce:italic>]pyridine core structure with the aim of eliminating the torsion force of compound <ce:bold>34</ce:bold> (<ce:cross-ref id="optzJnoobKL3a" refid="fig3">Fig.Â 3</ce:cross-ref>). To our delight, compound <ce:bold>35</ce:bold> recovered cancer cell growth inhibitory activity and exhibited comparable ability as compared to <ce:bold>8</ce:bold>. Next, a number of control compounds were designed and synthesized to test the essentiality of our new core structure. As showed in <ce:cross-ref id="crosref0210" refid="tbl3">TableÂ 3</ce:cross-ref>
                     <ce:float-anchor refid="tbl3"/></ce:float-anchor>, both biphenyl derivative <ce:bold>36</ce:bold> and 4-(furan-2-yl)phenyl derivative <ce:bold>37</ce:bold> displayed similar tendency as in <ce:bold>24</ce:bold> and <ce:bold>31</ce:bold>. Furthermore, we replaced 4-cyclohexylphenyl of compound <ce:bold>35</ce:bold> with benzo[<ce:italic>b</ce:italic>]thiophene-1,1-dioxide, which is reported to be a pharmacophore model for the inhibition of STAT3 and predicted to bind to the SH2 domain [<ce:cross-refs id="crosrefs0055" refid="bib46 bib47 bib48 bib49 bib50">46â50</ce:cross-refs>]. Surprisingly, the desired compound <ce:bold>38</ce:bold> showed good inhibitory activity against the three test cancer cell lines with IC<ce:inf loc="post">50</ce:inf> values of 1.2Â Î¼M, 1.5Â Î¼M and 1.1Â Î¼M, respectively. In view of the structural novelty and high potency, we selected compound <ce:bold>38</ce:bold> as our lead STAT3 inhibitor for further structural optimization.</ce:para>
                  <ce:para id="p0075" view="all">First, we fixed the phenyl group at the C-2 position of imidazo[1,2-a]pyridine and then examined effect on the inhibitory potency with various substituents on the pyridine scaffold. As described in <ce:cross-ref id="crosref0215" refid="tbl4">TableÂ 4</ce:cross-ref>
                     <ce:float-anchor refid="tbl4"/></ce:float-anchor>, removal of the C-7 methoxy in <ce:bold>38</ce:bold> afforded compound <ce:bold>39</ce:bold> exhibiting comparable antiproliferative activity with IC<ce:inf loc="post">50</ce:inf> values of around 1.0Â Î¼M. Replacement of C-7 methoxy with halogen atoms, such as chlorine (<ce:bold>40</ce:bold>) and bromine (<ce:bold>41</ce:bold>) was tolerated, especially for <ce:bold>41</ce:bold> displaying submicromolar inhibitory activity against the three cancer cell lines. The C-7 methyl derivative <ce:bold>42</ce:bold> also showed good activity. Moving the methoxy from C7 position to C8 (<ce:bold>43</ce:bold>) and C6 (<ce:bold>44</ce:bold>) position of imidazo[1,2-a]pyridine led to slightly decreased inhibitory activity as compared to <ce:bold>38</ce:bold>. Installation of the bromo group at the C-6 position of imidazo[1,2-a]pyridine afforded <ce:bold>45</ce:bold> displaying less potent anticancer activity against MDA-MB-231 and MGC-803Â cells than <ce:bold>41</ce:bold>, but retaining potency against A549Â cells. These results implied that the C-7 position of imidazo[1,2-a]pyridine may be a favorable spot for further optimization. Therefore, larger groups such as aryl or heteroaryl group were included in compounds <ce:bold>46</ce:bold>-<ce:bold>48</ce:bold>, and significant discrepancy in cell growth inhibitory activity was observed. For instance, C7-phenyl derivative <ce:bold>46</ce:bold> showed slightly weaker activity than <ce:bold>38</ce:bold>. In contrast, C7-<ce:italic>para</ce:italic>-methoxyphenyl derivative <ce:bold>47</ce:bold> recovered the potency against the three test cancer cell lines. Surprisingly, pyrazol derivative <ce:bold>48</ce:bold> also displayed good potency with submicromolar inhibitory activity against MGC-803 and A549Â cells.</ce:para>
                  <ce:para id="p0080" view="all">Afterwards, with imidazo[1,2-a]pyridine core structure substituted with C7 methoxy group, we explored the effect of various substitutions of the C2 phenyl ring in compound <ce:bold>38</ce:bold> on inhibitory activity. The para-substituted phenyl derivatives (<ce:bold>49-52</ce:bold>) were firstly explored. The fluoro derivative <ce:bold>49</ce:bold> exhibited good inhibitory activity against MGC-803Â cells and A549Â cells, but showed a decreased potency against MDA-MB-231Â cells with an IC<ce:inf loc="post">50</ce:inf> value greater than 5Â Î¼M. However, compound <ce:bold>50</ce:bold> bearing a trifluoromethyl demonstrated significantly increased potency against the three tested cancer cells with IC<ce:inf loc="post">50</ce:inf> values of 0.7Â Î¼M, 0.4Â Î¼M and 0.4Â Î¼M, respectively, which is the most active compound in this study, probably due to the strong hydrophobic nature of the trifluoromethyl group. To test this hypothesis, we investigated the antiproliferative effects of low hydrophobic or high hydrophilic groups, such as nitro (<ce:bold>51</ce:bold>) and methylsulfonyl (<ce:bold>52</ce:bold>). Nitro derivative <ce:bold>51</ce:bold> demonstrated weaker inhibitory activity than <ce:bold>38</ce:bold>. The high hydrophilic methylsulfonyl substituted <ce:bold>53</ce:bold> showed significantly reduced anticancer activity against all tested cancer cells with IC<ce:inf loc="post">50</ce:inf> values greater than 5Â Î¼M. Next, replacement of C-2 phenyl with thiophenyl (<ce:bold>53</ce:bold>) and naphthalenyl (<ce:bold>54</ce:bold>) were also investigated, and it was revealed that both compounds showed good antiproliferation activity with IC<ce:inf loc="post">50</ce:inf> values of around 1.0Â Î¼M. In addition, compounds <ce:bold>55</ce:bold>-<ce:bold>57</ce:bold> were also designed with a core structure of C6-methylated imidazo[1,2-a]pyridine, a privileged structure derived from the drug Zolpidem.<ce:sup loc="post">51</ce:sup> The three compounds demonstrated moderate to high cell growth inhibitory activity against the tested three cancer cell lines with IC<ce:inf loc="post">50</ce:inf> values ranging from 0.9Â Î¼M to 2.5Â Î¼M. Removing C6-methyl from compound <ce:bold>55</ce:bold> afforded compound <ce:bold>58</ce:bold>, resulting in less potent activity. Methylsulfonyl <ce:bold>59</ce:bold> and nitro <ce:bold>60</ce:bold> exhibited similar tendency as in compounds <ce:bold>52</ce:bold> and <ce:bold>51</ce:bold>. However, it should be noted that removal of C-2 phenyl group from imidazo[1,2-a]pyridine was not tolerated and led to dramatically decreased potency with IC<ce:inf loc="post">50</ce:inf> values greater than 20Â Î¼M for compound <ce:bold>61</ce:bold> as compared to compound <ce:bold>39</ce:bold>.</ce:para>
                  <ce:para id="p0085" view="all">
                     <ce:bold>
                        <ce:italic>InÂ vitro</ce:italic> metabolic stability assessment</ce:bold>. Based on the antiproliferative activity mentioned above as well as the solubility observed in the preparation, compound <ce:bold>38</ce:bold>, <ce:bold>39</ce:bold> and <ce:bold>50</ce:bold> were selected out for <ce:italic>inÂ vitro</ce:italic> metabolic stability study in human liver microsome (HLM). As shown in <ce:cross-ref id="crosref0220" refid="tbl5">TableÂ 5</ce:cross-ref>
                     <ce:float-anchor refid="tbl5"/></ce:float-anchor>, compound <ce:bold>38</ce:bold> and <ce:bold>50</ce:bold> exhibited poor stability in HLM with the <ce:italic>T</ce:italic>
                     <ce:inf loc="post">1/2</ce:inf> of 10.1Â min and 4.4Â min, respectively, while compound <ce:bold>39</ce:bold> offered an improved microsomal stability in HLM with the <ce:italic>T</ce:italic>
                     <ce:inf loc="post">1/2</ce:inf> of 24.2Â min. Taken together, compound <ce:bold>39</ce:bold> showed the best combination of microsomal stability and cell growth inhibitory potency, and was selected for further evaluation.</ce:para>
                  <ce:para id="p0090" view="all">
                     <ce:bold>Compound 39 directly bound to STAT3 protein</ce:bold>. To confirm a direct interaction between compound <ce:bold>39</ce:bold> and STAT3, a surface plasmon resonance (SPR) assay was performed, for which purified STAT3 was immobilized on CM5 sensor chips. As shown in <ce:cross-ref id="crosref0230" refid="fig4">Fig.Â 4</ce:cross-ref>
                     <ce:float-anchor refid="fig4"/></ce:float-anchor>, compound <ce:bold>39</ce:bold> exhibited high binding affinity with STAT3 with an equilibrium dissociation constant (K<ce:inf loc="post">D</ce:inf>) value of 0.432Â Î¼M, indicating that compound <ce:bold>39</ce:bold> directly binds to the STAT3 protein and might therefore block its activation via inhibition of STAT3 phosphorylation at Tyr705.</ce:para>
                  <ce:para id="p0095" view="all">
                     <ce:bold>Compound 39 selectively inhibited STAT3 Tyr705 phosphorylation</ce:bold>. To evaluate the effect of compound <ce:bold>39</ce:bold> on inhibiting phosphorylation of STAT3, we performed western blotting assays to detect the protein levels of phosphorylated STAT3 (pSTAT3) and total STAT3 in triple negative breast cancer (TNBC) cell lines with constitutively activated STAT3, including MDA-MB-231, MDA-MB-468, HCC70 and MDA-MB231-4175. Western blotting assays showed that compound <ce:bold>39</ce:bold> inhibited STAT3 phosphorylation at Tyr705 in a dose-dependent manner in these four cell lines, but had no effect on the total STAT3 (<ce:cross-ref id="crosref0235" refid="fig5">Fig.Â 5</ce:cross-ref>
                     <ce:float-anchor refid="fig5"/></ce:float-anchor>A), indicating that the reduced pSTAT3 levels did not dependent on the total level of STAT3 protein. In addition, we also evaluated the ability of compound <ce:bold>39</ce:bold> to inhibit STAT3 phosphorylation at Ser727, which also contributes to the transcriptional activity of STAT3. It was revealed that compound <ce:bold>39</ce:bold> slightly suppressed phosphorylation of Ser727 compared to Tyr705 in MDA-MB-231 and MDA-MB-231-4175Â cells at 3Â Î¼M, and did not inhibit Ser727 phosphorylation in MDA-MB-468 and HCC cells at 3Â Î¼M. These results suggest that compound <ce:bold>39</ce:bold> mainly binds to STAT3 SH2 domain as we designed.</ce:para>
                  <ce:para id="p0100" view="all">To address the selectivity of compound <ce:bold>39</ce:bold> among STAT isoforms, we further investigated the effects of compound <ce:bold>39</ce:bold> on phosphorylation of STAT1 and STAT5. As shown in <ce:cross-ref id="crosref0240" refid="fig5">Fig.Â 5</ce:cross-ref>B, compound <ce:bold>39</ce:bold> did not affect the total or phosphorylated levels of STAT1 and STAT5 in MDA-MB-231 and HCC cells even at the concentration of 3Â Î¼M, indicating that compound <ce:bold>39</ce:bold> selectively inhibits STAT3 over STAT1 and STAT5.</ce:para>
                  <ce:para id="p0105" view="all">
                     <ce:bold>Compound 39 significantly inhibited STAT3 dimerization</ce:bold>. Activated STAT3 proteins form a homodimer via reciprocal interaction between pY705 within one monomer and the SH2 domian of the other. To validate whether compound <ce:bold>39</ce:bold> disrupts STAT3 dimerization, HEK-293T cells were transfected with Flag-tagged STAT3 and HA-tagged STAT3 for co-localization and co-immunoprecipitation studies. HEK-293T cells that stably co-express HA-STAT3 and Flag-STAT3 were treated with compound <ce:bold>39</ce:bold> and DMSO as the solvent control. Then the cells were processed for immunofluorescence staining for Flag-STAT3 (red) and HA-STAT3 (green) and analyzed by confocal microscopy. As shown in <ce:cross-ref id="crosref0245" refid="fig6">Fig.Â 6</ce:cross-ref>
                     <ce:float-anchor refid="fig6"/></ce:float-anchor>A, the co-location (yellow) of HA-STAT3 and Flag-STAT3 was significantly reduced by compound <ce:bold>39</ce:bold> in a dose-dependent manner, suggesting that dimerization of HA-STAT3 and Flag-STAT3 was disrupted.</ce:para>
                  <ce:para id="p0110" view="all">Next, we treated the HEK-293T cells with compound <ce:bold>39</ce:bold> for immunoprecipitation analysis and revealed that compound <ce:bold>39</ce:bold> dose-dependently inhibited dimerization of HA-STAT3 and Flag-STAT3 after IL-6 stimulation (<ce:cross-ref id="crosref0250" refid="fig6">Fig.Â 6</ce:cross-ref>B). These results further validate that compound <ce:bold>39</ce:bold> binds to the STAT3-SH2 domain and inhibits STAT3 dimerization in intact cells.</ce:para>
                  <ce:para id="p0115" view="all">
                     <ce:bold>Compound 39 inhibited nuclear translocation of pY705-STAT3</ce:bold>. To demonstrate whether compound <ce:bold>39</ce:bold> would inhibit the nuclear translocation of pY705-STAT3, MDA-MB-231 breast cancer cells, which contain constitutively activated STAT3, were treated with either vehicle or compound <ce:bold>39</ce:bold> for 12Â h and then were subjected to immunofluorescence staining by a specific p-STAT3 primary antibody and Alexa Fluor secondary antibody. It was revealed that pY705-STAT3 was localized predominately in the nucleus in the absence of compound <ce:bold>39</ce:bold> (<ce:cross-ref id="crosref0255" refid="fig7">Fig.Â 7</ce:cross-ref>
                     <ce:float-anchor refid="fig7"/></ce:float-anchor>). In contrast, compound <ce:bold>39</ce:bold> treatment inhibited the translocation of pY705-STAT3 to the nucleus in a dose-dependent manner.</ce:para>
                  <ce:para id="p0120" view="all">
                     <ce:bold>Compound 39 inhibited STAT3 DNA-binding and STAT3-dependent transcriptional activation.</ce:bold> After translocation from the cytoplasm to the nucleus, STAT3 dimers bind to STAT3-specific DNA-response elements and activate their transcriptional activity. Therefore, we next evaluated the effects of compound <ce:bold>39</ce:bold> on DNA-binding ability and transcriptional activation of STAT3. Electrophoretic mobility shift assay (EMSA) was first performed to assess whether compound <ce:bold>39</ce:bold> blocks STAT3 DNA-binding activity. As shown in <ce:cross-ref id="crosref0260" refid="fig8">Fig.Â 8</ce:cross-ref>
                     <ce:float-anchor refid="fig8"/></ce:float-anchor>A, compound <ce:bold>39</ce:bold> remarkably decreased the DNA-binding of STAT3 in MDA-MB-231 and MDA-MB-468Â cells at the concentrations of 0.3Â Î¼M and 1Â Î¼M, respectively. However, the DNA-binding of STAT5 was not affected even at 3Â Î¼M. This suggests the preferential potential of compound <ce:bold>39</ce:bold> to inhibit DNA-binding ability of STAT3 over STAT5 in cancer cells.</ce:para>
                  <ce:para id="p0125" view="all">We next investigated whether STAT3-dependent transcriptional activation was disrupted by compound <ce:bold>39</ce:bold> using a luciferase reporter assay. HEK-293T cells were transiently co-transfected with pGL3-STAT3 (a STAT3-responsive promoter-firefly luciferase reporter) and renilla reporter (as normalization control) to act as gene reporter model to examine the effect of compound <ce:bold>39</ce:bold> on STAT3-dependent transcriptional activation. Compared to the control group, the cells treated with 1 or 3Â Î¼M compound <ce:bold>39</ce:bold> for 24Â h had lower luciferase activity (<ce:cross-ref id="crosref0265" refid="fig8">Fig.Â 8</ce:cross-ref>B), indicating that compound <ce:bold>39</ce:bold> inhibits STAT3-dependent transcriptional activity.</ce:para>
                  <ce:para id="p0130" view="all">
                     <ce:bold>Compound 39 downregulated the expression of STAT3 target genes.</ce:bold> In an effort to further provide evidence that compound <ce:bold>39</ce:bold> inhibits STAT3-dependent transcriptional activity, we evaluated the effect of compound <ce:bold>39</ce:bold> on regulating the expression of STAT3 target genes. TNBC cell lines, including MDA-MB-231, MDA-MB-468, HCC70 and MDA-MB-231-4175, were treated with compound <ce:bold>39</ce:bold> for 24Â h, and then were processed for western blotting. <ce:cross-ref id="crosref0270" refid="fig9">Fig.Â 9</ce:cross-ref>
                     <ce:float-anchor refid="fig9"/></ce:float-anchor> shows that compound <ce:bold>39</ce:bold> downregulated the expression of STAT3 target genes, including Bcl-xL, c-Myc and Mcl-1.</ce:para>
                  <ce:para id="p0135" view="all">
                     <ce:bold>Compound 39 inhibited cancer cell proliferation and colony formation.</ce:bold> To further evaluate the antiproliferative activities of compound <ce:bold>39</ce:bold> in cell models, its effects on TNBC cancer cell growth and colony survival were evaluated. MDA-MB-231-4175, MDA-MB-468 and HCC70 containing hyperactivated STAT3 were treated with various concentrations of compound <ce:bold>39</ce:bold> for 72Â h, and subsequently examined by Cell Counting Kit-8. As shown in <ce:cross-ref id="crosref0275" refid="fig10">Fig.Â 10</ce:cross-ref>
                     <ce:float-anchor refid="fig10"/></ce:float-anchor>A, compound <ce:bold>39</ce:bold> concentration-dependently reduced the proliferation of MDA-MB-231-4175, HCC70, and MDA-MB-468Â cells with the IC<ce:inf loc="post">50</ce:inf> values of 2.5Â Î¼M, 1.1Â Î¼M and 2.5Â Î¼M, respectively. Interestingly, <ce:bold>39</ce:bold> showed much weaker growth inhibition in MCF-7 (breast cancer cells without persistent activated STAT3) and normal cells (H9C2: cardiomyocyte) with IC<ce:inf loc="post">50</ce:inf> values of 7.22Â Î¼M and 6.79Â Î¼M, respectively, indicating its selectivity for STAT3 persistently activated cancer cell lines. Furthermore, compound <ce:bold>39</ce:bold> also significantly suppressed the colony formation of MDA-MB-231, MDA-MB-468, MDA-MB-231-4175 (<ce:cross-ref id="crosref0280" refid="fig10">Fig.Â 10</ce:cross-ref>B) and HCC70 (<ce:cross-ref id="crosref0285" refid="appsec1">FigureÂ S1</ce:cross-ref>) at as low as 0.3Â Î¼M concentration.</ce:para>
                  <ce:para id="p0140" view="all">To further demonstrate the specificity of compound <ce:bold>39</ce:bold> on STAT3 signaling pathway in MDA-MB-231Â cells, endogenous STAT3 was knocked down using siRNA. As shown in <ce:cross-ref id="crosref0290" refid="appsec1">FigureÂ S2A</ce:cross-ref>, STAT3 was successfully knocked down by siSTAT3. Cell viability test (<ce:cross-ref id="crosref0295" refid="appsec1">FigureÂ S2B</ce:cross-ref> and <ce:cross-ref id="crosref0300" refid="appsec1">FigureÂ S2C</ce:cross-ref>) revealed that STAT3 siRNA treatment of MDA-MB-231 led to loss of sensitivity to inhibition of <ce:bold>39</ce:bold>, indicating that STAT3 is required for anticancer activity of compound <ce:bold>39</ce:bold>.</ce:para>
                  <ce:para id="p0145" view="all">
                     <ce:bold>Compound 39 induced apoptosis in TNBC cancer cells</ce:bold>. To assess whether the proliferative inhibition induced by compound <ce:bold>39</ce:bold> in cancer cells was attributed to apoptosis [<ce:cross-refs id="crosrefs0060" refid="bib51 bib52 bib53 bib54 bib55">51â55</ce:cross-refs>], TNBC cells were incubated with compound <ce:bold>39</ce:bold>Â at different concentrations for 48Â h. Annexin V-FITC/propidium iodide (PI) staining was performed and the percentages of apoptotic cells were determined by flow cytometry. As shown in <ce:cross-ref id="crosref0305" refid="fig11">Fig.Â 11</ce:cross-ref>
                     <ce:float-anchor refid="fig11"/></ce:float-anchor>A, compound <ce:bold>39</ce:bold> induced apoptosis in MDA-MB-231, MDA-MB-231-4175 and MDA-MB-468Â cells in a dose-dependent manner with the apoptotic percentages of 14.6%, 10.0% and 40.6% at 3Â Î¼M, respectively. To further elucidate the potential mechanisms of apoptosis induced by compound <ce:bold>39</ce:bold>, several proteins as markers of apoptosis were determined by western blotting. As shown in <ce:cross-ref id="crosref0310" refid="fig11">Fig.Â 11</ce:cross-ref>B, cleavage of PARP and caspase 7 was induced after treatment of compound <ce:bold>39</ce:bold>Â at 1Â Î¼M in MDA-MB-231-4175 and MDA-MB-468Â cells and at 3Â Î¼M in MDA-MB-231Â cells, suggesting that compound <ce:bold>39</ce:bold> induces the apoptosis in TNBC cells at least partially through increasing the expression of cleaved-PARP and cleaved-caspase7.</ce:para>
                  <ce:para id="p0150" view="all">
                     <ce:bold>Compound 39 inhibited cancer cell migration and invasion.</ce:bold> Constitutively activated STAT3 is also reported to be correlated with cancer cell migration and invasion, which contribute to cancer metastasis and lead to poor patient survival. Therefore, compound <ce:bold>39</ce:bold> was also investigated for its effects on cancer cell migration and invasion in wound healing and transwell assays. In the wound healing assay, MDA-MB-231, MDA-MB-468, MDA-MB-231-4175 and HCC70Â cells were treated with compound <ce:bold>39</ce:bold>Â at the indicated concentrations for 12â96Â h. As shown in <ce:cross-ref id="crosref0315" refid="fig12">Fig.Â 12</ce:cross-ref>
                     <ce:float-anchor refid="fig12"/></ce:float-anchor>A, the cells migrated to fill the scratched area in the absence of compound <ce:bold>39</ce:bold>, whereas compound <ce:bold>39</ce:bold> treatment prevented this migration dose-dependently. Next, the ability of compound <ce:bold>39</ce:bold> to inhibit invasion was evaluated in transwell assay. As shown in <ce:cross-ref id="crosref0320" refid="fig12">Fig.Â 12</ce:cross-ref> B, compound <ce:bold>39</ce:bold> inhibited invasion in MDA-MB-231, MDA-MB-231-4175, HCC70 and MDA-MB-468Â cells in a dose-dependent manner. Together, these results imply that compound <ce:bold>39</ce:bold> inhibits migration and invasion of cancer cells <ce:italic>inÂ vitro</ce:italic>.</ce:para>
                  <ce:para id="p0155" view="all">
                     <ce:bold>
                        <ce:italic>InÂ vivo</ce:italic> Pharmacokinetic Properties of compound 39</ce:bold>. As compound <ce:bold>39</ce:bold> exhibited high potency <ce:italic>inÂ vitro</ce:italic>, the pharmacokinetic (PK) profiles were next evaluated in male SD rats after oral administration at 10Â mg/kg (<ce:cross-ref id="optIGCkVPV0Cv" refid="tbl6">TableÂ 6</ce:cross-ref>
                     <ce:float-anchor refid="tbl6"/></ce:float-anchor>). Compound <ce:bold>39</ce:bold> exhibited a quick oral absorption (T<ce:inf loc="post">max</ce:inf>Â =Â 1.67Â h) with short half-life (T<ce:inf loc="post">1/2</ce:inf>Â =Â 1.67Â h). The maximum plasma concentration (<ce:italic>C</ce:italic>
                     <ce:inf loc="post">max</ce:inf>) was determined to be 23.8Â ng/mL and small area under the curve (AUC) values were also observed.</ce:para>
                  <ce:para id="p0160" view="all">
                     <ce:bold>Compound 39 exhibited antitumor activity <ce:italic>inÂ vivo</ce:italic>
                     </ce:bold>. Upon the basis of the promising <ce:italic>inÂ vitro</ce:italic> profile of the STAT3 inhibitor compound <ce:bold>39</ce:bold>, we then evaluated its anticancer efficacy <ce:italic>inÂ vivo</ce:italic>. First, the <ce:italic>inÂ vivo</ce:italic> antitumor effect of compound <ce:bold>39</ce:bold> was performed in the MDA-MB-231-4175 xenograft model in mice via intraperitoneal injection every day for 20 consecutive days. As shown in <ce:cross-ref id="crosref0325" refid="fig13">Fig.Â 13</ce:cross-ref>
                     <ce:float-anchor refid="fig13"/></ce:float-anchor>, compound <ce:bold>39</ce:bold> inhibited tumor growth in a dose-dependent manner as measured by tumor volume (<ce:cross-ref id="crosref0330" refid="fig13">Fig.Â 13</ce:cross-ref>A) and weight (<ce:cross-ref id="crosref0335" refid="fig13">Fig.Â 13</ce:cross-ref>C), with tumor growth inhibition (TGI) of 20.1% at 5Â mg/kg and 40.2% at 15Â mg/kg. Meanwhile, compound <ce:bold>39</ce:bold> was found to be well tolerated and showed no apparent body weight loss during the treatment (<ce:cross-ref id="crosref0340" refid="fig13">Fig.Â 13</ce:cross-ref>B). Compound <ce:bold>39</ce:bold> was also evaluated for its effects on the tumor mitotic index (Ki67) and the STAT3 signaling in MDA-MB-231-4175 tumor tissues by immunohistochemistry analysis and western blotting. It was revealed that the expression of Ki67 was significantly reduced in compound <ce:bold>39</ce:bold>-treated groups compared to control group (<ce:cross-ref id="crosref0345" refid="fig13">Fig.Â 13</ce:cross-ref>D), suggesting that the number of the proliferating tumor cells was significantly decreased and tumor progression was slowed down in the mice after treatment of compound <ce:bold>39</ce:bold>. Afterwards, the expression of pY705-STAT3, STAT3, Bcl-xL and Mcl-1 in the tumor tissue was examined by western blotting. Compound <ce:bold>39</ce:bold> apparently reduced the level of pY705-STAT3 and subsequently downregulated the expression of STAT3 target genes Bcl-xL and Mcl-1 as shown in <ce:cross-ref id="crosref0350" refid="fig13">Fig.Â 13</ce:cross-ref>E. It is also noteworthy that no morphological change was observed in heart, liver, spleen, lung and kidney tissues for compound <ce:bold>39</ce:bold> treatment groups in HE staining (<ce:cross-ref id="crosref0355" refid="fig13">Fig.Â 13</ce:cross-ref>F). These results suggested that compound <ce:bold>39</ce:bold> inhibits the growth of MDA-MB-231-4175 xenograft tumor <ce:italic>inÂ vivo</ce:italic> through inhibiting the STAT3 signaling pathway and shows no obvious toxicity.</ce:para>
                  <ce:para id="p0165" view="all">Next, the antitumor efficacy of compound <ce:bold>39</ce:bold> was assessed in TNBC patient-derived xenograft (PDX) model in mice. The PDX model was performed in NOD/SCID mice and the mice were treated with compound <ce:bold>39</ce:bold> via intraperitoneal administration for 20 days with 5Â mg/kg or 15Â mg/kg per day. As shown in <ce:cross-ref id="crosref0360" refid="fig14">Fig.Â 14</ce:cross-ref>
                     <ce:float-anchor refid="fig14"/></ce:float-anchor>, compound <ce:bold>39</ce:bold> exhibited enhanced antitumor effects in the PDX model compared to that in the MDA-MB-231-4175 xenograft model (<ce:cross-ref id="crosref0365" refid="fig14">Fig.Â 14</ce:cross-ref>A and C), with TGI of 32.7% at 5Â mg/kg and 68.9% at 15Â mg/kg. The expression of Ki67 in the tumor tissues was also decreased in the compound <ce:bold>39</ce:bold> treatment groups in immunohistochemistry assay (<ce:cross-ref id="crosref0370" refid="fig14">Fig.Â 14</ce:cross-ref>D), which is similar to that in MDA-MB-231-4175 xenograft mice model. The immunoblotting results showed that compound <ce:bold>39</ce:bold> reduced the level of pY705-STAT3 and STAT3 target genes including Bcl-xL and Mcl-1 (<ce:cross-ref id="crosref0375" refid="fig14">Fig.Â 14</ce:cross-ref>E), while HE staining analysis displayed that no morphological change was observed in heart, liver, spleen, lung and kidney tissues in compound <ce:bold>39</ce:bold> treatment groups (<ce:cross-ref id="crosref0380" refid="fig14">Fig.Â 14</ce:cross-ref>F). Moreover, no apparent body weight loss (<ce:cross-ref id="crosref0385" refid="fig14">Fig.Â 14</ce:cross-ref>B) or other obvious signs of toxicity, such as loss of appetite, decreased activity, or lethargy were observed during the studies. Taken together, compound <ce:bold>39</ce:bold> inhibited STAT3 signaling and tumor growth in animal studies with no obvious toxicity <ce:italic>inÂ vivo</ce:italic>.</ce:para>
                  <ce:para id="p0170" view="all">To compare the <ce:italic>inÂ vivo</ce:italic> antitumor efficacy between compound <ce:bold>39</ce:bold> and the positive controls, <ce:bold>SH4-54</ce:bold> and <ce:bold>STX-119</ce:bold>, we further evaluated these three compounds in TNBC PDX model in mice for 20 days at 15Â mg/kg per day via intraperitoneal administration. As shown in <ce:cross-ref id="crosref0390" refid="appsec1">FigureÂ S3</ce:cross-ref>, compound <ce:bold>39</ce:bold> exhibited more potent <ce:italic>inÂ vivo</ce:italic> efficacy than <ce:bold>STX-119</ce:bold> and <ce:bold>SH4-54</ce:bold> (<ce:cross-ref id="crosref0395" refid="appsec1">FigureÂ S3A, B, C</ce:cross-ref>) with TGI of 85.1%, 63.6% and 414.8%, respectively. No apparent body weight loss (<ce:cross-ref id="crosref0400" refid="appsec1">FigureÂ S3D</ce:cross-ref>) was observed during the studies. Moreover, Compound <ce:bold>39</ce:bold> also showed more potent activity in reduction of the level of pY705-STAT3 and subsequent downregulation of the expression of STAT3 target genes c-Myc and Bcl-xL as shown in <ce:cross-ref id="crosref0405" refid="appsec1">FigureÂ S3E</ce:cross-ref>.</ce:para>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0045">Chemistry</ce:section-title>
                     <ce:para id="p0175" view="all">As shown in <ce:cross-ref id="crosref0410" refid="sch1">Scheme 1</ce:cross-ref>
                        <ce:float-anchor refid="sch1"/></ce:float-anchor>, condensation of acids <ce:bold>62a-c</ce:bold> with 4-cyclohexylaniline <ce:bold>63a</ce:bold> or (4-cyclohexylphenyl)methanamine <ce:bold>63b</ce:bold> afforded amides <ce:bold>7-9</ce:bold> and <ce:bold>12-14</ce:bold>. Among them, hydroxyl <ce:bold>9</ce:bold> and <ce:bold>14</ce:bold> were alkylated with ethyl 2-bromoacetate to provide <ce:bold>10</ce:bold> and <ce:bold>15</ce:bold>, followed by hydrolysis under alkaline condition to give carboxylic acid <ce:bold>11</ce:bold> and <ce:bold>16</ce:bold>.</ce:para>
                     <ce:para id="p0180" view="all">As illustrated in <ce:cross-ref id="crosref0415" refid="sch2">Scheme 2</ce:cross-ref>
                        <ce:float-anchor refid="sch2"/></ce:float-anchor>, acid <ce:bold>62b</ce:bold> was condensed with substituted amines <ce:bold>64a-q</ce:bold> to afford amides <ce:bold>17-27</ce:bold>. On the other hand, amide <ce:bold>17</ce:bold> underwent SuzukiâMiyaura coupling reaction with suitable arylboronic acids to give amides <ce:bold>28-33.</ce:bold>
                     </ce:para>
                     <ce:para id="p0185" view="all">As shown in <ce:cross-ref id="crosref0420" refid="sch3">Scheme 3</ce:cross-ref>
                        <ce:float-anchor refid="sch3"/></ce:float-anchor>, 2-aminepyridine <ce:bold>65</ce:bold> was condensed with ketone <ce:bold>66</ce:bold> to yield ester <ce:bold>67</ce:bold>, which was then hydrolyzed to acid <ce:bold>68</ce:bold>. Acid <ce:bold>68</ce:bold> was coupled with aniline <ce:bold>63a</ce:bold> to provide amide <ce:bold>34</ce:bold>.</ce:para>
                     <ce:para id="p0190" view="all">Imidazo[1,2-a]pyridine <ce:bold>69</ce:bold> was alkylated with ethyl diazoacetate in the presence of a Rh(II) catalyst to give ester <ce:bold>70</ce:bold> as we reported previously [<ce:cross-ref id="crosref0425" refid="bib56">56</ce:cross-ref>], which was then subjected to hydrolysis and condensation with various amine to afford amides <ce:bold>35-38</ce:bold> (<ce:cross-ref id="crosref0430" refid="sch4">Scheme 4</ce:cross-ref>
                        <ce:float-anchor refid="sch4"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0195" view="all">Recently, a novel synthetic route was developed to prepare esters <ce:bold>73a-u</ce:bold> [<ce:cross-ref id="crosref0435" refid="bib51">51</ce:cross-ref>] (<ce:cross-ref id="crosref0440" refid="sch5">Scheme 5</ce:cross-ref>
                        <ce:float-anchor refid="sch5"/></ce:float-anchor>), which were then subjected to hydrolysis and condensation with 6-aminobenzo[<ce:italic>b</ce:italic>]thiophene 1,1-dioxide to afford amides <ce:bold>39-61</ce:bold>.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0050">Conclusions</ce:section-title>
                  <ce:para id="p0200" view="all">In summary, we performed structure-based drug design approach to facilitate the discovery of novel STAT3 small-molecule inhibitors with desired druglike properties. Starting from the privileged structures in the previously reported STAT3 small-molecule inhibitors, a novel series of substituted 2-phenylquinolines were first designed and evaluated. Then, the core structure of 2-phenylquinoline was optimized to 2-arylimidazo[1,2-a]pyridine based on the molecular docking models. Further extensive optimization led to the identification of highly potent and selective STAT3 inhibitors, exemplified by compound <ce:bold>39</ce:bold> with the core structure of 2-phenylimidazo[1,2-<ce:italic>a</ce:italic>]pyridine. Compound <ce:bold>39</ce:bold> was able to selectively inhibit phosphorylation of STAT3, disrupt STAT3 dimerization, impair its nuclear translocation and DNA-binding ability, thereby downregulate transcriptional activity of STAT3, and ultimately suppress the growth, migration and invasion of human TNBC cells lines. Moreover, compound <ce:bold>39</ce:bold> demonstrated significant and dose-dependent tumor growth inhibition in both cell line-derived and patient derived xenograft tumor models in mice and was more potent than <ce:bold>SH4-54</ce:bold> and <ce:bold>STX-119</ce:bold>. Overall, these studies provide an example that highly potent and selective STAT3 small-molecule inhibitors with privileged structures can be successfully developed and compound <ce:bold>39</ce:bold> with favorable <ce:italic>inÂ vitro</ce:italic> and <ce:italic>inÂ vivo</ce:italic> pharmacological profiles deserves further investigation.</ce:para>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0055">Experimental section</ce:section-title>
                  <ce:para id="p0205" view="all">
                     <ce:bold>Chemical Reagents and General Method</ce:bold>. All commercially available starting materials and solvents are reagent grade and used without further purification. Column chromatography was carried out on silica gel (200â300 mesh) manufactured by Qingdao Haiyang Chemical Group Co., Ltd. Analytical TLC was performed on silica gel plates and visualized under ultraviolet light (254Â nm). <ce:sup loc="post">1</ce:sup>H and <ce:sup loc="post">13</ce:sup>C NMR spectra were recorded on a Broker spectrometer with 400 or 500Â MHz for proton (<ce:sup loc="post">1</ce:sup>H NMR), and 101Â MHz for carbon (<ce:sup loc="post">13</ce:sup>C NMR). Chemical shifts downfield from TMS were expressed in ppm, and the signals are described as br (broad singlet), d (doublet), dd (doublet of doublet), m (multiple), q (quarter), s (singlet), and t (triplet). Coupling constants (<ce:italic>J</ce:italic> values) were given in Hz. HRMS (ESI) and LC-MS (ES) were recorded on SHIMADZU LCMS-IT-TOF mass spectrometer and Thermo TSQ QUANTUM LC-MS spectrometer, respectively. Purity of final compounds was confirmed by analytical HPLC analysis on an Agilent HPLC system. Conditions were as follows: XSelect HSS T3 reversed-phase column (150Â mmÂ ÃÂ 4.60Â mm, 5Â Î¼m); flow rate 1Â mL/min; UV detection at 270 and 254Â nM; gradient: from 70% methanol in 30% water to 95% methanol in 5% water (for compound <ce:bold>1</ce:bold>-<ce:bold>33</ce:bold>) and from 5% methanol in 95% water to 95% methanol in 5% water (for compound <ce:bold>34</ce:bold>-<ce:bold>61</ce:bold>). The purity of all final compounds for biological evaluation was greater than 95%.</ce:para>
                  <ce:para id="p0210" view="all">
                     <ce:bold>N-(4-cyclohexylphenyl)-2-phenylquinoline-4-carboxamide (7).</ce:bold> To a solution of 2-phenylquinoline-4-carboxylic acid <ce:bold>62a</ce:bold> (250Â mg, 1Â mmol) and 4-cyclohexylaniline <ce:bold>63a</ce:bold> (193Â mg, 1.1Â mmol) in anhydrous DMF (5Â mL) were added HOAT (205Â mg, 1.5Â mmol), EDC (148Â mg, 1.5Â mmol) and DIPEA (194Â mg, 1.5Â mmol). The reaction mixture was stirred at room temperature for 4Â h. Then, the mixture was poured into ice water and extracted with ethyl acetate (10Â mLÂ ÃÂ 3). The combined organic layers were washed with brine and dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>. After filtration, the solvent was removed under vacuum and the residue was purified by silica gel column chromatography (CHCl<ce:inf loc="post">3</ce:inf>/MeOHÂ =Â 20 : 1) to afford compound <ce:bold>7</ce:bold> (324Â mg, 80%) as white solid, m.p. 233â235Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.74 (s, 1H), 8.36 (d, <ce:italic>J</ce:italic>Â =Â 7.1Â Hz, 2H), 8.31 (s, 1H), 8.18 (d, <ce:italic>J</ce:italic>Â =Â 8.5Â Hz, 2H), 7.86 (t, <ce:italic>J</ce:italic>Â =Â 7.7Â Hz, 1H), 7.73 (d, <ce:italic>J</ce:italic>Â =Â 8.5Â Hz, 2H), 7.67 (t, <ce:italic>J</ce:italic>Â =Â 7.6Â Hz, 1H), 7.63â7.52 (m, 3H), 7.26 (d, <ce:italic>J</ce:italic>Â =Â 8.5Â Hz, 2H), 1.81 (d, <ce:italic>J</ce:italic>Â =Â 9.3Â Hz, 4H), 1.72 (d, <ce:italic>J</ce:italic>Â =Â 12.4Â Hz, 1H), 1.48â1.34 (m, 4H), 1.33â1.05 (m, 2H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 165.58, 156.32, 148.40, 144.05, 143.64, 138.63, 137.08, 130.80, 130.44, 130.10, 129.42, 127.85, 127.38, 125.58, 123.72, 120.56, 117.23, 43.77, 34.55, 26.84, 26.08; MS (EI) <ce:italic>m/z</ce:italic> 407.21 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">26</ce:inf>N<ce:inf loc="post">2</ce:inf>O (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 407.2118; found 407.2111. HPLC retention time 6.176Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0215" view="all">Compounds <ce:bold>8</ce:bold>-<ce:bold>9</ce:bold> and <ce:bold>12</ce:bold>-<ce:bold>14</ce:bold> were prepared in a similar manner as described for compound <ce:bold>7.</ce:bold>
                  </ce:para>
                  <ce:para id="p0220" view="all">
                     <ce:bold>N-(4-cyclohexylphenyl)-7-methoxy-2-phenylquinoline-4-carboxamide (8).</ce:bold> Yellow solid, 72% yield, m.p. 211â213Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.70 (s, 1H), 8.34 (d, <ce:italic>J</ce:italic>Â =Â 7.1Â Hz, 2H), 8.14 (s, 1H), 8.08 (d, <ce:italic>J</ce:italic>Â =Â 9.1Â Hz, 1H), 7.72 (d, <ce:italic>J</ce:italic>Â =Â 8.0Â Hz, 2H), 7.62â7.48 (m, 4H), 7.31 (d, <ce:italic>J</ce:italic>Â =Â 8.8Â Hz, 1H), 7.24 (d, <ce:italic>J</ce:italic>Â =Â 8.0Â Hz, 2H), 3.98 (s, 3H), 1.80 (d, <ce:italic>J</ce:italic>Â =Â 8.8Â Hz, 4H), 1.71 (d, <ce:italic>J</ce:italic>Â =Â 12.5Â Hz, 1H), 1.51â1.32 (m, 4H), 1.29â1.20 (m, 1H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 165.71, 161.13, 156.56, 150.41, 143.99, 143.37, 138.80, 137.12, 130.31, 129.36, 127.74, 127.35, 126.78, 120.56, 118.77, 115.01, 108.39, 56.08, 43.78, 34.55, 26.85, 26.09; MS (EI) <ce:italic>m/z</ce:italic> 437.22 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">29</ce:inf>H<ce:inf loc="post">28</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 437.2224; found 437.2228. HPLC retention time 6.008Â min, 97.58% pure.</ce:para>
                  <ce:para id="p0225" view="all">
                     <ce:bold>N-(4-cyclohexylphenyl)-7-hydroxy-2-phenylquinoline-4-carboxamide (9).</ce:bold> Yellow solid, 78% yield, m.p. 333â335Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.31 (s, 1H), 9.45 (t, <ce:italic>J</ce:italic>Â =Â 5.8Â Hz, 1H), 8.33 (d, <ce:italic>J</ce:italic>Â =Â 7.3Â Hz, 2H), 8.10 (d, <ce:italic>J</ce:italic>Â =Â 9.1Â Hz, 1H), 7.98 (s, 1H), 7.66 (dt, <ce:italic>J</ce:italic>Â =Â 13.7, 6.9Â Hz, 3H), 7.35 (d, <ce:italic>J</ce:italic>Â =Â 2.2Â Hz, 1H), 7.30 (d, <ce:italic>J</ce:italic>Â =Â 7.9Â Hz, 2H), 7.21 (d, <ce:italic>J</ce:italic>Â =Â 7.9Â Hz, 2H), 7.17 (d, <ce:italic>J</ce:italic>Â =Â 2.3Â Hz, 1H), 2.40 (s, 1H), 1.80â1.74 (m, 4H), 1.58 (d, 1H), 1.40â1.32 (m, 4H), 1.30 (s, 1H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 165.88, 159.53, 156.36, 150.44, 143.92, 143.40, 138.96, 137.15, 130.17, 129.30, 127.69, 127.33, 126.91, 120.51, 117.87, 114.17, 111.16, 43.77, 34.55, 26.84, 26.08; MS (EI) <ce:italic>m/z</ce:italic> 423.20 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">26</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 423.2067; found 423.2066. HPLC retention time 4.213Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0230" view="all">
                     <ce:bold>N-(4-cyclohexylbenzyl)-2-phenylquinoline-4-carboxamide (12).</ce:bold> Yellow solid, 77% yield, m.p.162â164Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 9.36 (s, 1H), 8.32 (d, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 2H), 8.24 (d, <ce:italic>J</ce:italic>Â =Â 8.1Â Hz, 1H), 8.19 (s, 1H), 8.15 (d, <ce:italic>J</ce:italic>Â =Â 8.3Â Hz, 1H), 7.83 (t, <ce:italic>J</ce:italic>Â =Â 7.1Â Hz, 1H), 7.65 (t, <ce:italic>J</ce:italic>Â =Â 7.2Â Hz, 1H), 7.61â7.52 (m, 3H), 7.35 (d, <ce:italic>J</ce:italic>Â =Â 7.2Â Hz, 2H), 7.23 (d, <ce:italic>J</ce:italic>Â =Â 7.3Â Hz, 2H), 4.59 (s, 2H), 1.78 (d, <ce:italic>J</ce:italic>Â =Â 9.4Â Hz, 4H), 1.70 (d, <ce:italic>J</ce:italic>Â =Â 12.3Â Hz, 1H), 1.38 (dd, <ce:italic>J</ce:italic>Â =Â 19.3, 10.5Â Hz, 4H), 1.29â1.14 (m, 2H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 167.10, 156.29, 148.46, 146.83, 143.27, 138.76, 136.81, 130.62, 130.34, 130.05, 129.37, 127.87, 127.61, 127.20, 125.82, 123.94, 117.23, 43.98, 43.02, 34.51, 26.84, 26.08; MS (EI) <ce:italic>m/z</ce:italic> 421.22 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">29</ce:inf>H<ce:inf loc="post">28</ce:inf>N<ce:inf loc="post">2</ce:inf>O (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 421.2274; found 421.2268. HPLC retention time 5.463Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0235" view="all">
                     <ce:bold>N-(4-cyclohexylbenzyl)-7-methoxy-2-phenylquinoline-4-carboxamide (13).</ce:bold> White solid, 80% yield, m.p. 173â175Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 9.34 (t, <ce:italic>J</ce:italic>Â =Â 5.8Â Hz, 1H), 8.30 (d, <ce:italic>J</ce:italic>Â =Â 7.1Â Hz, 2H), 8.15 (d, <ce:italic>J</ce:italic>Â =Â 9.2Â Hz, 1H), 8.02 (s, 1H), 7.56 (q, <ce:italic>J</ce:italic>Â =Â 14.5, 6.9Â Hz, 3H), 7.52 (d, <ce:italic>J</ce:italic>Â =Â 2.3Â Hz, 1H), 7.33 (d, <ce:italic>J</ce:italic>Â =Â 8.0Â Hz, 2H), 7.29 (dd, <ce:italic>J</ce:italic>Â =Â 9.2, 2.6Â Hz, 1H), 7.22 (d, <ce:italic>J</ce:italic>Â =Â 8.1Â Hz, 2H), 4.55 (d, <ce:italic>J</ce:italic>Â =Â 5.8Â Hz, 2H), 3.96 (s, 3H), 2.46 (s, 1H), 1.77 (d, <ce:italic>J</ce:italic>Â =Â 10.7Â Hz, 4H), 1.69 (d, <ce:italic>J</ce:italic>Â =Â 12.4Â Hz, 1H), 1.37 (dd, <ce:italic>J</ce:italic>Â =Â 18.5, 9.7Â Hz, 4H), 1.26â1.23 (m, 1H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 167.22, 161.03, 156.52, 150.45, 146.81, 142.95, 138.90, 136.85, 130.23, 129.32, 127.81, 127.10, 120.30, 118.97, 115.00, 108.31, 56.03, 43.98, 42.98, 34.51, 26.84, 26.08; MS (EI) <ce:italic>m/z</ce:italic> 451.23 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">30</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 451.2380; found 451.2373. HPLC retention time 5.313Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0240" view="all">
                     <ce:bold>N-(4-cyclohexylbenzyl)-7-hydroxy-2-phenylquinoline-4-carboxamide (14).</ce:bold> Yellow solid, 84% yield, m.p. 158â160Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.32 (s, 1H), 9.27 (t, <ce:italic>J</ce:italic>Â =Â 5.8Â Hz, 1H), 8.25 (d, <ce:italic>J</ce:italic>Â =Â 7.3Â Hz, 2H), 8.07 (d, <ce:italic>J</ce:italic>Â =Â 9.1Â Hz, 1H), 7.91 (s, 1H), 7.54 (dt, <ce:italic>J</ce:italic>Â =Â 13.7, 6.9Â Hz, 3H), 7.36 (d, <ce:italic>J</ce:italic>Â =Â 2.2Â Hz, 1H), 7.32 (d, <ce:italic>J</ce:italic>Â =Â 7.9Â Hz, 2H), 7.22 (d, <ce:italic>J</ce:italic>Â =Â 7.9Â Hz, 2H), 7.19 (d, <ce:italic>J</ce:italic>Â =Â 2.3Â Hz, 1H), 4.54 (d, <ce:italic>J</ce:italic>Â =Â 5.7Â Hz, 2H), 2.46 (s, 1H), 1.81â1.74 (m, 4H), 1.68 (d, 1H), 1.42â1.33 (m, 4H), 1.23 (s, 1H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 167.40, 159.42, 156.38, 150.49, 146.80, 142.99, 139.06, 136.88, 130.11, 129.29, 127.89, 127.67, 127.19, 120.23, 118.07, 114.21, 111.08, 43.97, 42.93, 34.51, 26.83, 26.07; MS (EI) <ce:italic>m/z</ce:italic> 437.22 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">29</ce:inf>H<ce:inf loc="post">28</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 437.2224; found 437.2219. HPLC retention time 3.822Â min, 97.91% pure.</ce:para>
                  <ce:para id="p0245" view="all">
                     <ce:bold>N-(4-cyclohexylphenyl)-7-(2-ethoxy-2-oxoethoxy)-2-phenylquinoline-4-carboxamide (10).</ce:bold> To a mixture of compound <ce:bold>9</ce:bold> (210Â mg, 0.5Â mmol) and Cs<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (488Â mg, 1.5Â mmol) in anhydrous DMF was added ethyl bromoacetate (100Â mg, 0.6Â mmol) dropwise. The reaction mixture was stirred at room temperature for 4Â h. Then, the mixture was poured into ice water and extracted with ethyl acetate (10Â mLÂ ÃÂ 3). The combined organic layers were washed with brine and dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>. After filtration, the solvent was removed under vacuum and the residue was purified by silica gel column chromatography (CHCl<ce:inf loc="post">3</ce:inf>/MeOHÂ =Â 20 : 1) to afford compound <ce:bold>10</ce:bold> (193Â mg, 76%) as yellow solid, m.p. 246â248Â Â°C<ce:bold>.</ce:bold> 
                     <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.71 (s, 1H), 8.33 (d, <ce:italic>J</ce:italic>Â =Â 7.1Â Hz, 2H), 8.17 (s, 1H), 8.11 (d, <ce:italic>J</ce:italic>Â =Â 9.2Â Hz, 1H), 7.72 (d, <ce:italic>J</ce:italic>Â =Â 8.4Â Hz, 2H), 7.58 (dd, <ce:italic>J</ce:italic>Â =Â 13.9, 6.2Â Hz, 3H), 7.50 (d, <ce:italic>J</ce:italic>Â =Â 2.6Â Hz, 1H), 7.38 (dd, <ce:italic>J</ce:italic>Â =Â 9.2, 2.6Â Hz, 1H), 7.25 (d, <ce:italic>J</ce:italic>Â =Â 8.5Â Hz, 2H), 5.05 (s, 2H), 4.23 (q, <ce:italic>J</ce:italic>Â =Â 7.1Â Hz, 2H), 1.81 (d, <ce:italic>J</ce:italic>Â =Â 9.2Â Hz, 4H), 1.72 (d, <ce:italic>J</ce:italic>Â =Â 12.4Â Hz, 1H), 1.40 (dd, <ce:italic>J</ce:italic>Â =Â 18.4, 9.9Â Hz, 4H), 1.26â1.25 (m, 2H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.93, 165.64, 159.35, 156.74, 150.08, 144.04, 143.37, 138.70, 137.08, 130.38, 129.38, 127.76, 127.36, 127.01, 120.58, 120.35, 119.10, 115.34, 109.50, 65.34, 61.30, 43.78, 34.55, 26.84, 26.08, 14.55; MS (EI) <ce:italic>m/z</ce:italic> 509.24 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">32</ce:inf>H<ce:inf loc="post">32</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 509.2435; found 509.2439. HPLC retention time 5.227Â min, 98.14% pure.</ce:para>
                  <ce:para id="p0780" view="all">Ethyl 2-((4-((4-cyclohexylbenzyl)carbamoyl)-2-phenylquinolin-7-yl)oxy)acetate (15).</ce:para>
                  <ce:para id="p0250" view="all">Compound <ce:bold>15</ce:bold> was synthesized according to the procedure for the preparation of compound <ce:bold>10</ce:bold>.</ce:para>
                  <ce:para id="p0255" view="all">Starting from derivative <ce:bold>14</ce:bold>, compound <ce:bold>15</ce:bold> was obtained in in 72% yield, m.p. 164â166Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 9.34 (t, <ce:italic>J</ce:italic>Â =Â 5.6Â Hz, 1H), 8.28 (d, <ce:italic>J</ce:italic>Â =Â 7.3Â Hz, 2H), 8.17 (d, <ce:italic>J</ce:italic>Â =Â 9.2Â Hz, 1H), 8.04 (s, 1H), 7.59â7.52 (m, 3H), 7.46 (d, <ce:italic>J</ce:italic>Â =Â 2.1Â Hz, 1H), 7.37 (d, <ce:italic>J</ce:italic>Â =Â 2.2Â Hz, 1H), 7.33 (d, <ce:italic>J</ce:italic>Â =Â 8.0Â Hz, 2H), 7.22 (d, <ce:italic>J</ce:italic>Â =Â 7.9Â Hz, 2H), 5.03 (s, 2H), 4.55 (d, <ce:italic>J</ce:italic>Â =Â 5.6Â Hz, 2H), 4.24â4.18 (m, 2H), 2.50 (s, 1H), 1.81â1.75 (m, 4H), 1.69 (d, <ce:italic>J</ce:italic>Â =Â 12.4Â Hz, 1H), 1.43â1.28 (m, 5H), 1.23 (d, <ce:italic>J</ce:italic>Â =Â 7.0Â Hz, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.93, 167.13, 159.25, 156.71, 150.13, 146.82, 142.95, 138.82, 136.83, 130.30, 129.34, 127.92, 127.21, 120.16, 119.30, 115.35, 109.44, 65.33, 61.28, 43.98, 42.99, 34.51, 26.84, 26.08, 14.55; MS (EI) <ce:italic>m/z</ce:italic> 523.25 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">33</ce:inf>H<ce:inf loc="post">34</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 523.2591; found 523.2599. HPLC retention time 4.725Â min, 99.66% pure.</ce:para>
                  <ce:para id="p0260" view="all">
                     <ce:bold>N-(4-cyclohexylphenyl)-7-(carboxymethoxy)-2-phenylquinoline-4-carboxamide (11).</ce:bold> To a solution of compound <ce:bold>10</ce:bold> (152Â mg, 0.3Â mmol) in MeOH (4Â mL) was added the solution of LiOH.H<ce:inf loc="post">2</ce:inf>O (38Â mg, 0.9Â mmol) in H<ce:inf loc="post">2</ce:inf>O (6Â mL). The reaction mixture was stirred at room temperature for 1Â h. Then the mixture was concentrated in vacuum to 4Â mL and was cooled to 0â4Â Â°C. The resulting solution was acidified to pHÂ =Â 2 with 4Â N HCl and the precipitated solids were collected by filtration and dried to give compound <ce:bold>11</ce:bold> (127Â mg, 88%) as yellow solid<ce:bold>,</ce:bold> m.p. 237â239Â Â°C<ce:bold>.</ce:bold> 
                     <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.73 (s, 1H), 8.34 (d, <ce:italic>J</ce:italic>Â =Â 7.4Â Hz, 2H), 8.16 (s, 1H), 8.10 (d, <ce:italic>J</ce:italic>Â =Â 9.2Â Hz, 1H), 7.73 (d, <ce:italic>J</ce:italic>Â =Â 8.4Â Hz, 2H), 7.59â7.55 (m, 2H), 7.46 (d, <ce:italic>J</ce:italic>Â =Â 2.3Â Hz, 1H), 7.36 (dd, <ce:italic>J</ce:italic>Â =Â 9.2, 2.4Â Hz, 1H), 7.25 (d, <ce:italic>J</ce:italic>Â =Â 8.4Â Hz, 2H), 4.92 (s, 2H), 2.47 (s, 1H), 1.83â1.78 (m, 4H), 1.71 (d, <ce:italic>J</ce:italic>Â =Â 12.6Â Hz, 1H), 1.47â1.33 (m, 5H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 170.38, 165.67, 159.59, 156.64, 150.12, 144.00, 143.36, 138.73, 137.11, 130.34, 129.36, 127.76, 127.35, 126.90, 120.57, 118.97, 115.19, 109.34, 65.41, 43.78, 34.55, 26.85, 26.09; MS (EI) <ce:italic>m/z</ce:italic> 481.24 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">28</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 481.2122; found 481.2144. HPLC retention time 3.815Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0785" view="all">2-((4-((4-cyclohexylbenzyl)carbamoyl)-2-phenylquinolin-7-yl)oxy)acetic acid (16).</ce:para>
                  <ce:para id="p0265" view="all">Compound <ce:bold>16</ce:bold> was synthesized according to the procedure for the preparation of compound <ce:bold>11</ce:bold>. Compound <ce:bold>15</ce:bold> was used to afford compound <ce:bold>16</ce:bold> in 79% yield, m.p. 162â163Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 9.35 (t, <ce:italic>J</ce:italic>Â =Â 5.0Â Hz, 1H), 8.28 (d, <ce:italic>J</ce:italic>Â =Â 7.3Â Hz, 2H), 8.10 (d, <ce:italic>J</ce:italic>Â =Â 9.1Â Hz, 1H), 7.98 (s, 1H), 7.57â7.54 (m, 2H), 7.53â7.50 (m, 1H), 7.33 (d, <ce:italic>J</ce:italic>Â =Â 6.3Â Hz, 4H), 7.28 (d, <ce:italic>J</ce:italic>Â =Â 9.1Â Hz, 1H), 7.23 (d, <ce:italic>J</ce:italic>Â =Â 7.6Â Hz, 2H), 4.57 (s, 2H), 4.55 (d, <ce:italic>J</ce:italic>Â =Â 5.3Â Hz, 2H), 1.91 (s, 1H), 1.80â1.76 (m, 4H), 1.70 (d, <ce:italic>J</ce:italic>Â =Â 12.2Â Hz, 1H), 1.42â1.36 (m, 4H), 1.24 (s, 1H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 170.66, 167.28, 160.04, 156.45, 150.25, 146.80, 142.90, 138.87, 136.85, 130.20, 129.32, 127.89, 127.20, 126.80, 120.50, 118.88, 114.86, 109.18, 66.73, 43.97, 42.96, 34.51, 26.83, 26.07; MS (EI) <ce:italic>m/z</ce:italic> 495.22 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">31</ce:inf>H<ce:inf loc="post">30</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 495.2278; found 495.2270. HPLC retention time 5.044Â min, 98.49% pure.</ce:para>
                  <ce:para id="p0270" view="all">Compounds <ce:bold>17-27</ce:bold> were synthesized according to the procedure for the preparation of compound <ce:bold>7</ce:bold>.</ce:para>
                  <ce:para id="p0275" view="all">
                     <ce:bold>N-(4-bromophenyl)-7-methoxy-2-phenylquinoline-4-carboxamide (17).</ce:bold> Yellow solid, 80% yield, m.p. 212â214Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.96 (s, 1H), 8.36 (d, <ce:italic>J</ce:italic>Â =Â 7.2Â Hz, 2H), 8.20 (s, 1H), 8.08 (d, <ce:italic>J</ce:italic>Â =Â 9.1Â Hz, 1H), 7.82 (d, <ce:italic>J</ce:italic>Â =Â 8.3Â Hz, 2H), 7.64â7.52 (m, 6H), 7.33 (d, <ce:italic>J</ce:italic>Â =Â 8.9Â Hz, 1H), 3.99 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 166.04, 161.16, 156.56, 150.41, 142.88, 138.73, 132.13, 130.35, 129.35, 127.77, 126.71, 122.44, 120.60, 118.63, 116.30, 115.18, 108.41, 56.09; MS (EI) <ce:italic>m/z</ce:italic> 433.05 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">17</ce:inf>BrN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 433.0546; found 433.0544. HPLC retention time 13.237Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0280" view="all">
                     <ce:bold>N-(4-fluorophenyl)-7-methoxy-2-phenylquinoline-4-carboxamide (18).</ce:bold> Yellow solid, 76% yield, m.p. 234â236Â Â°C.<ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 11.05 (s, 1H), 8.37 (d, <ce:italic>J</ce:italic>Â =Â 7.2Â Hz, 2H), 8.20 (s, 1H), 8.11 (d, <ce:italic>J</ce:italic>Â =Â 9.2Â Hz, 1H), 7.90 (dd, <ce:italic>J</ce:italic>Â =Â 8.9, 5.1Â Hz, 2H), 7.60â7.51 (m, 4H), 7.32 (dd, <ce:italic>J</ce:italic>Â =Â 9.2, 2.5Â Hz, 1H), 7.25 (t, <ce:italic>J</ce:italic>Â =Â 8.8Â Hz, 2H), 3.98 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (126Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 165.84, 161.10, 158.96 (d, <ce:italic>J</ce:italic>Â =Â 240Â Hz), 156.57, 150.41, 142.88, 138.81, 135.81, 130.30, 129.33, 127.81, 126.80, 122.38, 120.51, 118.74, 115.85 (d, <ce:italic>J</ce:italic>Â =Â 22.5Â Hz), 115.33, 108.38, 56.08; MS (EI) <ce:italic>m/z</ce:italic> 373.13 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">17</ce:inf>FN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 373.1347; found 373.1351. HPLC retention time 10.037Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0285" view="all">
                     <ce:bold>N-(4-chlorophenyl)-7-methoxy-2-phenylquinoline-4-carboxamide (19).</ce:bold> Yellow solid, 76% yield, m.p. 210â212Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.92 (s, 1H), 8.35 (d, <ce:italic>J</ce:italic>Â =Â 7.1Â Hz, 2H), 8.20 (s, 1H), 8.08 (d, <ce:italic>J</ce:italic>Â =Â 9.2Â Hz, 1H), 7.86 (d, <ce:italic>J</ce:italic>Â =Â 8.8Â Hz, 2H), 7.63â7.52 (m, 4H), 7.48 (d, <ce:italic>J</ce:italic>Â =Â 8.8Â Hz, 2H), 7.32 (dd, <ce:italic>J</ce:italic>Â =Â 9.2, 2.5Â Hz, 1H), 3.98 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 166.03, 161.17, 156.57, 150.43, 142.94, 138.74, 138.30, 130.34, 129.23, 128.24, 127.76, 126.71, 122.06, 120.61, 118.65, 115.13, 108.43, 56.08; MS (EI) <ce:italic>m/z</ce:italic> 389.10 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">17</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 389.1051; found 389.1059. HPLC retention time 12.555Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0290" view="all">
                     <ce:bold>7-Methoxy-2-phenyl-N-(p-tolyl)quinoline-4-carboxamide (20).</ce:bold> Yellow solid, 68% yield, m.p. 209â211Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.71 (s, 1H), 8.36 (d, <ce:italic>J</ce:italic>Â =Â 7.2Â Hz, 2H), 8.16 (s, 1H), 8.09 (d, <ce:italic>J</ce:italic>Â =Â 9.2Â Hz, 1H), 7.71 (d, <ce:italic>J</ce:italic>Â =Â 8.3Â Hz, 2H), 7.61â7.53 (m, 4H), 7.32 (dd, <ce:italic>J</ce:italic>Â =Â 9.2, 2.5Â Hz, 1H), 7.22 (d, <ce:italic>J</ce:italic>Â =Â 8.3Â Hz, 2H), 3.99 (s, 3H), 2.32 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 171.78, 165.72, 161.12, 156.57, 150.41, 143.33, 138.80, 136.85, 133.60, 130.31, 129.66, 129.35, 127.76, 126.79, 120.50, 118.77, 115.04, 108.38, 56.07, 21.03; MS (EI) <ce:italic>m/z</ce:italic> 369.15 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">20</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 369.1598; found 369.1593. HPLC retention time 10.714Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0295" view="all">
                     <ce:bold>7-Methoxy-N-(4-methoxyphenyl)-2-phenylquinoline-4-carboxamide (21).</ce:bold> Yellow solid, 70% yield, m.p. 208â210Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.68 (s, 1H), 8.36 (d, <ce:italic>J</ce:italic>Â =Â 6.8Â Hz, 2H), 8.16 (s, 1H), 8.11 (d, <ce:italic>J</ce:italic>Â =Â 9.0Â Hz, 1H), 7.75 (d, <ce:italic>J</ce:italic>Â =Â 8.1Â Hz, 2H), 7.57 (d, <ce:italic>J</ce:italic>Â =Â 12.5Â Hz, 4H), 7.32 (d, <ce:italic>J</ce:italic>Â =Â 8.8Â Hz, 1H), 6.99 (d, <ce:italic>J</ce:italic>Â =Â 8.1Â Hz, 2H), 3.99 (s, 3H), 3.78 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 165.49, 161.11, 156.31, 150.43, 143.32, 138.84, 132.48, 130.28, 129.34, 127.77, 126.86, 122.10, 120.45, 118.83, 115.10, 114.39, 108.37, 56.06, 55.70; MS(EI) <ce:italic>m/z</ce:italic> 385.15(MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">20</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 385.1547; found 385.1550. HPLC retention time 8.678Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0300" view="all">
                     <ce:bold>N-(4-butylphenyl)-7-methoxy-2-phenylquinoline-4-carboxamide (22).</ce:bold> Yellow solid, 74% yield, m.p. 244â246Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.75 (s, 1H), 8.35 (d, <ce:italic>J</ce:italic>Â =Â 6.8Â Hz, 2H), 8.16 (s, 1H), 8.09 (d, <ce:italic>J</ce:italic>Â =Â 9.1Â Hz, 1H), 7.73 (d, <ce:italic>J</ce:italic>Â =Â 7.9Â Hz, 2H), 7.57 (d, <ce:italic>J</ce:italic>Â =Â 12.7Â Hz, 4H), 7.32 (d, <ce:italic>J</ce:italic>Â =Â 8.7Â Hz, 1H), 7.22 (d, <ce:italic>J</ce:italic>Â =Â 7.7Â Hz, 2H), 3.99 (s, 3H), 2.58 (t, <ce:italic>J</ce:italic>Â =Â 7.1Â Hz, 2H), 1.61â1.52 (m, 2H), 1.38â1.29 (m, 2H), 0.92 (t, <ce:italic>J</ce:italic>Â =Â 7.0Â Hz, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 165.73, 161.10, 156.57, 150.42, 143.23, 138.85, 138.58, 137.08, 130.27, 129.32, 128.97, 127.78, 126.82, 120.56, 118.81, 115.17, 108.39, 56.07, 34.79, 33.71, 22.15, 14.27. MS (EI) <ce:italic>m/z</ce:italic> 411.20(MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">27</ce:inf>H<ce:inf loc="post">26</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 411.2067; found 411.2060. HPLC retention time 17.986min, 100.00% pure.</ce:para>
                  <ce:para id="p0305" view="all">
                     <ce:bold>N-(4-isopropylphenyl)-7-methoxy-2-phenylquinoline-4-carboxamide (23).</ce:bold> Yellow solid, 74% yield, m.p. 260â262Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.72 (s, 1H), 8.34 (d, <ce:italic>J</ce:italic>Â =Â 7.1Â Hz, 2H), 8.15 (s, 1H), 8.08 (d, <ce:italic>J</ce:italic>Â =Â 9.2Â Hz, 1H), 7.73 (d, <ce:italic>J</ce:italic>Â =Â 8.4Â Hz, 2H), 7.63â7.53 (m, 4H), 7.31 (dd, <ce:italic>J</ce:italic>Â =Â 9.2, 2.6Â Hz, 1H), 7.27 (d, <ce:italic>J</ce:italic>Â =Â 8.4Â Hz, 2H), 3.98 (s, 3H), 2.90 (dt, <ce:italic>J</ce:italic>Â =Â 13.9, 6.8Â Hz, 1H), 1.22 (d, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 6H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 165.73, 161.10, 150.41, 144.73, 143.24, 138.84, 137.14, 130.29, 129.33, 127.78, 126.95, 120.64, 120.47, 118.80, 115.15, 108.38, 56.07, 33.45, 24.45; MS (EI) <ce:italic>m/z</ce:italic> 397.19 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">26</ce:inf>H<ce:inf loc="post">24</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 397.1911; found 397.1917. HPLC retention time 13.625Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0310" view="all">
                     <ce:bold>N-([1,1â²-biphenyl]-4-yl)-7-methoxy-2-phenylquinoline-4-carboxamide (24).</ce:bold> Yellow solid, 62% yield, m.p. 213â214Â Â°C.<ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.90 (s, 1H), 8.36 (d, 2H), 8.21 (s, 1H), 8.11 (d, <ce:italic>J</ce:italic>Â =Â 9.2Â Hz, 1H), 7.94 (d, <ce:italic>J</ce:italic>Â =Â 8.6Â Hz, 2H), 7.73 (dd, <ce:italic>J</ce:italic>Â =Â 14.8, 8.1Â Hz, 4H), 7.62â7.54 (m, 4H), 7.48 (t, <ce:italic>J</ce:italic>Â =Â 7.7Â Hz, 2H), 7.38â7.32 (m, 2H), 4.00 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 165.97, 161.17, 156.59, 150.45, 143.21, 140.11, 138.79, 136.25, 130.34, 129.42, 127.77, 127.48, 126.83, 120.87, 120.59, 118.74, 115.10, 108.43, 56.08; MS (EI) <ce:italic>m/z</ce:italic> 431.17 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">29</ce:inf>H<ce:inf loc="post">22</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 431.1754; found 431.1753. HPLC retention time 14.596Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0315" view="all">
                     <ce:bold>N-(4â²-isopropyl-[1,1â²-biphenyl]-4-yl)-7-methoxy-2-phenylquinoline-4-carboxamide (25).</ce:bold> White solid, 70% yield, m.p. 248â250Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.89 (s, 1H), 8.37 (d, <ce:italic>J</ce:italic>Â =Â 7.2Â Hz, 2H), 8.20 (s, 1H), 8.11 (d, <ce:italic>J</ce:italic>Â =Â 9.0Â Hz, 1H), 7.91 (d, <ce:italic>J</ce:italic>Â =Â 7.8Â Hz, 2H), 7.70 (d, <ce:italic>J</ce:italic>Â =Â 7.9Â Hz, 2H), 7.63â7.52 (m, 6H), 7.33 (d, <ce:italic>J</ce:italic>Â =Â 7.7Â Hz, 3H), 3.99 (s, 3H), 2.98â2.87 (m, 1H), 1.24 (d, <ce:italic>J</ce:italic>Â =Â 6.6Â Hz, 6H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 165.91, 161.16, 156.58, 150.43, 147.88, 143.23, 138.78, 138.55, 137.69, 136.28, 130.34, 129.37, 127.77, 127.34, 126.78, 120.84, 120.58, 118.74, 115.08, 108.42, 56.09, 33.57, 24.35; MS (EI) <ce:italic>m/z</ce:italic> 473.22 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">32</ce:inf>H<ce:inf loc="post">28</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 473.2224; found 473.2224. HPLC retention time 15.478Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0320" view="all">
                     <ce:bold>N-(4â²-fluoro-[1,1â²-biphenyl]-4-yl)-7-methoxy-2-phenylquinoline-4-carboxamide (26).</ce:bold> White solid, 66% yield, m.p. 255â257Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.91 (s, 1H), 8.37 (d, <ce:italic>J</ce:italic>Â =Â 7.4Â Hz, 2H), 8.21 (s, 1H), 8.11 (d, <ce:italic>J</ce:italic>Â =Â 9.1Â Hz, 1H), 7.93 (d, <ce:italic>J</ce:italic>Â =Â 8.2Â Hz, 2H), 7.73 (t, <ce:italic>J</ce:italic>Â =Â 9.8Â Hz, 4H), 7.61â7.52 (m, 4H), 7.31 (q, <ce:italic>J</ce:italic>Â =Â 20.1, 10.9Â Hz, 3H), 3.99 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 165.97, 163.17, 161.17, 156.58, 150.43, 143.19, 138.77, 136.61, 135.21, 130.35, 129.37, 128.80, 127.77, 127.44, 126.75, 120.86, 120.60, 118.72, 116.27, 116.10, 115.09, 108.42, 56.09; MS (EI) <ce:italic>m/z</ce:italic> 449.16 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">29</ce:inf>H<ce:inf loc="post">21</ce:inf>FN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 449.1660; found 449.1660. HPLC retention time 14.603Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0325" view="all">
                     <ce:bold>7-Methoxy-N-(4â²-methoxy-[1,1â²-biphenyl]-4-yl)-2-phenylquinoline-4-carboxamide (27).</ce:bold> Yellow solid, 72% yield, m.p. 252â254Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.86 (s, 1H), 8.36 (d, <ce:italic>J</ce:italic>Â =Â 7.0Â Hz, 2H), 8.20 (s, 1H), 8.10 (d, <ce:italic>J</ce:italic>Â =Â 9.2Â Hz, 1H), 7.89 (d, <ce:italic>J</ce:italic>Â =Â 8.7Â Hz, 2H), 7.66 (dd, <ce:italic>J</ce:italic>Â =Â 16.2, 8.7Â Hz, 4H), 7.62â7.52 (m, 4H), 7.33 (dd, <ce:italic>J</ce:italic>Â =Â 9.2, 2.6Â Hz, 1H), 7.09â6.99 (m, 2H), 3.99 (s, 3H), 3.80 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 165.87, 161.16, 159.20, 156.58, 150.42, 143.25, 138.77, 138.15, 136.00, 132.51, 130.34, 129.37, 127.91, 126.83, 120.86, 120.58, 118.73, 115.07, 114.85, 108.41, 56.09, 55.66; MS (EI) <ce:italic>m/z</ce:italic> 461.18 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">24</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 461.1860; found 461.1860. HPLC retention time 14.045Â min, 98.26% pure.</ce:para>
                  <ce:para id="p0330" view="all">
                     <ce:bold>Methoxy-N-(4'-(methylthio)-[1,1â²-biphenyl]-4-yl)-2-phenylquinoline-4-carboxamide (28).</ce:bold> To a mixture of compound <ce:bold>17</ce:bold> (215Â mg, 0.5Â mmol) and K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (207Â mg, 1.5Â mmol) in 1,4-dioxane (4Â mL) and water (1Â mL) was added 4-(methylthio)phenyl boronic acid (100Â mg, 0.6Â mmol). The mixture was degassed before addition of tetrakis(triphenylphosphine)palladium (58Â mg, 0.05Â mmol) under nitrogen atmosphere. The mixture was heated under reflux overnight and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (CHCl<ce:inf loc="post">3</ce:inf>/MeOHÂ =Â 20 : 1) to afford compound <ce:bold>28</ce:bold> (179Â mg, 75%) as white solid, m.p. 239â241Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.89 (s, 1H), 8.39â8.35 (m, 2H), 8.21 (s, 1H), 8.11 (d, <ce:italic>J</ce:italic>Â =Â 9.2Â Hz, 1H), 7.92 (d, <ce:italic>J</ce:italic>Â =Â 8.7Â Hz, 2H), 7.73 (d, <ce:italic>J</ce:italic>Â =Â 8.7Â Hz, 2H), 7.66 (d, <ce:italic>J</ce:italic>Â =Â 8.5Â Hz, 2H), 7.61â7.53 (m, 4H), 7.38â7.32 (m, 3H), 3.99 (s, 3H), 2.52 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 165.92, 161.16, 156.58, 150.42, 143.20, 138.73, 137.63, 136.60, 135.56, 135.12, 130.35, 129.37, 127.77, 127.01, 124.91, 121.04, 120.73, 118.72, 115.09, 108.42, 56.09, 15.22; MS (EI) <ce:italic>m/z</ce:italic> 477.16 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">24</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">2</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 477.1631; found 477.1631. HPLC retention time 14.747Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0335" view="all">Compounds <ce:bold>29-33</ce:bold> were synthesized according to the procedure for the preparation of compound <ce:bold>28</ce:bold>.</ce:para>
                  <ce:para id="p0340" view="all">
                     <ce:bold>7-Methoxy-2-phenyl-N-(4-(thiophen-2-yl)phenyl)quinoline-4-carboxamide (29).</ce:bold> White solid, 63% yield, m.p. 272â274Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.86 (s, 1H), 8.36 (d, <ce:italic>J</ce:italic>Â =Â 7.0Â Hz, 2H), 8.21 (s, 1H), 8.10 (d, <ce:italic>J</ce:italic>Â =Â 9.2Â Hz, 1H), 7.93â7.84 (m, 3H), 7.78 (d, <ce:italic>J</ce:italic>Â =Â 8.7Â Hz, 2H), 7.65 (dd, <ce:italic>J</ce:italic>Â =Â 5.0, 2.9Â Hz, 1H), 7.62â7.51 (m, 5H), 7.33 (dd, <ce:italic>J</ce:italic>Â =Â 9.2, 2.6Â Hz, 1H), 3.99 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 165.87, 161.15, 156.57, 150.42, 143.19, 141.51, 138.77, 138.37, 131.49, 130.34, 129.37, 127.77, 127.54, 126.91, 126.53, 120.76, 120.58, 118.72, 115.09, 108.41, 56.09; MS (EI) <ce:italic>m/z</ce:italic> 437.12 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">27</ce:inf>H<ce:inf loc="post">20</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">2</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 437.1318; found 437.1320. HPLC retention time 13.290Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0345" view="all">
                     <ce:bold>7-Methoxy-2-phenyl-N-(4-(pyridin-3-yl)phenyl)quinoline-4-carboxamide (30).</ce:bold> White solid, 69% yield, m.p. 118â120Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.96 (s, 1H), 8.95 (d, <ce:italic>J</ce:italic>Â =Â 1.9Â Hz, 1H), 8.57 (dd, <ce:italic>J</ce:italic>Â =Â 4.7, 1.5Â Hz, 1H), 8.37 (d, <ce:italic>J</ce:italic>Â =Â 7.0Â Hz, 2H), 8.22 (s, 1H), 8.15â8.07 (m, 2H), 7.97 (d, <ce:italic>J</ce:italic>Â =Â 8.7Â Hz, 2H), 7.82 (d, <ce:italic>J</ce:italic>Â =Â 8.7Â Hz, 2H), 7.64â7.54 (m, 4H), 7.50 (dd, <ce:italic>J</ce:italic>Â =Â 7.9, 4.8Â Hz, 1H), 7.34 (dd, <ce:italic>J</ce:italic>Â =Â 9.2, 2.6Â Hz, 1H), 3.99 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 166.05, 161.18, 156.59, 150.43, 148.69, 147.87, 143.13, 139.45, 138.76, 135.50, 134.17, 133.05, 130.36, 129.37, 127.74, 126.74, 124.35, 120.97, 120.62, 118.69, 115.10, 108.43, 56.10; MS (EI) <ce:italic>m/z</ce:italic> 432.17 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">21</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 432.1707; found 432.1709. HPLC retention time 9,878Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0350" view="all">
                     <ce:bold>N-(4-(furan-2-yl)phenyl)-7-methoxy-2-phenylquinoline-4-carboxamide (31).</ce:bold> White solid, 61% yield, m.p. 264â266Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.91 (s, 1H), 8.37 (d, <ce:italic>J</ce:italic>Â =Â 7.0Â Hz, 2H), 8.22 (s, 1H), 8.12 (d, <ce:italic>J</ce:italic>Â =Â 9.2Â Hz, 1H), 7.91 (d, <ce:italic>J</ce:italic>Â =Â 8.8Â Hz, 2H), 7.76 (d, <ce:italic>J</ce:italic>Â =Â 8.6Â Hz, 3H), 7.61â7.51 (m, 4H), 7.34 (dd, <ce:italic>J</ce:italic>Â =Â 9.2, 2.6Â Hz, 1H), 6.92 (d, <ce:italic>J</ce:italic>Â =Â 3.0Â Hz, 1H), 6.61 (dd, <ce:italic>J</ce:italic>Â =Â 3.3, 1.8Â Hz, 1H), 3.99 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 166.34, 161.58, 156.99, 153.82, 150.85, 143.49, 139.18, 130.76, 129.78, 128.19, 127.18, 124.88, 121.15, 119.13, 115.54, 112.99, 108.83, 106.08, 56.50; MS (EI) <ce:italic>m/z</ce:italic> 421.15 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">27</ce:inf>H<ce:inf loc="post">20</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf>(MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 421.1547; found 421.1544. HPLC retention time 12.966Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0355" view="all">
                     <ce:bold>N-(4-(benzofuran-2-yl)phenyl)-7-methoxy-2-phenylquinoline-4-carboxamide (32).</ce:bold> Yellow solid, 77% yield, m.p. 247â249Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 11.00 (s, 1H), 8.37 (d, <ce:italic>J</ce:italic>Â =Â 7.0Â Hz, 2H), 8.23 (s, 1H), 8.11 (d, <ce:italic>J</ce:italic>Â =Â 9.2Â Hz, 1H), 7.98 (s, 4H), 7.68â7.62 (m, 2H), 7.61â7.52 (m, 4H), 7.40 (d, <ce:italic>J</ce:italic>Â =Â 0.6Â Hz, 1H), 7.36â7.25 (m, 3H), 3.99 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 166.06, 161.18, 156.58, 155.59, 154.62, 150.43, 143.02, 139.89, 138.74, 130.36, 129.37, 127.77, 126.74, 125.84, 124.89, 123.73, 121.50, 120.73, 118.67, 115.15, 111.51, 108.43, 101.76, 56.10; MS (EI) <ce:italic>m/z</ce:italic> 471.17 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">31</ce:inf>H<ce:inf loc="post">22</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 471.1703; found 471.1701. HPLC retention time 17.385Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0360" view="all">
                     <ce:bold>N-(4-(1H-indol-6-yl)phenyl)-7-methoxy-2-phenylquinoline-4-carboxamide (33).</ce:bold> Yellow solid, 79% yield, m.p. 228â230Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 11.15 (s, 1H), 10.85 (s, 1H), 8.38 (dd, <ce:italic>J</ce:italic>Â =Â 8.3, 1.3Â Hz, 2H), 8.22 (s, 1H), 8.14 (d, <ce:italic>J</ce:italic>Â =Â 9.2Â Hz, 1H), 7.92 (d, <ce:italic>J</ce:italic>Â =Â 8.7Â Hz, 2H), 7.88â7.85 (m, 1H), 7.73 (d, <ce:italic>J</ce:italic>Â =Â 8.7Â Hz, 2H), 7.62â7.52 (m, 4H), 7.50 (d, <ce:italic>J</ce:italic>Â =Â 8.4Â Hz, 1H), 7.44 (dd, <ce:italic>J</ce:italic>Â =Â 8.5, 1.7Â Hz, 1H), 7.39 (t, 1H), 7.35 (dd, <ce:italic>J</ce:italic>Â =Â 9.2, 2.6Â Hz, 1H), 6.52â6.47 (m, 1H), 4.00 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 165.83, 161.16, 156.59, 150.44, 143.33, 138.80, 138.17, 137.70, 135.86, 131.34, 130.34, 129.37, 128.75, 127.78, 127.32, 126.81, 126.54, 120.88, 120.64, 118.78, 118.28, 115.08, 112.27, 108.42, 101.98, 56.09; MS (EI) <ce:italic>m/z</ce:italic> 470.18 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">31</ce:inf>H<ce:inf loc="post">23</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 470.1863; found 470.1857. HPLC retention time 11.307Â min, 98.85% pure.</ce:para>
                  <ce:para id="p0365" view="all">Compound <ce:bold>34</ce:bold> was synthesized according to the procedure for the preparation of compound <ce:bold>7</ce:bold>.</ce:para>
                  <ce:para id="p0370" view="all">
                     <ce:bold>N-(4-cyclohexylphenyl)-7-methoxy-2-phenylimidazo[1,2-a]pyridine-3-carboxamide (34).</ce:bold> White solid, 82% yield, m.p. 237â240Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, CDCl<ce:inf loc="post">3</ce:inf>) Î´ 9.42 (d, <ce:italic>J</ce:italic>Â =Â 7.6Â Hz, 1H), 7.74 (d, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 2H), 7.54 (d, <ce:italic>J</ce:italic>Â =Â 6.3Â Hz, 3H), 7.48 (s, 1H), 7.16 (d, <ce:italic>J</ce:italic>Â =Â 7.9Â Hz, 2H), 7.10 (d, <ce:italic>J</ce:italic>Â =Â 7.8Â Hz, 2H), 6.96 (s, 1H), 6.69 (d, <ce:italic>J</ce:italic>Â =Â 7.6Â Hz, 1H), 3.90 (s, 3H), 2.44 (s, 1H), 1.82 (d, <ce:italic>J</ce:italic>Â =Â 7.4Â Hz, 4H), 1.73 (d, <ce:italic>J</ce:italic>Â =Â 12.5Â Hz, 1H), 1.36 (t, <ce:italic>J</ce:italic>Â =Â 9.6Â Hz, 4H), 1.26 (s, 1H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, CDCl<ce:inf loc="post">3</ce:inf>) Î´ 159.85, 158.89, 148.82, 148.59, 144.12, 135.38, 134.03, 129.88, 129.64, 129.16, 129.03, 127.27, 119.58, 113.99, 108.25, 94.93, 55.64, 44.00, 34.49, 26.87, 26.13; MS (EI) <ce:italic>m/z</ce:italic> 426.21 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">27</ce:inf>H<ce:inf loc="post">27</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 426.2176; found 426.2181. HPLC retention time 12.815min, 100.00% pure.</ce:para>
                  <ce:para id="p0375" view="all">
                     <ce:bold>Ethyl 2-(7-methoxy-2-phenylimidazo[1,2-a]pyridin-3-yl)acetate (71).</ce:bold> A dried flask was charged with 7-methoxy-2-phenylimidazo[1,2-a]pyridine (450Â mg, 2Â mmol), Ph<ce:inf loc="post">2</ce:inf>(oct)<ce:inf loc="post">4</ce:inf> (78Â mg, 0.1Â mmol), and CHCl<ce:inf loc="post">3</ce:inf> (4Â mL). Diazoester (342Â mg, 3Â mmol) was added into the mixture dropwise under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for 4Â h and then concentrated in vacuum. The crud product was purified by chromatography (EtOAc: HexaneÂ =Â 1 : 2) to yield compound 71 (435Â mg, 70%) as white solid. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, CDCl<ce:inf loc="post">3</ce:inf>) Î´ 7.99â7.94 (m, 1H), 7.81 (d, <ce:italic>J</ce:italic>Â =Â 7.2Â Hz, 2H), 7.46 (dd, <ce:italic>J</ce:italic>Â =Â 10.3, 4.9Â Hz, 2H), 7.37 (d, <ce:italic>J</ce:italic>Â =Â 7.2Â Hz, 1H), 6.97 (d, <ce:italic>J</ce:italic>Â =Â 1.7Â Hz, 1H), 6.58 (dd, <ce:italic>J</ce:italic>Â =Â 7.4, 2.4Â Hz, 1H), 4.21 (dd, <ce:italic>J</ce:italic>Â =Â 7.1, 3.2Â Hz, 2H), 3.98 (s, 2H), 3.86 (s, 3H), 1.27 (s, 3H); MS (EI) <ce:italic>m/z</ce:italic> 310.13 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0380" view="all">Compound <ce:bold>72</ce:bold> was synthesized according to the procedure for the preparation of compound <ce:bold>11</ce:bold>.</ce:para>
                  <ce:para id="p0385" view="all">
                     <ce:bold>2-(7-methoxy-2-phenylimidazo[1,2-a]pyridin-3-yl)acetic acid (72).</ce:bold> White solid, 75% yield. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, CD<ce:inf loc="post">3</ce:inf>OD) Î´ 8.64 (s, 1H), 7.69 (s, 2H), 7.64â7.56 (m, 3H), 7.33 (s, 1H), 7.19 (s, 1H), 4.19 (s, 2H), 4.08 (s, 3H); MS (EI) <ce:italic>m/z</ce:italic> 282.10 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0390" view="all">Compounds <ce:bold>35-38</ce:bold> were synthesized according to the procedure for the preparation of compound <ce:bold>7</ce:bold>.</ce:para>
                  <ce:para id="p0395" view="all">
                     <ce:bold>N-(4-cyclohexylphenyl)-2-(7-methoxy-2-phenylimidazo[1,2-a]pyridin-3-yl)acetamide (35).</ce:bold> White solid, 72% yield, m.p. 207â209Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.35 (s, 1H), 8.29 (d, <ce:italic>J</ce:italic>Â =Â 7.1Â Hz, 1H), 7.80 (d, <ce:italic>J</ce:italic>Â =Â 7.1Â Hz, 2H), 7.57â7.44 (m, 4H), 7.35 (t, <ce:italic>J</ce:italic>Â =Â 6.4Â Hz, 1H), 7.16 (d, <ce:italic>J</ce:italic>Â =Â 7.6Â Hz, 2H), 7.00 (s, 1H), 6.72â6.64 (m, 1H), 4.21 (s, 2H), 3.86 (s, 3H), 2.47â2.39 (m, 1H), 1.81â1.72 (m, 4H), 1.71â1.66 (m, 1H), 1.40â1.31 (m, 4H), 1.26â1.22 (m, 1H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 167.71, 157.80, 145.77, 143.28, 142.53, 137.26, 135.16, 128.97, 128.10, 127.70, 127.29, 126.13, 119.85, 114.59, 106.86, 94.74, 56.06, 43.68, 34.53, 31.99, 26.83, 26.07; MS (EI) <ce:italic>m/z</ce:italic> 440.22 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">29</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 440.2333; found 440.2336. HPLC retention time 19.171Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0400" view="all">
                     <ce:bold>([1,1â²-biphenyl]-4-yl)-2-(7-methoxy-2-phenylimidazo[1,2-a]pyridin-3-yl)acetamide (36).</ce:bold> White solid, 76% yield, m.p. 217â218Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.46 (s, 1H), 8.24 (d, <ce:italic>J</ce:italic>Â =Â 7.5Â Hz, 1H), 7.71 (d, <ce:italic>J</ce:italic>Â =Â 7.6Â Hz, 2H), 7.66 (d, <ce:italic>J</ce:italic>Â =Â 8.1Â Hz, 2H), 7.58 (d, <ce:italic>J</ce:italic>Â =Â 8.0Â Hz, 4H), 7.39 (dt, <ce:italic>J</ce:italic>Â =Â 14.9, 7.4Â Hz, 4H), 7.28 (dt, <ce:italic>J</ce:italic>Â =Â 11.8, 6.7Â Hz, 2H), 6.93 (s, 1H), 6.62 (d, <ce:italic>J</ce:italic>Â =Â 7.4Â Hz, 1H), 4.18 (s, 2H), 3.79 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.04, 157.76, 145.84, 142.67, 140.12, 138.95, 135.59, 135.24, 129.38, 129.01, 128.07, 127.79, 127.57, 126.73, 126.16, 120.11, 114.43, 106.84, 94.80, 56.08, 32.10; MS (EI) <ce:italic>m/z</ce:italic> 434.18 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">23</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 434.1865; found 434.1863. HPLC retention time 13.844Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0405" view="all">
                     <ce:bold>N-(4-(furan-2-yl)phenyl)-2-(7-methoxy-2-phenylimidazo[1,2-a]pyridin-3-yl)acetamide(37).</ce:bold> White solid, 74% yield, m.p. 212â214Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 11.00 (s, 1H), 8.34 (d, <ce:italic>J</ce:italic>Â =Â 7.0Â Hz, 1H), 7.77 (d, <ce:italic>J</ce:italic>Â =Â 6.8Â Hz, 2H), 7.70 (d, <ce:italic>J</ce:italic>Â =Â 7.6Â Hz, 2H), 7.63 (s, 1H), 7.58 (d, <ce:italic>J</ce:italic>Â =Â 7.5Â Hz, 2H), 7.39 (t, <ce:italic>J</ce:italic>Â =Â 6.5Â Hz, 2H), 7.28 (t, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 1H), 6.92 (s, 1H), 6.77 (s, 1H), 6.59 (d, <ce:italic>J</ce:italic>Â =Â 7.1Â Hz, 1H), 6.49 (s, 1H), 4.24 (s, 2H), 3.79 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.11, 157.72, 153.48, 145.77, 142.88, 142.67, 138.99, 135.23, 128.97, 128.08, 127.66, 126.26, 126.05, 124.38, 119.97, 114.54, 112.48, 106.80, 105.30, 94.78, 56.07, 32.04; MS (EI) <ce:italic>m/z</ce:italic> 424.16 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">26</ce:inf>H<ce:inf loc="post">21</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 424.1656; found 424.1653. HPLC retention time 10.207Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0410" view="all">
                     <ce:bold>N-(1,1-dioxidobenzo[b]thiophen-6-yl)-2-(7-methoxy-2-phenylimidazo[1,2-a]pyridin-3-yl) acetamide (38).</ce:bold> White solid, 73% yield, m.p. 167â168Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.93 (s, 1H), 8.31 (d, <ce:italic>J</ce:italic>Â =Â 7.4Â Hz, 1H), 8.15 (s, 1H), 7.81â7.74 (m, 3H), 7.58 (dd, <ce:italic>J</ce:italic>Â =Â 16.8, 7.5Â Hz, 2H), 7.48 (t, <ce:italic>J</ce:italic>Â =Â 7.4Â Hz, 2H), 7.36 (t, <ce:italic>J</ce:italic>Â =Â 7.2Â Hz, 1H), 7.29 (d, <ce:italic>J</ce:italic>Â =Â 6.8Â Hz, 1H), 7.01 (s, 1H), 6.69 (d, <ce:italic>J</ce:italic>Â =Â 7.0Â Hz, 1H), 4.29 (s, 2H), 3.38 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.80, 157.83, 145.90, 142.80, 141.87, 137.69, 135.11, 133.29, 130.54, 129.06, 128.08, 127.77, 127.08, 126.23, 126.06, 123.79, 113.89, 111.94, 106.91, 94.77, 56.08, 32.23; MS (EI) <ce:italic>m/z</ce:italic> 446.11 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">19</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">4</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 446.1169; found 446.1162. HPLC retention time 15.632Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0415" view="all">Compounds <ce:bold>74a-u</ce:bold> were synthesized according to the procedure for the preparation of compound <ce:bold>11</ce:bold>.</ce:para>
                  <ce:para id="p0420" view="all">
                     <ce:bold>2-(2-phenylimidazo[1,2-a]pyridin-3-yl)acetic acid (74a).</ce:bold> White solid, 85% yield. <ce:sup loc="post">1</ce:sup>H NMR (400.</ce:para>
                  <ce:para id="p0425" view="all">MHz, CD<ce:inf loc="post">3</ce:inf>OD) Î´ 8.86 (d, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 1H), 8.11â8.06 (m, 1H), 8.02 (d, <ce:italic>J</ce:italic>Â =Â 8.9Â Hz, 1H), 7.78â7.73 (m, 2H), 7.69â7.59 (m, 4H), 4.30 (s, 2H); MS (EI) <ce:italic>m/z</ce:italic> 252.15 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0430" view="all">
                     <ce:bold>2-(7-chloro-2-phenylimidazo[1,2-a]pyridin-3-yl)acetic acid (74b).</ce:bold> White solid, 82% yield. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, CD<ce:inf loc="post">3</ce:inf>OD) Î´ 8.82 (d, <ce:italic>J</ce:italic>Â =Â 7.2Â Hz, 1H), 8.04 (s, 1H), 7.72 (d, <ce:italic>J</ce:italic>Â =Â 6.0Â Hz, 2H), 7.62 (dd, <ce:italic>J</ce:italic>Â =Â 19.0, 6.4Â Hz, 4H), 4.24 (s, 2H); MS (EI) <ce:italic>m/z</ce:italic> 286.05 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0435" view="all">
                     <ce:bold>2-(7-bromo-2-phenylimidazo[1,2-a]pyridin-3-yl)acetic acid (74c).</ce:bold> White solid, 88% yield. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, CD<ce:inf loc="post">3</ce:inf>OD) Î´ 8.78 (d, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 1H), 8.26 (s, 1H), 7.75 (d, <ce:italic>J</ce:italic>Â =Â 7.0Â Hz, 3H), 7.67 (d, <ce:italic>J</ce:italic>Â =Â 6.6Â Hz, 3H), 4.27 (s, 2H); MS (EI) <ce:italic>m/z</ce:italic> 330.00 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0440" view="all">
                     <ce:bold>2-(7-methyl-2-phenylimidazo[1,2-a]pyridin-3-yl)acetic acid (74d).</ce:bold> White solid, 81% yield. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz,CD<ce:inf loc="post">3</ce:inf>OD) Î´ 8.69 (d, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 1H), 7.75 (s, 1H), 7.73â7.68 (m, 2H), 7.64 (d, <ce:italic>J</ce:italic>Â =Â 7.0Â Hz, 2H), 7.44 (d, <ce:italic>J</ce:italic>Â =Â 6.8Â Hz, 1H), 4.29 (s, 2H), 2.65 (s, 3H); MS (EI) <ce:italic>m/z</ce:italic> 266.11 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0445" view="all">
                     <ce:bold>2-(8-methoxy-2-phenylimidazo[1,2-a]pyridin-3-yl)acetic acid (74e).</ce:bold> White solid, 84% yield. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, CD<ce:inf loc="post">3</ce:inf>OD) Î´ 8.37 (s, 1H), 7.70 (d, <ce:italic>J</ce:italic>Â =Â 3.4Â Hz, 2H), 7.63 (d, <ce:italic>J</ce:italic>Â =Â 3.7Â Hz, 3H), 7.49 (s, 2H), 4.20 (d, <ce:italic>J</ce:italic>Â =Â 4.5Â Hz, 5H); MS (EI) <ce:italic>m/z</ce:italic> 282.11 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0450" view="all">
                     <ce:bold>2-(6-methoxy-2-phenylimidazo[1,2-a]pyridin-3-yl)acetic acid (74f).</ce:bold> White solid, 79% yield. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, CDCl<ce:inf loc="post">3</ce:inf>) Î´ 8.09 (s, 1H), 7.70 (d, <ce:italic>J</ce:italic>Â =Â 5.9Â Hz, 3H), 7.50 (dd, <ce:italic>J</ce:italic>Â =Â 18.8, 6.7Â Hz, 4H), 4.06 (s, 2H), 3.92 (s, 3H); MS (EI) <ce:italic>m/z</ce:italic> 282.12 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0455" view="all">
                     <ce:bold>2-(6-bromo-2-phenylimidazo[1,2-a]pyridin-3-yl)acetic acid (74g).</ce:bold> White solid, 81% yield. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, CDCl<ce:inf loc="post">3</ce:inf>) Î´ 9.08 (s, 1H), 7.95 (dd, <ce:italic>J</ce:italic>Â =Â 48.2, 41.2Â Hz, 3H), 7.61 (d, <ce:italic>J</ce:italic>Â =Â 43.9Â Hz, 4H), 4.18 (d, <ce:italic>J</ce:italic>Â =Â 16.4Â Hz, 2H); MS (EI) <ce:italic>m/z</ce:italic> 330.00 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0460" view="all">
                     <ce:bold>2-(2,7-diphenylimidazo[1,2-a]pyridin-3-yl)acetic acid (74h).</ce:bold> White solid, 85% yield. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, CD<ce:inf loc="post">3</ce:inf>OD) Î´ 8.85 (s, 1H), 8.15 (s, 1H), 7.91 (s, 3H), 7.77 (s, 2H), 7.66 (d, <ce:italic>J</ce:italic>Â =Â 6.8Â Hz, 3H), 7.58 (dd, <ce:italic>J</ce:italic>Â =Â 11.7, 6.6Â Hz, 3H), 4.29 (s, 2H); MS (EI) <ce:italic>m/z</ce:italic> 328.12 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0465" view="all">
                     <ce:bold>2-(7-(4-methoxyphenyl)-2-phenylimidazo[1,2-a]pyridin-3-yl)acetic acid (74i).</ce:bold> White solid, 86% yield. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz,CD<ce:inf loc="post">3</ce:inf>OD) Î´ 8.82 (s, 1H), 8.09 (s, 1H), 7.91 (d, <ce:italic>J</ce:italic>Â =Â 8.2Â Hz, 4H), 7.77 (d, <ce:italic>J</ce:italic>Â =Â 6.4Â Hz, 2H), 7.70â7.66 (m, 2H), 7.15 (d, <ce:italic>J</ce:italic>Â =Â 8.2Â Hz, 2H), 4.29 (s, 2H), 3.90 (s, 3H); MS (EI) <ce:italic>m/z</ce:italic> 358.13(MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0470" view="all">
                     <ce:bold>2-(7-(1-methyl-1H-pyrazol-4-yl)-2-phenylimidazo[1,2-a]pyridin-3-yl)acetic acid (74j).</ce:bold> White solid, 81% yield. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, CD<ce:inf loc="post">3</ce:inf>OD) Î´ 8.75 (s, 1H), 8.44 (s, 1H), 8.18 (s, 1H), 8.04 (s, 1H), 7.82 (s, 1H), 7.73 (d, <ce:italic>J</ce:italic>Â =Â 6.3Â Hz, 2H), 7.66 (d, <ce:italic>J</ce:italic>Â =Â 6.0Â Hz, 3H), 4.31 (s, 2H), 4.01 (s, 3H); MS (EI) <ce:italic>m/z</ce:italic> 332.13 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0475" view="all">
                     <ce:bold>2-(2-(4-fluorophenyl)-7-methoxyimidazo[1,2-a]pyridin-3-yl)acetic acid (74k).</ce:bold> White solid, 83% yield. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, CD<ce:inf loc="post">3</ce:inf>OD) Î´ 8.63 (d, <ce:italic>J</ce:italic>Â =Â 7.5Â Hz, 1H), 7.74 (dd, <ce:italic>J</ce:italic>Â =Â 8.3, 5.2Â Hz, 2H), 7.38 (t, <ce:italic>J</ce:italic>Â =Â 8.5Â Hz, 2H), 7.30 (s, 1H), 7.20 (d, <ce:italic>J</ce:italic>Â =Â 7.3Â Hz, 1H), 4.23 (s, 2H), 4.09 (s, 3H); MS (EI) <ce:italic>m/z</ce:italic>.300.09 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0480" view="all">
                     <ce:bold>2-(7-methoxy-2-(4-(trifluoromethyl)phenyl)imidazo[1,2-a]pyridin-3-yl)acetic acid (74l).</ce:bold> White solid, 78% yield. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, CD<ce:inf loc="post">3</ce:inf>OD) Î´ 8.67 (s, 1H), 7.95 (s, 4H), 7.36 (s, 1H), 7.23 (s, 1H), 4.26 (s, 2H), 4.11 (s, 3H); MS (EI) <ce:italic>m/z</ce:italic> 350.09 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0485" view="all">
                     <ce:bold>2-(7-methoxy-2-(4-nitrophenyl)imidazo[1,2-a]pyridin-3-yl)acetic acid (74m).</ce:bold> White solid, 82% yield. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, CD<ce:inf loc="post">3</ce:inf>OD) Î´ 8.66 (d, <ce:italic>J</ce:italic>Â =Â 6.3Â Hz, 1H), 8.47 (d, <ce:italic>J</ce:italic>Â =Â 6.7Â Hz, 2H), 7.99 (d, <ce:italic>J</ce:italic>Â =Â 6.5Â Hz, 2H), 7.34 (s, 1H), 7.22 (d, <ce:italic>J</ce:italic>Â =Â 5.5Â Hz, 1H), 4.26 (s, 2H), 4.10 (s, 3H); MS (EI) <ce:italic>m/z</ce:italic> 269.08 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0490" view="all">
                     <ce:bold>2-(7-methoxy-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)acetic acid (74n).</ce:bold> White solid, 86% yield. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, CDCl<ce:inf loc="post">3</ce:inf>) Î´ 8.11 (d, <ce:italic>J</ce:italic>Â =Â 7.5Â Hz, 1H), 7.90 (q, <ce:italic>J</ce:italic>Â =Â 8.5Â Hz, 4H), 6.80 (d, <ce:italic>J</ce:italic>Â =Â 2.3Â Hz, 1H), 6.63 (dd, <ce:italic>J</ce:italic>Â =Â 7.5, 2.4Â Hz, 1H), 3.84â3.76 (m, 5H), 3.02 (s, 3H); MS (EI) <ce:italic>m/z</ce:italic> 360.08 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0495" view="all">
                     <ce:bold>2-(7-methoxy-2-(thiophen-2-yl)imidazo[1,2-a]pyridin-3-yl)acetic acid (74o).</ce:bold> White solid, 82% yield. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, CD<ce:inf loc="post">3</ce:inf>OD) Î´ 8.64 (s, 1H), 7.79 (s, 1H), 7.65 (s, 1H), 7.31 (s, 2H), 7.18 (s, 1H), 4.33 (s, 2H), 4.09 (s, 3H); MS (EI) <ce:italic>m/z</ce:italic> 288.06 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0500" view="all">
                     <ce:bold>2-(7-methoxy-2-(naphthalen-2-yl)imidazo[1,2-a]pyridin-3-yl)acetic acid (74p).</ce:bold> White solid, 71% yield. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, MeOD) Î´ 8.41 (s, 1H), 7.69 (m, 7H), 7.53 (s, 3H), 4.24 (d, <ce:italic>J</ce:italic>Â =Â 4.5Â Hz, 5H); MS (EI) <ce:italic>m/z</ce:italic> 333.11 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0505" view="all">
                     <ce:bold>2-(2-(4-cyanophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl)acetic acid (74q).</ce:bold> White solid, 86% yield. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, CD<ce:inf loc="post">3</ce:inf>OD) Î´ 8.68 (s, 1H), 8.05â7.89 (m, 6H), 4.30 (s, 2H), 2.55 (s, 3H); MS (EI) <ce:italic>m/z</ce:italic> 291.10 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0510" view="all">
                     <ce:bold>2-(2-(4-chlorophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl)acetic acid (74r).</ce:bold> White solid, 81% yield. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, CD<ce:inf loc="post">3</ce:inf>OD) Î´ 8.65 (s, 1H), 7.92 (s, 2H), 7.71 (s, 2H), 7.66 (s, 2H), 4.28 (d, <ce:italic>J</ce:italic>Â =Â 16.9Â Hz, 5H); MS (EI) <ce:italic>m/z</ce:italic> 300.07(MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0515" view="all">
                     <ce:bold>2-(2-(p-tolyl)imidazo[1,2-a]pyridin-3-yl)acetic acid (74s).</ce:bold> White solid, 89% yield. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, CD<ce:inf loc="post">3</ce:inf>OD) Î´ 8.83 (s, 1H), 8.02 (d, <ce:italic>J</ce:italic>Â =Â 16.8Â Hz, 2H), 7.60 (d, <ce:italic>J</ce:italic>Â =Â 16.6Â Hz, 3H), 7.45 (d, <ce:italic>J</ce:italic>Â =Â 6.7Â Hz, 2H), 4.27 (s, 2H), 2.45 (s, 3H); MS (EI) <ce:italic>m/z</ce:italic> 266.11 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0520" view="all">
                     <ce:bold>2-(2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)acetic acid (74t).</ce:bold> White solid, 80% yield. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, MeOD) Î´ 8.65 (s, 1H), 7.97 (m, 4H), 7.26 (d, <ce:italic>J</ce:italic>Â =Â 34.0Â Hz, 2H), 4.15 (d, <ce:italic>J</ce:italic>Â =Â 48.7Â Hz, 5H); MS (EI) <ce:italic>m/z</ce:italic> 331.06(MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0525" view="all">
                     <ce:bold>2-(2-(4-cyanophenyl)imidazo[1,2-a]pyridin-3-yl)acetic acid (74u).</ce:bold> White solid, 85% yield. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, MeOD) Î´ 8.87 (d, <ce:italic>J</ce:italic>Â =Â 6.0Â Hz, 1H), 8.08 (m, 2H), 7.98 (s, 4H), 7.63 (s, 1H), 4.34 (s, 2H); MS (EI) <ce:italic>m/z</ce:italic> 278.08 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>.</ce:para>
                  <ce:para id="p0530" view="all">Compounds <ce:bold>39-61</ce:bold> were synthesized according to the procedure for the preparation of compound <ce:bold>7</ce:bold>.</ce:para>
                  <ce:para id="p0535" view="all">
                     <ce:bold>N-(1,1-dioxidobenzo[b]thiophen-6-yl)-2-(7-methoxy-2-phenylimidazo[1,2-a]pyridin-3-yl) acetamide (39).</ce:bold> White solid, 78% yield, m.p. 201â203Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.99 (s, 1H), 8.46 (d, <ce:italic>J</ce:italic>Â =Â 6.7Â Hz, 1H), 8.17 (s, 1H), 7.82â7.77 (m, 3H), 7.65 (d, <ce:italic>J</ce:italic>Â =Â 9.0Â Hz, 1H), 7.59 (dd, <ce:italic>J</ce:italic>Â =Â 11.5, 7.6Â Hz, 2H), 7.50 (t, <ce:italic>J</ce:italic>Â =Â 7.4Â Hz, 2H), 7.40 (t, <ce:italic>J</ce:italic>Â =Â 7.2Â Hz, 1H), 7.34â7.28 (m, 2H), 6.98 (t, <ce:italic>J</ce:italic>Â =Â 6.7Â Hz, 1H), 4.36 (s, 2H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.60, 144.52, 143.51, 141.86, 137.71, 134.86, 133.29, 130.56, 129.12, 128.38, 128.06, 127.08, 126.11, 125.53, 125.12, 123.83, 117.10, 115.19, 112.49, 111.99, 32.31; MS (EI) <ce:italic>m/z</ce:italic> 416.10 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">19</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">4</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 416.1063; found: 416.060. HPLC retention time 12.255Â min, 96.70% pure.</ce:para>
                  <ce:para id="p0540" view="all">
                     <ce:bold>2-(7-chloro-2-phenylimidazo[1,2-a]pyridin-3-yl)-N-(1,1-dioxidobenzo[b]thiophen-6-yl) acetamide (40).</ce:bold> White solid, 76% yield, m.p. 230â232Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.93 (s, 1H), 8.52 (d, <ce:italic>J</ce:italic>Â =Â 7.4Â Hz, 1H), 8.12 (s, 1H), 7.81 (d, <ce:italic>J</ce:italic>Â =Â 2.0Â Hz, 1H), 7.77â7.73 (m, 3H), 7.58 (dd, <ce:italic>J</ce:italic>Â =Â 16.4, 7.6Â Hz, 2H), 7.50 (t, <ce:italic>J</ce:italic>Â =Â 7.7Â Hz, 2H), 7.40 (t, <ce:italic>J</ce:italic>Â =Â 7.3Â Hz, 1H), 7.29 (d, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 1H), 7.06 (dd, <ce:italic>J</ce:italic>Â =Â 7.3, 2.1Â Hz, 1H), 4.35 (s, 2H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.37, 144.23, 141.79, 137.68, 134.41, 133.29, 130.57, 130.26, 129.20, 128.33, 127.09, 126.79, 126.12, 123.83, 115.85, 113.48, 111.97, 32.21; MS (EI) <ce:italic>m/z</ce:italic> 450.06 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">16</ce:inf>ClN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 450.0674; found: 450.0676. HPLC retention time 11.189Â min, 97.88% pure.</ce:para>
                  <ce:para id="p0545" view="all">
                     <ce:bold>(7-bromo-2-phenylimidazo[1,2-a]pyridin-3-yl)-N-(1,1-dioxidobenzo[b]thiophen-6-yl) acetamide (41)</ce:bold>. White solid, 71% yield, m.p. 247â249Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.93 (s, 1H), 8.45 (d, <ce:italic>J</ce:italic>Â =Â 7.3Â Hz, 1H), 8.12 (s, 1H), 7.96 (s, 1H), 7.75 (d, <ce:italic>J</ce:italic>Â =Â 7.2Â Hz, 3H), 7.58 (dd, <ce:italic>J</ce:italic>Â =Â 16.7, 7.5Â Hz, 2H), 7.50 (t, <ce:italic>J</ce:italic>Â =Â 7.6Â Hz, 2H), 7.40 (t, <ce:italic>J</ce:italic>Â =Â 7.2Â Hz, 1H), 7.29 (d, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 1H), 7.15 (d, <ce:italic>J</ce:italic>Â =Â 7.3Â Hz, 1H), 4.34 (s, 2H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.36, 144.63, 144.11, 141.85, 137.68, 134.40, 133.29, 130.55, 129.19, 128.36, 127.07, 126.72, 126.09, 123.83, 118.99, 118.09, 115.77, 111.98, 32.22; MS (EI) <ce:italic>m/z</ce:italic> 494.01 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">16</ce:inf>BrN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 494.0168; found: 494.0161. HPLC retention time 11.676Â min, 96.27% pure.</ce:para>
                  <ce:para id="p0550" view="all">
                     <ce:bold>N-(1,1-dioxidobenzo[b]thiophen-6-yl)-2-(7-methyl-2-phenylimidazo[1,2-a]pyridin-3-yl) acetamide (42).</ce:bold> White solid, 76% yield, m.p. 202â204Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.95 (s, 1H), 8.29 (d, <ce:italic>J</ce:italic>Â =Â 6.8Â Hz, 1H), 8.14 (s, 1H), 7.78 (t, <ce:italic>J</ce:italic>Â =Â 7.2Â Hz, 3H), 7.61â7.56 (m, 2H), 7.49 (t, <ce:italic>J</ce:italic>Â =Â 7.6Â Hz, 2H), 7.39 (t, <ce:italic>J</ce:italic>Â =Â 7.3Â Hz, 1H), 7.29 (d, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 1H), 7.13 (d, <ce:italic>J</ce:italic>Â =Â 6.6Â Hz, 1H), 6.89 (t, <ce:italic>J</ce:italic>Â =Â 6.8Â Hz, 1H), 4.31 (s, 2H), 2.56 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.63, 144.86, 142.95, 141.85, 137.69, 134.96, 133.29, 130.55, 129.07, 128.43, 127.98, 127.09, 126.56, 126.08, 123.81, 123.26, 115.55, 112.51, 111.93, 32.42, 17.06; MS (EI) <ce:italic>m/z</ce:italic> 430.12(MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">19</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 430.1220; found: 430.1220. HPLC retention time 12.859Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0555" view="all">
                     <ce:bold>N-(1,1-dioxidobenzo[b]thiophen-6-yl)-2-(8-methoxy-2-phenylimidazo[1,2-a]pyridin-3-yl) acetamide (43).</ce:bold> White solid, 78% yield, m.p. 219â221Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 11.07 (s, 1H), 8.16 (s, 1H), 8.06 (d, <ce:italic>J</ce:italic>Â =Â 6.5Â Hz, 1H), 7.79 (d, <ce:italic>J</ce:italic>Â =Â 6.2Â Hz, 3H), 7.66â7.56 (m, 2H), 7.49 (t, <ce:italic>J</ce:italic>Â =Â 7.2Â Hz, 2H), 7.37 (t, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 1H), 7.29 (d, <ce:italic>J</ce:italic>Â =Â 6.7Â Hz, 1H), 6.88 (t, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 1H), 6.73 (d, <ce:italic>J</ce:italic>Â =Â 7.3Â Hz, 1H), 4.33 (s, 2H), 3.98 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.57, 148.81, 142.48, 141.87, 138.84, 137.67, 134.82, 133.30, 130.54, 129.07, 128.28, 127.96, 127.07, 126.07, 123.80, 118.11, 116.08, 112.55, 111.92, 102.02, 56.23, 32.50; MS (EI) <ce:italic>m/z</ce:italic> 446.11 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">19</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">4</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 446.1169; found: 446.1166. HPLC retention time 14.234Â min, 98.64% pure.</ce:para>
                  <ce:para id="p0560" view="all">
                     <ce:bold>N-(1,1-dioxidobenzo[b]thiophen-6-yl)-2-(6-methoxy-2-phenylimidazo[1,2-a]pyridin-3-yl) acetamide (44).</ce:bold> White solid, 71% yield, m.p. 233â234Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 11.34 (s, 1H), 8.17 (d, <ce:italic>J</ce:italic>Â =Â 27.5Â Hz, 2H), 7.81 (dd, <ce:italic>J</ce:italic>Â =Â 21.5, 8.0Â Hz, 3H), 7.61â7.55 (m, 3H), 7.48 (t, <ce:italic>J</ce:italic>Â =Â 7.5Â Hz, 2H), 7.36 (t, <ce:italic>J</ce:italic>Â =Â 7.0Â Hz, 1H), 7.28 (d, <ce:italic>J</ce:italic>Â =Â 6.8Â Hz, 1H), 7.12 (d, <ce:italic>J</ce:italic>Â =Â 9.7Â Hz, 1H), 4.39 (s, 2H), 3.84 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.70, 149.09, 141.97, 141.42, 137.67, 134.82, 133.31, 130.51, 129.08, 128.13, 127.91, 127.08, 126.04, 123.77, 119.99, 117.34, 116.47, 111.89, 107.59, 57.07, 32.40; MS (EI) <ce:italic>m/z</ce:italic> 446.11 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">19</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">4</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 446.1169; found: 446.1164. HPLC retention time 14.748Â min, 98.68% pure.</ce:para>
                  <ce:para id="p0565" view="all">
                     <ce:bold>2-(6-bromo-2-phenylimidazo[1,2-a]pyridin-3-yl)-N-(1,1-dioxidobenzo[b]thiophen-6-yl) acetamide (45).</ce:bold> White solid, 72% yield, m.p. 223â225Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.95 (s, 1H), 8.86 (s, 1H), 8.13 (s, 1H), 7.79â7.73 (m, 3H), 7.64â7.56 (m, 3H), 7.50 (t, <ce:italic>J</ce:italic>Â =Â 7.6Â Hz, 2H), 7.45â7.37 (m, 2H), 7.29 (d, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 1H), 4.37 (s, 2H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.46, 144.10, 143.03, 141.85, 137.70, 134.39, 133.29, 130.56, 129.21, 128.30, 128.02, 127.11, 126.08, 125.81, 123.79, 118.19, 116.13, 111.91, 106.47, 32.23; MS (EI) <ce:italic>m/z</ce:italic> 494.01 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">16</ce:inf>BrN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 494.0168; found: 446.0168. HPLC retention time 13.345min,100.00% pure.</ce:para>
                  <ce:para id="p0570" view="all">
                     <ce:bold>N-(1,1-dioxidobenzo[b]thiophen-6-yl)-2-(2,7-diphenylimidazo[1,2-a]pyridin-3-yl)acetamide (46).</ce:bold> White solid, 71% yield, m.p. 146â148Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 11.11 (s, 1H), 8.55 (d, <ce:italic>J</ce:italic>Â =Â 7.2Â Hz, 1H), 8.30 (d, <ce:italic>J</ce:italic>Â =Â 4.6Â Hz, 1H), 8.16 (s, 1H), 7.96 (s, 1H), 7.87â7.81 (m, 3H), 7.59 (q, <ce:italic>J</ce:italic>Â =Â 6.7Â Hz, 2H), 7.52 (q, <ce:italic>J</ce:italic>Â =Â 8.0Â Hz, 2H), 7.41â7.38 (m, 2H), 7.29 (d, <ce:italic>J</ce:italic>Â =Â 6.8Â Hz, 1H), 7.18 (d, <ce:italic>J</ce:italic>Â =Â 8.2Â Hz, 1H), 6.88 (d, 1H), 6.69 (d, <ce:italic>J</ce:italic>Â =Â 8.2Â Hz, 1H), 6.10 (s, 1H), 4.40 (s, 2H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.60, 144.97, 144.26, 141.86, 138.38, 137.71, 136.63, 134.84, 133.29, 130.57, 129.58, 129.16, 128.70, 128.32, 127.05, 126.11, 125.70, 123.83, 115.17, 113.34, 111.85, 32.35; MS (EI) <ce:italic>m/z</ce:italic> 492.13 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">29</ce:inf>H<ce:inf loc="post">21</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 492.1376; found: 492.1378. HPLC retention time 15.083Â min, 98.37% pure.</ce:para>
                  <ce:para id="p0575" view="all">
                     <ce:bold>N-(1,1-dioxidobenzo[b]thiophen-6-yl)-2-(7-(4-methoxyphenyl)-2-phenylimidazo[1,2-a] pyridin-3-yl)acetamide (47).</ce:bold> White solid, 78% yield, m.p. 136â138Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.98 (s, 1H), 8.49 (d, <ce:italic>J</ce:italic>Â =Â 7.2Â Hz, 1H), 8.15 (s, 1H), 7.88 (d, <ce:italic>J</ce:italic>Â =Â 1.0Â Hz, 1H), 7.83 (s, 1H), 7.82â7.75 (m, 4H), 7.63â7.56 (m, 2H), 7.50 (t, <ce:italic>J</ce:italic>Â =Â 7.6Â Hz, 2H), 7.39 (t, <ce:italic>J</ce:italic>Â =Â 7.4Â Hz, 1H), 7.34 (dd, <ce:italic>J</ce:italic>Â =Â 7.3, 1.8Â Hz, 1H), 7.29 (d, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 1H), 7.08 (d, <ce:italic>J</ce:italic>Â =Â 8.8Â Hz, 2H), 4.37 (s, 2H), 3.83 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.64, 159.98, 145.11, 144.00, 141.86, 137.70, 136.40, 134.88, 133.30, 130.61, 129.14, 128.27, 128.06, 127.10, 126.09, 125.56, 123.81, 115.00, 112.19, 111.94, 111.56, 55.74, 32.33; MS (EI) <ce:italic>m/z</ce:italic> 522.14 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">23</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">4</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 522.1482; found: 522.1483. HPLC retention time 13.398Â min, 99.57% pure.</ce:para>
                  <ce:para id="p0580" view="all">
                     <ce:bold>N-(1,1-dioxidobenzo[b]thiophen-6-yl)-2-(7-(1-methyl-1H-pyrazol-4-yl)-2-phenylimidazo [1,2-a]pyridin-3-yl)acetamide (48).</ce:bold> White solid, 79% yield, m.p. 135â136Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.94 (s, 1H), 8.44 (d, <ce:italic>J</ce:italic>Â =Â 7.1Â Hz, 1H), 8.34 (s, 1H), 8.14 (s, 1H), 8.07 (s, 1H), 7.83â7.76 (m, 4H), 7.59 (dd, <ce:italic>J</ce:italic>Â =Â 11.2, 7.6Â Hz, 2H), 7.50 (t, <ce:italic>J</ce:italic>Â =Â 7.6Â Hz, 2H), 7.39 (d, <ce:italic>J</ce:italic>Â =Â 7.3Â Hz, 1H), 7.30â7.22 (m, 2H), 4.34 (s, 2H), 3.90 (s, 3H). MS(EI) <ce:italic>m/z</ce:italic> 496.14 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.66, 145.08, 143.52, 141.85, 137.70, 137.07, 134.84, 133.29, 130.56, 129.85, 129.12, 128.23, 128.02, 127.09, 126.09, 125.64, 123.82, 120.76, 114.94, 111.97, 111.19, 110.23, 32.29, 19.03; MS (EI) <ce:italic>m/z</ce:italic> 496.14 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">27</ce:inf>H<ce:inf loc="post">21</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">3</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 496.1438; found: 496.1436. HPLC retention time 10.522Â min, 97.28% pure.</ce:para>
                  <ce:para id="p0585" view="all">
                     <ce:bold>N- (1,1-dioxidobenzo[b]thiophen-6-yl)-2-(2-(4-fluorophenyl)-7-methoxyimidazo[1,2-a] Pyridin-3-yl)acetamide (49).</ce:bold> White solid, 73% yield, m.p. 207â209Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.95 (s, 1H), 8.31 (d, <ce:italic>J</ce:italic>Â =Â 7.5Â Hz, 1H), 8.14 (s, 1H), 7.78 (t, <ce:italic>J</ce:italic>Â =Â 6.6Â Hz, 2H), 7.58 (dd, <ce:italic>J</ce:italic>Â =Â 17.1, 7.6Â Hz, 2H), 7.30 (dd, <ce:italic>J</ce:italic>Â =Â 15.2, 7.7Â Hz, 3H), 7.00 (d, <ce:italic>J</ce:italic>Â =Â 2.0Â Hz, 1H), 6.69 (dd, <ce:italic>J</ce:italic>Â =Â 7.5, 2.3Â Hz, 1H), 5.76 (s, 1H), 4.26 (s, 2H), 3.86 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (126Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.74, 162.07 (d, <ce:italic>J</ce:italic>Â =Â 244.4Â Hz), 157.88, 145.89, 141.84, 137.68, 133.29, 131.63, 130.55, 129.97, 127.06, 126.08, 123.82, 116.03, 115.86, 113.76, 111.97, 106.98, 94.77, 56.09, 32.16; MS (EI) <ce:italic>m/z</ce:italic> 464.10 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">18</ce:inf>FN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">4</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 464.1075; found: 464.1074. HPLC retention time 16.149Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0590" view="all">
                     <ce:bold>N-(1,1-dioxidobenzo[b]thiophen-6-yl)-2-(7-methoxy-2-(4-(trifluoromethyl)phenyl)imidazo [1,2-a]pyridin-3-yl)acetamide (50).</ce:bold> White solid, 77% yield, m.p. 213â216Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.93 (s, 1H), 8.34 (d, <ce:italic>J</ce:italic>Â =Â 7.5Â Hz, 1H), 8.14 (s, 1H), 7.98 (d, <ce:italic>J</ce:italic>Â =Â 8.1Â Hz, 2H), 7.84 (d, <ce:italic>J</ce:italic>Â =Â 8.2Â Hz, 2H), 7.76 (s, 1H), 7.58 (dd, <ce:italic>J</ce:italic>Â =Â 16.3, 7.5Â Hz, 2H), 7.29 (d, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 1H), 7.04 (d, <ce:italic>J</ce:italic>Â =Â 2.0Â Hz, 1H), 6.72 (d, <ce:italic>J</ce:italic>Â =Â 7.4Â Hz, 1H), 4.32 (s, 2H), 3.87 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.52, 158.13, 146.17, 141.79, 141.26, 139.17, 137.68, 133.28, 130.58, 128.54, 127.81, 127.06, 126.35, 126.03, 123.88, 115.21, 112.03, 107.42, 94.84, 56.16, 32.18; MS (EI) <ce:italic>m/z</ce:italic> 514.10 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">18</ce:inf>F<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">4</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 514.1043; found: 514.1042. HPLC retention time 14.887Â min, 97.07% pure.</ce:para>
                  <ce:para id="p0595" view="all">
                     <ce:bold>N-(1,1-dioxidobenzo[b]thiophen-6-yl)-2-(7-methoxy-2-(4-nitrophenyl)imidazo[1,2-a] pyridin-3-yl)acetamide (51).</ce:bold> White solid, 80% yield, m.p. 245â247Â Â°C. For compound 52:<ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 11.01 (s, 1H), 8.35 (dd, <ce:italic>J</ce:italic>Â =Â 14.0, 8.3Â Hz, 3H), 8.14 (s, 1H), 8.07 (d, <ce:italic>J</ce:italic>Â =Â 8.9Â Hz, 2H), 7.79 (dd, <ce:italic>J</ce:italic>Â =Â 8.2, 1.9Â Hz, 1H), 7.58 (dd, <ce:italic>J</ce:italic>Â =Â 11.3, 7.6Â Hz, 2H), 7.28 (d, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 1H), 7.04 (d, <ce:italic>J</ce:italic>Â =Â 2.4Â Hz, 1H), 6.74 (dd, <ce:italic>J</ce:italic>Â =Â 7.5, 2.5Â Hz, 1H), 4.37 (s, 2H), 3.88 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.36, 158.31, 146.64, 146.35, 141.82, 140.52, 137.64, 133.29, 130.56, 128.66, 127.03, 126.40, 126.13, 124.37, 123.91, 116.31, 112.06, 107.72, 94.82, 56.18, 32.22; MS (EI) <ce:italic>m/z</ce:italic> 491.10 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">18</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">6</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 491.1020; found: 491.1017. HPLC retention time 13.263Â min, 97.66% pure.</ce:para>
                  <ce:para id="p0600" view="all">
                     <ce:bold>N-(1,1-dioxidobenzo[b]thiophen-6-yl)-2-(7-methoxy-2-(4-(methylsulfonyl)phenyl)imidazo [1,2-a]pyridin-3-yl)acetamide (52).</ce:bold> White solid, 69% yield, m.p. 153â155Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 11.00 (s, 1H), 8.36 (d, <ce:italic>J</ce:italic>Â =Â 7.6Â Hz, 1H), 8.14 (s, 1H), 8.09â7.97 (m, 4H), 7.81â7.76 (m, 1H), 7.58 (dd, <ce:italic>J</ce:italic>Â =Â 14.8, 7.5Â Hz, 2H), 7.29 (d, <ce:italic>J</ce:italic>Â =Â 6.7Â Hz, 1H), 7.04 (d, <ce:italic>J</ce:italic>Â =Â 2.3Â Hz, 1H), 6.73 (dd, <ce:italic>J</ce:italic>Â =Â 7.5, 1.3Â Hz, 1H), 4.34 (s, 2H), 3.87 (s, 3H), 3.25 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.44, 158.18, 146.24, 141.77, 141.03, 140.09, 139.62, 137.67, 133.25, 130.57, 128.50, 127.80, 127.03, 126.33, 126.14, 123.91, 115.60, 112.07, 107.50, 94.85, 56.16, 44.07, 32.21; MS (EI) <ce:italic>m/z</ce:italic> 524.09 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">21</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">6</ce:inf>S<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 524.0945; found: 524.0951. HPLC retention time 10.781Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0605" view="all">
                     <ce:bold>N-(1,1-dioxidobenzo[b]thiophen-6-yl)-2-(7-methoxy-2-(thiophen-2-yl)imidazo[1,2-a] pyridin-3-yl)acetamide (53).</ce:bold> White solid, 80% yield, m.p. 146â148Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.95 (s, 1H), 8.33 (d, <ce:italic>J</ce:italic>Â =Â 7.4Â Hz, 1H), 8.11 (s, 1H), 7.78 (d, <ce:italic>J</ce:italic>Â =Â 8.1Â Hz, 1H), 7.56 (dd, <ce:italic>J</ce:italic>Â =Â 14.2, 4.7Â Hz, 3H), 7.40 (s, 1H), 7.27 (d, <ce:italic>J</ce:italic>Â =Â 5.9Â Hz, 1H), 7.15 (s, 1H), 6.99 (s, 1H), 6.67 (d, <ce:italic>J</ce:italic>Â =Â 7.4Â Hz, 1H), 4.36 (s, 2H), 3.86 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.46, 158.03, 145.89, 141.84, 138.48, 137.69, 137.48, 133.28, 130.54, 128.44, 127.09, 126.14, 124.01, 123.74, 113.12, 111.86, 106.97, 94.56, 56.11, 31.99; MS (EI) <ce:italic>m/z</ce:italic> 452.07 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">17</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">4</ce:inf>S<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 452.0733; found: 452.0742. HPLC retention time 12.357Â min, 98.68% pure.</ce:para>
                  <ce:para id="p0610" view="all">
                     <ce:bold>N-(1,1-dioxidobenzo[b]thiophen-6-yl)-2-(7-methoxy-2-(naphthalen-2-yl)imidazo[1,2-a] pyridin-3-yl)acetamide (54).</ce:bold> White solid, 78% yield, m.p. 136â138Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 11.01 (s, 1H), 8.36 (d, <ce:italic>J</ce:italic>Â =Â 7.5Â Hz, 1H), 8.24 (s, 1H), 8.17 (s, 1H), 8.01 (d, <ce:italic>J</ce:italic>Â =Â 8.6Â Hz, 1H), 7.99â7.91 (m, 3H), 7.81 (dd, <ce:italic>J</ce:italic>Â =Â 8.2, 1.7Â Hz, 1H), 7.59 (dd, <ce:italic>J</ce:italic>Â =Â 12.6, 7.6Â Hz, 2H), 7.56â7.50 (m, 2H), 7.29 (d, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 1H), 7.04 (d, <ce:italic>J</ce:italic>Â =Â 2.4Â Hz, 1H), 6.71 (dd, <ce:italic>J</ce:italic>Â =Â 7.5, 2.4Â Hz, 1H), 4.41 (d, <ce:italic>J</ce:italic>Â =Â 25.1Â Hz, 2H), 3.88 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.89, 157.91, 146.05, 142.62, 141.90, 137.71, 133.30, 132.66, 130.56, 128.61, 128.04, 127.11, 126.82, 126.52, 126.28, 126.11, 123.84, 114.43, 111.97, 106.99, 94.78, 56.11, 32.36; MS (EI) <ce:italic>m/z</ce:italic> 496.13 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">21</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">4</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 496.1326; found: 496.1324. HPLC retention time 12.366Â min, 96.04% pure.</ce:para>
                  <ce:para id="p0615" view="all">
                     <ce:bold>N-(1,1-dioxidobenzo[b]thiophen-6-yl)-2-(6-methyl-2-(p-tolyl)imidazo[1,2-a]pyridin-3-yl) acetamide (55).</ce:bold> White solid, 75% yield, m.p. 252â254Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.92 (s, 1H), 8.26 (s, 1H), 8.14 (s, 1H), 7.78 (dd, <ce:italic>J</ce:italic>Â =Â 8.2, 1.9Â Hz, 1H), 7.63 (d, <ce:italic>J</ce:italic>Â =Â 8.1Â Hz, 2H), 7.61â7.56 (m, 2H), 7.52 (d, <ce:italic>J</ce:italic>Â =Â 9.1Â Hz, 1H), 7.28 (d, <ce:italic>J</ce:italic>Â =Â 7.0Â Hz, 3H), 7.16 (dd, <ce:italic>J</ce:italic>Â =Â 9.2, 1.5Â Hz, 1H), 4.28 (s, 2H), 2.34 (d, <ce:italic>J</ce:italic>Â =Â 8.6Â Hz, 6H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.70, 143.52, 141.90, 137.69, 137.17, 133.31, 132.22, 130.53, 129.67, 128.12, 127.83, 127.10, 126.04, 123.77, 122.81, 121.49, 116.46, 114.47, 111.89, 32.32, 21.28, 18.28; MS (EI) <ce:italic>m/z</ce:italic> 444.13 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">21</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 444.1376; found: 444.1376. HPLC retention time 8.613Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0620" view="all">
                     <ce:bold>2-(2-(4-cyanophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl)-N-(1,1-dioxidobenzo[b]thiophen-6-yl)acetamide (56).</ce:bold> White solid, 71% yield, m.p. 229â231Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 11.01 (s, 1H), 8.32 (s, 1H), 8.15 (s, 1H), 8.00â7.92 (m, 4H), 7.79 (d, <ce:italic>J</ce:italic>Â =Â 8.2Â Hz, 1H), 7.59 (dd, <ce:italic>J</ce:italic>Â =Â 11.7, 7.8Â Hz, 3H), 7.29 (d, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 1H), 7.22 (d, <ce:italic>J</ce:italic>Â =Â 9.1Â Hz, 1H), 4.35 (s, 2H), 2.33 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.29, 143.84, 141.81, 141.34, 139.65, 137.66, 133.30, 133.07, 130.56, 128.67, 127.07, 126.13, 123.87, 122.94, 122.27, 119.45, 116.79, 116.45, 112.01, 110.17, 32.28, 18.27; MS (EI) <ce:italic>m/z</ce:italic> 455.11 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">18</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">3</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 455.1172; found: 455.1177. HPLC retention time 8.357Â min, 98.80% pure.</ce:para>
                  <ce:para id="p0625" view="all">
                     <ce:bold>2-(2-(4-chlorophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl)-N-(1,1-dioxidobenzo [b]thiophen -6-yl)acetamide (57)</ce:bold>. White solid, 73% yield, m.p. 217â219Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.94 (s, 1H), 8.29 (s, 1H), 8.15 (s, 1H), 7.79â7.75 (m, 3H), 7.61â7.53 (m, 5H), 7.29 (d, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 1H), 7.20 (d, <ce:italic>J</ce:italic>Â =Â 9.2Â Hz, 1H), 4.29 (s, 2H), 2.33 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.44, 143.49, 141.82, 137.69, 133.67, 133.28, 132.73, 130.56, 129.87, 129.15, 128.53, 127.07, 126.12, 123.87, 122.92, 122.05, 116.44, 115.21, 112.01, 32.22, 18.26; MS (EI) <ce:italic>m/z</ce:italic> 464.08 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">18</ce:inf>ClN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 464.0830; found: 464.0837. HPLC retention time 11.831Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0630" view="all">
                     <ce:bold>N-(1,1-dioxidobenzo[b]thiophen-6-yl)-2-(2-(p-tolyl)imidazo[1,2-a]pyridin-3-yl)acetamide (58).</ce:bold> White solid, 71% yield, m.p. 225â227Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (400Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.92 (s, 1H), 8.46 (d, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 1H), 8.13 (s, 1H), 7.77 (dd, <ce:italic>J</ce:italic>Â =Â 8.2, 1.8Â Hz, 1H), 7.61 (m, 5H), 7.31 (m, 4H), 7.00 (t, <ce:italic>J</ce:italic>Â =Â 6.5Â Hz, 1H), 4.33 (s, 2H), 2.36 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.52, 141.80, 137.54, 133.25, 130.56, 129.73, 128.29, 127.06, 126.10, 125.58, 123.81, 116.72, 114.98, 112.66, 111.95, 32.24, 21.29; MS (EI) <ce:italic>m/z</ce:italic> 430.12 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">19</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 430.1220; found: 430.1219. HPLC retention time 10.558Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0635" view="all">
                     <ce:bold>N-(1,1-dioxidobenzo[b]thiophen-6-yl)-2-(2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a] pyridine-3-yl)acetamide(59).</ce:bold> White solid, 62% yield, m.p. 156â159Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 11.34 (s, 1H), 8.55 (s, 1H), 8.07 (d, <ce:italic>J</ce:italic>Â =Â 31.7Â Hz, 5H), 7.84 (s, 1H), 7.63 (d, <ce:italic>J</ce:italic>Â =Â 34.5Â Hz, 3H), 7.32 (d, <ce:italic>J</ce:italic>Â =Â 38.3Â Hz, 2H), 7.01 (s, 1H), 4.45 (s, 2H), 3.26 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.38, 144.76, 141.89, 141.61, 139.92, 137.67, 133.30, 130.57, 128.87, 127.86, 127.04, 126.12, 125.76, 123.88, 117.38, 116.82, 112.96, 112.04, 44.08, 32.20; MS (EI) <ce:italic>m/z</ce:italic> 494.08 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">19</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">5</ce:inf>S<ce:inf loc="post">2</ce:inf> (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 494.0839; found: 494.0835. HPLC retention time 9.322Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0640" view="all">
                     <ce:bold>2-(2-(4-cyanophenyl)imidazo[1,2-a]pyridin-3-yl)-N-(1,1-dioxidobenzo[b]thiophen-6-yl) acetamide (60).</ce:bold> White solid, 66% yield, m.p. 243â244Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.99 (s, 1H), 8.48 (d, <ce:italic>J</ce:italic>Â =Â 6.9Â Hz, 1H), 8.13 (s, 1H), 8.01 (d, <ce:italic>J</ce:italic>Â =Â 8.2Â Hz, 2H), 7.95 (d, <ce:italic>J</ce:italic>Â =Â 8.2Â Hz, 2H), 7.78 (d, <ce:italic>J</ce:italic>Â =Â 8.1Â Hz, 1H), 7.67 (d, <ce:italic>J</ce:italic>Â =Â 9.1Â Hz, 1H), 7.59 (dd, <ce:italic>J</ce:italic>Â =Â 15.4, 7.5Â Hz, 2H), 7.36 (m, 1H), 7.29 (d, <ce:italic>J</ce:italic>Â =Â 6.8Â Hz, 1H), 7.02 (t, <ce:italic>J</ce:italic>Â =Â 6.7Â Hz, 1H), 4.39 (s, 2H); <ce:sup loc="post">13</ce:sup>C NMR (101Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.23, 144.75, 141.74, 141.56, 139.50, 137.68, 133.27, 133.11, 130.61, 128.86, 127.08, 126.18, 125.84, 125.67, 123.90, 119.42, 117.39, 116.79, 113.01, 112.04, 110.37, 32.27; MS (EI) <ce:italic>m/z</ce:italic> 441.10 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">18</ce:inf>ClN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 441.1016; found:441.1017. HPLC retention time 9.322Â min, 98.00% pure.</ce:para>
                  <ce:para id="p0645" view="all">
                     <ce:bold>N-(1,1-dioxidobenzo[b]thiophen-6-yl)-2-(imidazo[1,2-a]pyridin-3-yl)acetamide (61).</ce:bold> White solid, 82% yield, m.p. 222â224Â Â°C. <ce:sup loc="post">1</ce:sup>H NMR (500Â MHz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 10.87 (s, 1H), 8.41 (d, <ce:italic>J</ce:italic>Â =Â 6.8Â Hz, 1H), 8.12 (s, 1H), 7.74 (d, <ce:italic>J</ce:italic>Â =Â 8.2Â Hz, 1H), 7.55 (m, 4H), 7.25 (dd, <ce:italic>J</ce:italic>Â =Â 13.3, 7.3Â Hz, 2H), 6.93 (t, <ce:italic>J</ce:italic>Â =Â 6.7Â Hz, 1H), 4.19 (s, 2H); <ce:sup loc="post">13</ce:sup>C NMR (101Â Hz, DMSOâ<ce:italic>d</ce:italic>
                     <ce:inf loc="post">6</ce:inf>) Î´ 168.46, 145.36, 141.92, 137.70, 133.27, 133.22, 130.51, 127.03, 125.99, 125.50, 124.30, 123.69, 118.96, 117.41, 112.20, 111.81, 32.23; MS (EI) <ce:italic>m/z</ce:italic> 340.07 (MÂ +Â H)<ce:sup loc="post">+</ce:sup>; HRMS (ESI) calcd for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">13</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S (MÂ +Â H)<ce:sup loc="post">+</ce:sup>: 340.0750; found: 340.0743. HPLC retention time 6.732Â min, 100.00% pure.</ce:para>
                  <ce:para id="p0650" view="all">
                     <ce:bold>Cell lines and cell culture</ce:bold>. HEK-293T cells, triple-negative breast cancer MDA-MB-231 and MDA-MB231-4175Â cell lines were obtained from American Type Culture Collection and cultured in Dulbecco Modified Eagle Medium (DMEM, Gibco, USA) plus 10% (v/v) fetal bovine serum (FBS, Gibco, USA), 50Â Î¼g/mL penicillin and 50Â Î¼g/mL streptomycin (Gibco). A549, MGC-803, HCC70 and MDA-MB-468Â cell lines were obtained from American Type Culture Collection and cultured in RPMI 1640 medium (Gibco, USA) with 10% (v/v) FBS, 50Â Î¼g/mL penicillin and 50Â Î¼g/mL streptomycin (Gibco, USA). All cells were incubated at 37Â Â°C in an incubator containing 5% CO<ce:inf loc="post">2</ce:inf>.</ce:para>
                  <ce:para id="p0655" view="all">
                     <ce:bold>Reagents and antibodies</ce:bold>. The compound <ce:bold>39</ce:bold> was dissolved in sterile dimethyl sulfoxide (DMSO; MP, 196055) and stored atÂ â20Â Â°C. For animal studies, <ce:bold>39</ce:bold> was dissolved in PBS (0.01Â M; 8.1Â mM Na<ce:inf loc="post">2</ce:inf>HPO<ce:inf loc="post">4</ce:inf>Â·12H<ce:inf loc="post">2</ce:inf>O, 1.9Â mM NaH<ce:inf loc="post">2</ce:inf>PO<ce:inf loc="post">4</ce:inf>Â·2H<ce:inf loc="post">2</ce:inf>O and 145Â mM NaCl, pH 7.2â7.4; cat# G0002, Servicebio, China) containing 15% Cremophor EL (Millipore, 238470-1SET). The primary antibodies for phosphorylated (p-)STAT3 (Y705, #9145; S727, #9134), phosphorylated (p-)STAT1 (Y701, #9167), phosphorylated (p-)STAT5 (Y694, #9351), STAT5 (#25656), Î²-actin (#3700), c-myc (#5605), Mcl-1 (#4572), HA-tag (#3742), PARP (#9542), cleaved-caspase7 (#9491), second-fluorescence antibodies Alexa FluorÂ® 488 Conjuate2 (#4412) and Alexa FluorÂ® 555 Conjuate2 (#4409) were purchased from Cell Signaling Technology, Inc. The antibodies against STAT3 (10253-2-AP) and STAT1 (10144-2-AP) were purchased from ProteinTech Group, Inc. Bcl-xL antibody (sc-8392) was from Santa Cruz Biotechnology. Monoclonal ANTI-FLAGÂ® M2 antibody was from Sigma-Aldrich. The second antibodies Goat Anti-Rabbit IgG H&L (HRP) (ab6721) and Goat Anti-Mouse IgG H&L (HRP) (ab6789) antibodies were purchased from Abcam.</ce:para>
                  <ce:para id="p0660" view="all">
                     <ce:bold>Plasmids</ce:bold>. pGL3-STAT3 is a STAT3-dependent luciferase reporter with seven copies of the Stat3-specific binding sequence (AATCCCAGAA) in the C-reactive protein gene promoter. This new construct was verified by sequencing. STAT3C (or CSTAT3) is a an engineered constitutively dimerizeable STAT3, through substituting cysteine residues for specific amino acids within the C-terminal loop in the SH2 domain. Flag-STAT3 was purchased from FulenGen (#EX-Z2385-M35, Guangzhou, China) and STAT3 sequence was confirmed by sequence. HA-STAT3 in pCDNA3.1 backbone was purchased from PPL (#BC00627, Nanjing, China). STAT3 protein expression plasmid was constructed by inserting full length STAT3 into plasmid pET28a. The insert was confirmed by DNA sequencing.</ce:para>
                  <ce:para id="p0665" view="all">
                     <ce:bold>Molecular docking</ce:bold>. In this study, the STAT3 crystal structure (PDB ID: <ce:inter-ref id="intref0015" xlink:href="pdb:1BG1" xlink:type="simple">1BG1</ce:inter-ref>) was obtained from the PDB database, and the Maestro 11.1 (Schrodinger, Inc.) was used for molecular docking. Firstly, the âProtein Preparation Wizardâ module in Schrodinger software is used to optimize the structure of STAT3 protein, including removing water molecules, hydrogenation, energy minimization and treatment of metal ions and disulfide bonds. The small molecule was imported into the software and then optimized by the âLig Prepâ module, including the formation of 3D structure and low energy conformation. Next, the SH2 domain of the protein was extracted as the active pocket center, and the âReceptor Grid Generationâ module in the software was applied to generate the pocket Grid points. Finally, we dock STAT3 protein and small molecule by using the âLigand Dockingâ module in Schrodinger software. During docking, the STAT3 protein is considered rigid, while the small molecule is considered flexible. The Glide Score scoring function was applied to calculate the interaction and binding capacity of small molecule and STAT3 protein. As the main docking parameter, XP precision can calculate the binding free energy of ligand and receptor. The greater the negative absolute value is, the greater the affinity between ligand and receptor is. In addition, we also used the âProtein Surface Analyzerâ module to analyze the STAT3 protein structure based on electronegativity and marked with different colors.</ce:para>
                  <ce:para id="p0670" view="all">
                     <ce:bold>
                        <ce:italic>InÂ vitro</ce:italic> Metabolic Stability Study.</ce:bold> Microsomes in 0.1Â M TRIS buffer pH 7.4 (final concentration 0.33Â mg/mL), co-factor MgCl<ce:inf loc="post">2</ce:inf> (final concentration 5Â mM) and tested compound (final concentration 0.1Â Î¼M, co-solvent (0.01% DMSO) and 0.005% Bovin serum albumin (BSA)) were incubated at 37Â Â°C for 10Â min. The reaction was started by the addition of NADPH (final concentration 1Â mM). Aliquots were sampled at 0, 7, 17, 30 and 60Â min respectively and methanol (cold in 4Â Â°C) was added to terminate the reaction. After centrifugation (4000Â rpm,5Â min), samples were then analyzed by LC-MS/MS.</ce:para>
                  <ce:para id="p0675" view="all">
                     <ce:bold>Surface Plasmon Resonance (SPR) analysis</ce:bold>. SPR assay was performed using Biacore 8K (GE Healthcare, USA). Purified STAT3 protein (0.1Â mg/mL) was dissolved in PBS and immobilized onto the CM5 chip (GE Healthcare, USA). Different concentrations of <ce:bold>39</ce:bold> were dissolved in PBS (0.1% DMSO) and passed over the chip to produce diverse response signals. The binding affinity (K<ce:inf loc="post">D</ce:inf>) was evaluated using the Biacore Insight Evaluation Software.</ce:para>
                  <ce:para id="p0680" view="all">
                     <ce:bold>Cell viability assay</ce:bold>. Cell viability assay was performed using Cell Counting Kit-8 (Bimake, B34302) to measure anti-proliferative activity of designed compounds. The cells were seeded in 96-well plates with 1000â8000Â cells per well and allowed to grow overnight. Subsequently, cells were treated with vehicle (0.1% DMSO, as the solvent control) or different concentrations of compounds for 72Â h. Before testing, the cells were added to 1/10 volume of CCK-8 each well and incubated for 0.5â4Â h at 37Â Â°C until the OD values of vehicle are about 0.8â1.5. Then, the absorbance (also called optical density, OD) of each hole at 480Â nm was determined by microplate reader (FLUOstar Omega ACU, Germany). Cell viability (%)Â = (OD<ce:inf loc="post">compounds</ce:inf>-OD<ce:inf loc="post">blank</ce:inf>)/(OD<ce:inf loc="post">vehicle</ce:inf>-OD<ce:inf loc="post">blank</ce:inf>) X 100%. âBlankâ represents medium only. Finally, the IC<ce:inf loc="post">50</ce:inf> values were evaluated by GraphPad Prism 7. The concentration range used for this assay was from 0.1Â Î¼M to 100Â Î¼M.</ce:para>
                  <ce:para id="p0685" view="all">
                     <ce:bold>Colony formation assay</ce:bold>. Colony formation assay was performed to examine the effect of <ce:bold>39</ce:bold> on cell colony survival. MDA-MB-231, MDA-MB-468, MDA-MB231-4175 and HCC70Â cells were seeded in 6-well plates with 0.5Â ÃÂ 10<ce:sup loc="post">3</ce:sup>â1Â ÃÂ 10<ce:sup loc="post">3</ce:sup>Â cells per well. The second day, various concentrations of <ce:bold>39</ce:bold> were added into the cells. After that, the cell culture medium was changed and the corresponding concentration of <ce:bold>39</ce:bold> was added every 2â3 days until the colonies visible. About 10â15 days later, the cells were fixed using 4% paraformaldehyde fix solution (Beyotime, China) and stained with crystal violet (Beyotime, China). The results of colonies were scanned by printer, processed with image J and analyzed with GraphPad Prism 7. All experiments were set in triplicate.</ce:para>
                  <ce:para id="p0690" view="all">
                     <ce:bold>Wounding healing assay</ce:bold>. Wounding healing assay was performed to measure whether <ce:bold>39</ce:bold> inhibit TNBC cells migration. MDA-MB-231, MDA-MB-468, MDA-MB231-4175 and HCC70Â cells were seeded in 6-well plates with 0.8Â ÃÂ 10<ce:sup loc="post">6</ce:sup>â1.2Â ÃÂ 10<ce:sup loc="post">6</ce:sup>Â cells per well. When the cell fusion degree reaches 100%, the cells were scratched with pipette tips. Then, the cells were treated with 0â3Â Î¼M <ce:bold>39</ce:bold> until the vehicle cells migrate into the scratched area. About 12â96Â h later, pictures of the cells were taken with microscope. All experiments were set in triplicate.</ce:para>
                  <ce:para id="p0695" view="all">
                     <ce:bold>Transwell assay for cell invasion</ce:bold>. Invasion assay was performed in 24-well TranswellÂ® plates with 8.0Â Î¼m pore polycarbonate filters (Corning, USA). MDA-MB-231, MDA-MB-468, MDA-MB231-4175 and HCC70Â cells were seeded in the top chamber of insert at 1.5Â ÃÂ 10<ce:sup loc="post">4</ce:sup>â3Â ÃÂ 10<ce:sup loc="post">4</ce:sup>Â cells/well. Then, the cells were treated with different concentrations of <ce:bold>39</ce:bold>. After the treatment with <ce:bold>39</ce:bold> for 12Â h, the cells in the top chamber were carefully removed by cotton and then washed with PBS twice, and the invaded cells in the bottom chamber were fixed with 4% paraformaldehyde and stained with crystal violet. Finally, the invaded cells were photographed and calculated. All experiments were set in triplicate.</ce:para>
                  <ce:para id="p0700" view="all">
                     <ce:bold>Apoptosis assay</ce:bold>. Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) Cell Death Detection Kit (BestBio, China) was applied in cell apoptosis assay. The MDA-MB-231, MDA-MB-468 and MDA-MB231-4175Â cells were seeded in 6-well plates and treated with vehicle (0.1% DMSO, as the solvent control) or <ce:bold>39</ce:bold> for 48Â h. Then, the cells were digested with trypsin without EDTA, then, washed with cold PBS twice and resuspended in 400Â Î¼L 1X binding buffer solution. Subsequently, the cells were incubated with Annexin V-FITC (5Â Î¼l) for 5Â min and PI (10Â Î¼l) for 15Â min at 4Â Â°C in the dark. Finally, the samples were detected within 1Â h by flow cytometry (Millipore, USA) and processed by FlowJo 7.6 software. All experiments were set in triplicate.</ce:para>
                  <ce:para id="p0705" view="all">
                     <ce:bold>RNA interference</ce:bold>. MDA-MB-231Â cells were seeded into 6-well or 96-well plates. After incubating for 18â24Â h, cells grew to 60â70%. According to the manufacturer's protocol of DharmaFECT (T-2001-03, Dharmacon, USA), cells were transfected with negative control or siRNA targeting STAT3. For STAT3 interference, the sequence of siRNA targeting STAT3:</ce:para>
                  <ce:para id="p0710" view="all">STAT3-F: 5â²-UCCAGUUUCUUAAUUUGUUGACGGGUC-3â;</ce:para>
                  <ce:para id="p0715" view="all">STAT3-R: 5â²-GACCCGUCAACAAAUUAAGAAACUGGA-3â;</ce:para>
                  <ce:para id="p0720" view="all">A nonspecific oligonucleotide without complementary to any human gene was used as negative control. All above siRNAs were synthesized by Sangon Biotech (Guangdong, China).</ce:para>
                  <ce:para id="p0725" view="all">
                     <ce:bold>Western blotting analysis</ce:bold>. The human breast cancer cells were treated with vehicle (0.1% DMSO, as the solvent control) and various concentrations of <ce:bold>39</ce:bold> for 3, 24 or 48Â h. Subsequently, the cells were lysed with RIPA buffer(50Â mM Tris (pH 7.4), 150Â mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS sodium orthovanadate, sodium fluoride, EDTA, leupeptin containing 1Â mM PMSF (Beyotime, China) and 1% phosphatase inhibitor cocktail (Bimake, China) and the specimen were quantified with Pierceâ¢ BCA Protein Assay Kit (Thermo, 23225). The cell lysates containing 20â50Â Î¼g of proteins were denatured by boiling and then analyzed by electrophoresis on 8 or 12% SDS-PAGE gels and transferred onto polyvinylidene difluoride membranes (Millipore, USA). The membranes were blocked with 5% Bovine Serum Albumin (Beyotime, China) for 1Â h at room temperature, and then, incubated with primary antibodies (pY705-STAT3, pS727-STAT3, STAT3, Mcl-1, Bcl-xL, c-Myc, Î²-actin, PARP and cleaved-caspase7) overnight at 4Â Â°C. After washed three times with TBST (TBS with 0.1% Tween-20) buffer, the membranes were incubated with corresponding anti-rabbit (Abcam, ab6721) or anti-mouse (Abcam, ab6789) HRP-conjugated secondary antibodies for 1Â h at room temperature. Finally, the membranes were washed with TBST buffer three times for 10Â min each time and then developed with ECL kit (Tanon, China) following the manufacturer's protocol.</ce:para>
                  <ce:para id="p0730" view="all">
                     <ce:bold>Immunofluorescence for colocalization</ce:bold>. HEK-293T cells were seeded in confocal dishes and incubated overnight. Then, the cells were transfected with HA-STAT3 and Flag-STAT3. 24Â h later, HEK-293T cells were treated with vehicle (0.1% DMSO) and <ce:bold>39</ce:bold> for 24Â h. The cells were added to 100Â ng/mL IL-6 (PeproTech, China) for 30Â min before imaged. Subsequently, HEK-293T cells were fixed with 4% paraformaldehyde for 15Â min and permeabilized with 0.3% Triton X-100 for 10Â min. The samples were blocked with goat serum (Boster, China) for 1Â h at room temperature, and then, incubated with HA-tag and Flag-tag antibody at 1: 500 dilution (in goat serum) at 4Â Â°C overnight. After washed three times with PBS, the cells were incubated with two Alexa Fluor secondary antibodies, Alexa Fluor 555 Conjugate and Alexa Fluor 488 Conjugate for Flag-STAT3 and HA-STAT3 detection, respectively, for 1Â h at room temperature in the dark. Then, the cells were rinsed with DAPI (Yeasen, China) for 10Â min in the dark followed by washed three times with PBS. Finally, the specimens were examined by Laser Scanning Confocal Microscope FV3000 (Olympus, Japan) and imaged using Olympus software.</ce:para>
                  <ce:para id="p0735" view="all">
                     <ce:bold>Co-immunoprecipitation</ce:bold>. HEK-293T cells were seeded into 6-well plates with the concentration of 5Â ÃÂ 10<ce:sup loc="post">5</ce:sup>Â cells per well and allowed to grow overnight. Then, the cells were transiently transfected with 2500Â ng HA-STAT3 and 2500Â ng Flag-STAT3. After 24Â h, HEK-293T cells, which stably express HA- and Flag-tagged STAT3, were treated with vehicle (0.1% DMSO, as the solvent control) and <ce:bold>39</ce:bold> for 3Â h. Then, the cells were added to 100Â ng/mL IL-6 to stimulate the interaction between HA-STAT3 and Flag-STAT3 proteins. Subsequently, the cell lysates were extracted for IP by cell lysis buffer (Beyotime, China) containing 1Â mM PMSF and 1% phosphatase inhibitor cocktail. Anti-Flag Affinity Gel (Bimake, B23101) was washed three times with PBST (PBS with 0.2% Tween) and incubated with 600â800Â Î¼g lysates at 4Â Â°C overnight. Then, the mixtures were washed three times with PBST to remove unbound proteins and boiled in 50Â Î¼L 1Â ÃÂ SDS-PAGE loading buffer for 5Â min. Finally, the samples were run on SDS-PAGE gel, transferred to polyvinylidene difluoride membranes and then blotted for HA-tag and Flag-tag antibodies.</ce:para>
                  <ce:para id="p0740" view="all">
                     <ce:bold>Reporter gene assay for STAT3 transcriptional activity</ce:bold>. HEK-293T cells were plated into 96-well plates with 2.5Â ÃÂ 10<ce:sup loc="post">4</ce:sup>Â cells per well and incubated overnight. Subsequently, the cells were transiently transfected with 50Â ng pGL3-STAT3 (a STAT3-dependent luciferase reporter, containing seven copies of the Stat3-specific binding sequence (AATCCCAGAA), 50Â ng STAT3C and 40Â ng TK-Renilla as control. After 24Â h, HEK-293T cells were treated with vehicle and <ce:bold>39</ce:bold> for 24Â h. Samples were processed with Dual Luciferase Reporter Gene Assay Kit (Beyotime, China) following the manufacturer's protocol. The luciferase activity was measured in the luminometer (Promega, GloMaxÂ® Navigator, USA).</ce:para>
                  <ce:para id="p0745" view="all">
                     <ce:bold>Electrophoretic Mobility Shift Assay</ce:bold>. MDA-MB-231 and MDA-MB-468Â cells were treated with vehicle and <ce:bold>39</ce:bold> for 3Â h. Then, nuclear extract preparations of the cells were collected with Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime, China) following the manufacturer's protocol and quantified with Pierceâ¢ BCA Protein Assay Kit (Thermo, USA). 8â10Â Î¼g nuclear proteins were incubated with biotin-STAT3 (Beyotime, China) or biotin-STAT5 probe (Beyotime, China) prior to EMSA. The STAT3 or STAT5 DNA-protein complexes were separated in 6% native polyacrylamide gels and transferred to a positively charged nylon membrane. The membrane was detected by EMSA/gel-shift Kit (Beyotime, China) following the manufacturer's instructions.</ce:para>
                  <ce:para id="p0750" view="all">
                     <ce:bold>Pharmacokinetic study</ce:bold>. Compound <ce:bold>39</ce:bold> was dissolved in DMSO/0.5% HPMCÂ = (5/95, v/v) and was given to SD rats by oral administration. Animal procedures were performed according to institutional ethical guidelines of animal care. The blood samples were collected at 0.25, 0.5, 1, 2, 4, 8, 24h after administration, and then plasma samples were harvested. 20Â Î¼L plasma samples were precipitated by 200Â Î¼L acetonitrile/methanol (1/1, v/v), and the supernatant was mixed with equal volume of water before analysis. The analysis was performed on a LC-MS/MS system consisted of triple quadrupole mass spectrometer (TQ-S; Waters; America) and liquid chromatography (ACQUITY I-Class; Waters; USA). The chromatographic separation was performed on an ACQUITY UPLCr BEH Phenyl 1.7Â Î¼m column (50Â mmÂ ÃÂ 2.1Â mm I.D., 1.7Â Î¼m) (Waters; USA). The mobile phase consisted of 0.1% formic acid in water and 0.1% formic in acetonitrile.</ce:para>
                  <ce:para id="p0755" view="all">
                     <ce:bold>Animal studies</ce:bold>. In human breast carcinoma cells xenograft tumor model, 2Â ÃÂ 10<ce:sup loc="post">6</ce:sup>â3Â ÃÂ 10<ce:sup loc="post">6</ce:sup> MDA-MB231-4175Â cells were subcutaneously injected into the flank of 4-5-week-old NOD-SCID female mice (SCXK 2018-0008). In human triple-negative breast cancer patient-derived tumor xenograft (TNBC PDX) model, we used the tumor tissues from the TNBC patient (No. J00099327, Jackson Lab, USA) in serum-free DMEM, which was then cut into pieces. Approximately 2Â mm<ce:sup loc="post">3</ce:sup> patient tumor tissue fragments were subcutaneously implanted into the flank of female NOD-SCID mice (SCXK 2018-0008) using a trocar. For these two models, when tumor volume reached about 100Â mm<ce:sup loc="post">3</ce:sup>, the mice were randomly divided into three groups (nÂ =Â 6/group) including vehicle (treated with PBS containing 15% Cremophor EL), 5Â mg/kg and 15Â mg/kg <ce:bold>39</ce:bold> (diluted in PBS containing 15% Cremophor EL). Mice were administered with different doses of <ce:bold>39</ce:bold> by intraperitoneal injection every day. The volume (V) of the tumor was measured every 2â3 days and calculated using the formula, VÂ =Â Ï/6Â ÃÂ S<ce:sup loc="post">2</ce:sup>Â ÃÂ L, where S is the minor axis and L is the major axis. At day 20, the mice were sacrificed and their tumor tissues were harvested and weighed. The tumor tissues were detected by immunohistochemistry assay using Ki67 antibody. The hearts, livers, spleen, lungs, kidneys of the mice were also collected for hematological analysis to study the toxicology of <ce:bold>39</ce:bold>. For immunoblot assay, we gained the protein samples of tumor lysed with RIPA buffer (Beyotime, China) subjecting to western blot analysis as described above. All animal procedures were approved by Animal Care and Use Committee of Sun Yat-Sen Univeristy, Guangzhou, China.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0010" view="all">
               <ce:section-title id="sectitle0070">Declaration of competing interest</ce:section-title>
               <ce:para id="p0760" view="all">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0075">Acknowledgments</ce:section-title>
               <ce:para id="p0765" view="all">This work was supported by grants from <ce:grant-sponsor id="gs1" sponsor-id="https://doi.org/10.13039/501100001809" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">National Natural Science Foundation of China</ce:grant-sponsor> (Grant <ce:grant-number refid="gs1">21977128</ce:grant-number> and <ce:grant-number refid="gs1">81973359</ce:grant-number>) and <ce:grant-sponsor id="gs3" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Guangzhou Science and Technology Planning Programme</ce:grant-sponsor> (<ce:grant-number refid="gs3">202103000097</ce:grant-number> and <ce:grant-number refid="gs3">202002030408</ce:grant-number>). <ce:grant-sponsor id="gs2" sponsor-id="https://doi.org/10.13039/501100003453" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Natural Science Foundation of Guangdong</ce:grant-sponsor> (Grant <ce:grant-number refid="gs2">2018A030313300</ce:grant-number> and <ce:grant-number refid="gs2">2019A1515011215</ce:grant-number>) and <ce:grant-sponsor id="gs4" sponsor-id="https://doi.org/10.13039/501100012226" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Fundamental Research Funds for the Central Universities</ce:grant-sponsor> (<ce:grant-number refid="gs4">20ykpy117</ce:grant-number> and <ce:grant-number refid="gs4">19ykpy125</ce:grant-number>) were also highly appreciated.</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0080">Supplementary data</ce:section-title>
                  <ce:para id="p0770" view="all">The following is the Supplementary data to this article:<ce:display>
                        <ce:e-component id="mmc1">
                           <ce:label>Multimedia component 1</ce:label>
                           <ce:alt-text id="alttext0015" role="short">Multimedia component 1</ce:alt-text>
                           <ce:link locator="mmc1" xlink:href="pii:S0223523421003743/mmc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:type="simple"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0085">Supplementary data</ce:section-title>
                  <ce:para id="p0775" view="all">Supplementary data to this article can be found online at <ce:inter-ref id="intref0020" xlink:href="https://doi.org/10.1016/j.ejmech.2021.113525" xlink:type="simple">https://doi.org/10.1016/j.ejmech.2021.113525</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0090">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Debnath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Neamati</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6645</sb:first-page>
                              <sb:last-page>6668</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0020">B. Debnath, S. Xu, N. Neamati, Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein, J. Med. Chem. 55 (2012) 6645-6668.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Qu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: where are we and where should we go?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>187</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>111922</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0025">Q. Huang, Y. Zhong, H. Dong, Q. Zheng, S. Shi, K. Zhu, X. Qu, W. Hu, X. Zhang, Y. Wang, Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go? , Eur. J. Med. Chem. 187 (2020) 111922.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Al Zaid Siddiquee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 as a target for inducing apoptosis in solid and hematological tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>254</sb:first-page>
                              <sb:last-page>267</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">K. Al Zaid Siddiquee, J. Turkson, STAT3 as a target for inducing apoptosis in solid and hematological tumors, Cell Res, 18 (2008) 254-267.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sansone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bromberg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting the interleukin-6/Jak/stat pathway in human malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1005</sb:first-page>
                              <sb:last-page>1014</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">P. Sansone, J. Bromberg, Targeting the interleukin-6/Jak/stat pathway in human malignancies, J Clin Oncol, 30 (2012) 1005-1014.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Miklossy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Hilliard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic modulators of STAT signalling for human diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>611</sb:first-page>
                              <sb:last-page>629</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">G. Miklossy, T.S. Hilliard, J. Turkson, Therapeutic modulators of STAT signalling for human diseases, Nat Rev Drug Discov, 12 (2013) 611-629.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>O'Keefe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Grandis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting the IL-6/JAK/STAT3 signalling axis in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>234</sb:first-page>
                              <sb:last-page>248</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">D.E. Johnson, R.A. O'Keefe, J.R. Grandis, Targeting the IL-6/JAK/STAT3 signalling axis in cancer, Nat Rev Clin Oncol, 15 (2018) 234-248.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Beebe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>191</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>74</sb:first-page>
                              <sb:last-page>91</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">J.D. Beebe, J.Y. Liu, J.T. Zhang, Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we? Pharmacol Ther, 191 (2018) 74-91.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Herrmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Buettner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Revisiting STAT3 signalling in cancer: new and unexpected biological functions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>736</sb:first-page>
                              <sb:last-page>746</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">H. Yu, H. Lee, A. Herrmann, R. Buettner, R. Jove, Revisiting STAT3 signalling in cancer: new and unexpected biological functions, Nat Rev Cancer, 14 (2014) 736-746.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.H.</ce:given-name>
                                 <ce:surname>Leung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.T.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Zhong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Leung</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antagonizing STAT3 dimerization with a rhodium(III) complex</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Angew Chem. Int. Ed. Engl.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>53</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9178</sb:first-page>
                              <sb:last-page>9182</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">D.L. Ma, L.J. Liu, K.H. Leung, Y.T. Chen, H.J. Zhong, D.S. Chan, H.M. Wang, C.H. Leung, Antagonizing STAT3 dimerization with a rhodium(III) complex, Angew Chem Int Ed Engl, 53 (2014) 9178-9182.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>La Sala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Michiels</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kukenshoner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Brandstoetter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Maurer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Koide</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Lau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Pojer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Koide</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Sexl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Dumoutier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Hantschel</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selective inhibition of STAT3 signaling using monobodies targeting the coiled-coil and N-terminal domains</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4115</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">G. La Sala, C. Michiels, T. Kukenshoner, T. Brandstoetter, B. Maurer, A. Koide, K. Lau, F. Pojer, S. Koide, V. Sexl, L. Dumoutier, O. Hantschel, Selective inhibition of STAT3 signaling using monobodies targeting the coiled-coil and N-terminal domains, Nat Commun, 11 (2020) 4115.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Feedback activation of STAT3 as a cancer drug-resistance mechanism</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Pharmacol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>37</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>47</sb:first-page>
                              <sb:last-page>61</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">C. Zhao, H. Li, H.J. Lin, S. Yang, J. Lin, G. Liang, Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism, Trends Pharmacol Sci, 37 (2016) 47-61.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Zhuang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Du</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Settleman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>207</sb:first-page>
                              <sb:last-page>221</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">H.J. Lee, G. Zhuang, Y. Cao, P. Du, H.J. Kim, J. Settleman, Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells, Cancer Cell, 26 (2014) 207-221.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Spitzner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ebner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Wolff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.M.</ce:given-name>
                                 <ce:surname>Ghadimi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wienands</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Grade</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3: a novel molecular mediator of resistance to chemoradiotherapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancers (Basel)</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1986</sb:first-page>
                              <sb:last-page>2011</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">M. Spitzner, R. Ebner, H.A. Wolff, B.M. Ghadimi, J. Wienands, M. Grade, STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy, Cancers (Basel), 6 (2014) 1986-2011.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Pavlinov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Salkovski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.N.</ce:given-name>
                                 <ce:surname>Aldrich</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Beclin 1-ATG14L protein-protein interaction inhibitor selectively inhibits autophagy through disruption of VPS34 complex I</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Am. Chem. Soc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>142</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8174</sb:first-page>
                              <sb:last-page>8182</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">I. Pavlinov, M. Salkovski, L.N. Aldrich, Beclin 1-ATG14L Protein-Protein Interaction Inhibitor Selectively Inhibits Autophagy through Disruption of VPS34 Complex I, J Am Chem Soc, 142 (2020) 8174-8182.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>McAulay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Hoyt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Thomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Schimpl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Bodnarchuk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Lewis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Barratt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bhavsar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Robinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Deery</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Ogg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.J.L.</ce:given-name>
                                 <ce:surname>Bernardes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Ward</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Waring</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.G.</ce:given-name>
                                 <ce:surname>Kettle</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Alkynyl benzoxazines and dihydroquinazolines as cysteine targeting covalent warheads and their application in identification of selective irreversible kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Am. Chem. Soc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>142</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>10358</sb:first-page>
                              <sb:last-page>10372</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">K. McAulay, E.A. Hoyt, M. Thomas, M. Schimpl, M.S. Bodnarchuk, H.J. Lewis, D. Barratt, D. Bhavsar, D.M. Robinson, M.J. Deery, D.J. Ogg, G.J.L. Bernardes, R.A. Ward, M.J. Waring, J.G. Kettle, Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors, J Am Chem Soc, 142 (2020) 10358-10372.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Niu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kortylewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Burdelya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Shain</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Bhattacharya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Gabrilovich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Heller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Coppola</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Dalton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pardoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>48</sb:first-page>
                              <sb:last-page>54</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">T. Wang, G. Niu, M. Kortylewski, L. Burdelya, K. Shain, S. Zhang, R. Bhattacharya, D. Gabrilovich, R. Heller, D. Coppola, W. Dalton, R. Jove, D. Pardoll, H. Yu, Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells, Nat Med, 10 (2004) 48-54.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of STAT3 in leading the crosstalk between human cancers and the immune system</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>415</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>117</sb:first-page>
                              <sb:last-page>128</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">Y. Wang, Y. Shen, S. Wang, Q. Shen, X. Zhou, The role of STAT3 in leading the crosstalk between human cancers and the immune system, Cancer Lett, 415 (2018) 117-128.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Karakasheva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.W.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Qiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Waldron</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Soni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Klein-Szanto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Sahu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Basu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ohashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Baba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.T.</ce:given-name>
                                 <ce:surname>Giaccone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Walker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Frank</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.P.</ce:given-name>
                                 <ce:surname>Wileyto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Long</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Dunagin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Raj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Diehl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.K.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Bass</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Rustgi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>IL-6 mediates cross-talk between tumor cells and activated fibroblasts in the tumor microenvironment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>78</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4957</sb:first-page>
                              <sb:last-page>4970</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">T.A. Karakasheva, E.W. Lin, Q. Tang, E. Qiao, T.J. Waldron, M. Soni, A.J. Klein-Szanto, V. Sahu, D. Basu, S. Ohashi, K. Baba, Z.T. Giaccone, S.R. Walker, D.A. Frank, E.P. Wileyto, Q. Long, M.C. Dunagin, A. Raj, J.A. Diehl, K.K. Wong, A.J. Bass, A.K. Rustgi, IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment, Cancer Res, 78 (2018) 4957-4970.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kitamura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ohno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Toyoshima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ohtake</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Homma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kawamura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Takahashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Taketomi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>108</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1947</sb:first-page>
                              <sb:last-page>1952</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">H. Kitamura, Y. Ohno, Y. Toyoshima, J. Ohtake, S. Homma, H. Kawamura, N. Takahashi, A. Taketomi, Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy, Cancer Sci, 108 (2017) 1947-1952.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.M.</ce:given-name>
                                 <ce:surname>Song Tl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Laurensia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Pang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kizhakeyil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Wijaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nagarajan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.K.</ce:given-name>
                                 <ce:surname>Chia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Cheah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Rao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.K.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Iqbal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Grigoropoulos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Chng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Teh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.K.</ce:given-name>
                                 <ce:surname>Verma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer-T-cell lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>132</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1146</sb:first-page>
                              <sb:last-page>1158</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">N.M. Song TL, Laurensia Y, Lim J, Tan J, Li Z, Pang W, Kizhakeyil A, Wijaya G, Huang D, Nagarajan S, Chia BK, Cheah D, Liu Y, Zhang F, Rao H, Tang T, Wong EK, Bei J, Iqbal J, Grigoropoulos N, Ng S, Chng W, Teh B, Tan S, Verma NK, Fan H, Lim S, Ong C, Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer-T-cell lymphoma, Blood, 132 (2018) 1146-1158.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Atsaves</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Tsesmetzis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Chioureas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Leventaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Drakos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Panaretakis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Grander</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Medeiros</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.H.</ce:given-name>
                                 <ce:surname>Young</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.Z.</ce:given-name>
                                 <ce:surname>Rassidakis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1633</sb:first-page>
                              <sb:last-page>1637</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">V. Atsaves, N. Tsesmetzis, D. Chioureas, L. Kis, V. Leventaki, E. Drakos, T. Panaretakis, D. Grander, L.J. Medeiros, K.H. Young, G.Z. Rassidakis, PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma, Leukemia, 31 (2017) 1633-1637.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Jing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Fang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Bifunctional naphthoquinone aromatic amide-oxime derivatives exert combined immunotherapeutic and antitumor effects through simultaneous targeting of indoleamine-2,3-dioxygenase and signal transducer and activator of transcription 3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>63</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1544</sb:first-page>
                              <sb:last-page>1563</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">R. Huang, X. Jing, X. Huang, Y. Pan, Y. Fang, G. Liang, Z. Liao, H. Wang, Z. Chen, Y. Zhang, Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3, J Med Chem, 63 (2020) 1544-1563.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Matsuno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Masuda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Uehara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Muroya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Takahashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yokotagawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Furuya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Okawara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Otsuka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ogo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ashizawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Oshita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Tai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ishii</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Akiyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Asai</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of a new series of STAT3 inhibitors by virtual screening</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>371</sb:first-page>
                              <sb:last-page>375</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">K. Matsuno, Y. Masuda, Y. Uehara, H. Sato, A. Muroya, O. Takahashi, T. Yokotagawa, T. Furuya, T. Okawara, M. Otsuka, N. Ogo, T. Ashizawa, C. Oshita, S. Tai, H. Ishii, Y. Akiyama, A. Asai, Identification of a New Series of STAT3 Inhibitors by Virtual Screening, ACS Med Chem Lett, 1 (2010) 371-375.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sharmeen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Datti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Wrana</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Trudel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Schimmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5605</sb:first-page>
                              <sb:last-page>5609</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">B.D. Page, S. Fletcher, P. Yue, Z. Li, X. Zhang, S. Sharmeen, A. Datti, J.L. Wrana, S. Trudel, A.D. Schimmer, J. Turkson, P.T. Gunning, Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain, Bioorg Med Chem Lett, 21 (2011) 5605-5609.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Haftchenary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Luchman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.O.</ce:given-name>
                                 <ce:surname>Jouk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Veloso</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.R.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Dawson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Grinshtein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Shahani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Kerman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Kaplan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Griffin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Aman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Al-Awar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Weiss</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potent targeting of the STAT3 protein in brain cancer stem cells: a promising route for treating glioblastoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1102</sb:first-page>
                              <sb:last-page>1107</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">S. Haftchenary, H.A. Luchman, A.O. Jouk, A.J. Veloso, B.D. Page, X.R. Cheng, S.S. Dawson, N. Grinshtein, V.M. Shahani, K. Kerman, D.R. Kaplan, C. Griffin, A.M. Aman, R. Al-Awar, S. Weiss, P.T. Gunning, Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma, ACS Med Chem Lett, 4 (2013) 1102-1107.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.W.</ce:given-name>
                                 <ce:surname>Hui Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Shaomeng</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Jiayuh</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ low-molecular weight compound discovered through virtual database screening inhibits Stat 3 function in breast cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>4700-1705</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0145">R.W. Hui Song, Shaomeng Wang, and Jiayuh Lin, A low-molecular weight compound discovered through virtual database screening inhibits Stat 3 function in breast cancer cells, Proc Natl Acad Sci USA, 102 (2005) 4700-1705.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Karakasheva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.W.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Qiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Waldron</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Soni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Klein-Szanto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Sahu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Basu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ohashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Baba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.T.</ce:given-name>
                                 <ce:surname>Giaccone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Walker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Frank</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.P.</ce:given-name>
                                 <ce:surname>Wileyto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Long</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Dunagin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Raj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Diehl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.K.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Bass</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Rustgi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>IL-6 mediates cross-talk between tumor cells and activated fibroblasts in the tumor microenvironment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>78</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4957</sb:first-page>
                              <sb:last-page>4970</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">T.A. Karakasheva, E.W. Lin, Q. Tang, E. Qiao, T.J. Waldron, M. Soni, A.J. Klein-Szanto, V. Sahu, D. Basu, S. Ohashi, K. Baba, Z.T. Giaccone, S.R. Walker, D.A. Frank, E.P. Wileyto, Q. Long, M.C. Dunagin, A. Raj, J.A. Diehl, K.K. Wong, A.J. Bass, A.K. Rustgi, IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment, Cancer Res, 78 (2018) 4957-4970.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Chinnaswamy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>McEachern</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Meagher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Stuckey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ potent and selective small-molecule degrader of STAT3 achieves complete tumor regression inÂ vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>498</sb:first-page>
                              <sb:last-page>511 e417</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0155">L. Bai, H. Zhou, R. Xu, Y. Zhao, K. Chinnaswamy, D. McEachern, J. Chen, C.Y. Yang, Z. Liu, M. Wang, L. Liu, H. Jiang, B. Wen, P. Kumar, J.L. Meagher, D. Sun, J.A. Stuckey, S. Wang, A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression InÂ Vivo, Cancer Cell, 36 (2019) 498-511 e417.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>McEachern</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Chinnaswamy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Dai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Meagher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Stuckey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>11280</sb:first-page>
                              <sb:last-page>11300</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">H. Zhou, L. Bai, R. Xu, Y. Zhao, J. Chen, D. McEachern, K. Chinnaswamy, B. Wen, L. Dai, P. Kumar, C.Y. Yang, Z. Liu, M. Wang, L. Liu, J.L. Meagher, H. Yi, D. Sun, J.A. Stuckey, S. Wang, Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein, J Med Chem, 62 (2019) 11280-11300.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.B.</ce:given-name>
                                 <ce:surname>Becker S</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>MÃ¼ller</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Three-dimensional structure of the Stat3beta homodimer bound to DNA</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>394</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>145</sb:first-page>
                              <sb:last-page>151</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">G.B. Becker S, Muller CW, Three-dimensional structure of the Stat3beta homodimer bound to DNA, Nature, 394 (1998) 145-151.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Musharrafieh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Tuohy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Kitamura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Bellampalli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Khanna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of quinoline analogues as potent antivirals against enterovirus D68 (EV-D68)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4074</sb:first-page>
                              <sb:last-page>4090</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">R. Musharrafieh, J. Zhang, P. Tuohy, N. Kitamura, S.S. Bellampalli, Y. Hu, R. Khanna, J. Wang, Discovery of Quinoline Analogues as Potent Antivirals against Enterovirus D68 (EV-D68), J Med Chem, 62 (2019) 4074-4090.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Felicetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Cannalire</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pietrella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Latacz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Lubelska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Manfroni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Barreca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Massari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Tabarrini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Kiec-Kononowicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Schindler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.W.</ce:given-name>
                                 <ce:surname>Kaatz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Cecchetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sabatini</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>2-Phenylquinoline S. aureus NorA efflux pump inhibitors: evaluation of the importance of methoxy group introduction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7827</sb:first-page>
                              <sb:last-page>7848</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">T. Felicetti, R. Cannalire, D. Pietrella, G. Latacz, A. Lubelska, G. Manfroni, M.L. Barreca, S. Massari, O. Tabarrini, K. Kiec-Kononowicz, B.D. Schindler, G.W. Kaatz, V. Cecchetti, S. Sabatini, 2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction, J Med Chem, 61 (2018) 7827-7848.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Krapf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wiese</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and biological evaluation of 4-Anilino-quinazolines and -quinolines as inhibitors of breast cancer resistance protein (ABCG2)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>59</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5449</sb:first-page>
                              <sb:last-page>5461</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">M.K. Krapf, M. Wiese, Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2), J Med Chem, 59 (2016) 5449-5461.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.D.</ce:given-name>
                                 <ce:surname>Cushing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Hao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Andrews</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Cardozo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Duquette</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Fisher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Gonzalez-Lopez de Turiso</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.R.</ce:given-name>
                                 <ce:surname>Henne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.L.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hungate</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Kelly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Lucas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>McCarter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.R.</ce:given-name>
                                 <ce:surname>McGee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Medina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>San Miguel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Mohn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Pattaropong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.H.</ce:given-name>
                                 <ce:surname>Pettus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Reichelt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Rzasa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Seganish</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Tasker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Wahl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wannberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Whittington</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Whoriskey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zalameda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Metz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery and inÂ vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kdelta inhibitors for inflammation and autoimmune disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>480</sb:first-page>
                              <sb:last-page>511</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">T.D. Cushing, X. Hao, Y. Shin, K. Andrews, M. Brown, M. Cardozo, Y. Chen, J. Duquette, B. Fisher, F. Gonzalez-Lopez de Turiso, X. He, K.R. Henne, Y.L. Hu, R. Hungate, M.G. Johnson, R.C. Kelly, B. Lucas, J.D. McCarter, L.R. McGee, J.C. Medina, T. San Miguel, D. Mohn, V. Pattaropong, L.H. Pettus, A. Reichelt, R.M. Rzasa, J. Seganish, A.S. Tasker, R.C. Wahl, S. Wannberg, D.A. Whittington, J. Whoriskey, G. Yu, L. Zalameda, D. Zhang, D.P. Metz, Discovery and inÂ vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kdelta inhibitors for inflammation and autoimmune disease, J Med Chem, 58 (2015) 480-511.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sabatini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Gosetto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Iraci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Barreca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Massari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Sancineto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Manfroni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Tabarrini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Dimovska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.W.</ce:given-name>
                                 <ce:surname>Kaatz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Cecchetti</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4975</sb:first-page>
                              <sb:last-page>4989</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">S. Sabatini, F. Gosetto, N. Iraci, M.L. Barreca, S. Massari, L. Sancineto, G. Manfroni, O. Tabarrini, M. Dimovska, G.W. Kaatz, V. Cecchetti, Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance, J Med Chem, 56 (2013) 4975-4989.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Madak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.R.</ce:given-name>
                                 <ce:surname>Cuthbertson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Miyata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Tamura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Petrunak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Stuckey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.D.</ce:given-name>
                                 <ce:surname>Showalter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Neamati</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis, and biological evaluation of 4-quinoline carboxylic acids as inhibitors of dihydroorotate dehydrogenase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5162</sb:first-page>
                              <sb:last-page>5186</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0195">J.T. Madak, C.R. Cuthbertson, Y. Miyata, S. Tamura, E.M. Petrunak, J.A. Stuckey, Y. Han, M. He, D. Sun, H.D. Showalter, N. Neamati, Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase, J Med Chem, 61 (2018) 5162-5186.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.M.</ce:given-name>
                                 <ce:surname>Fox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Sugimoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Iio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Yoshida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Hao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Labelle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Rubenstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>McMinn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Jackson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Shan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Miao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Matsui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ogawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Suzuki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kobayashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ozeki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Okuma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ishii</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Tomimoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Furakawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Tanaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Matsushita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Takahashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Inaba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sagawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Kayser</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of 6-phenylpyrimido[4,5-b][1,4]oxazines as potent and selective acyl CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitors with inÂ vivo efficacy in rodents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3464</sb:first-page>
                              <sb:last-page>3483</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0200">B.M. Fox, K. Sugimoto, K. Iio, A. Yoshida, J.K. Zhang, K. Li, X. Hao, M. Labelle, M.L. Smith, S.M. Rubenstein, G. Ye, D. McMinn, S. Jackson, R. Choi, B. Shan, J. Ma, S. Miao, T. Matsui, N. Ogawa, M. Suzuki, A. Kobayashi, H. Ozeki, C. Okuma, Y. Ishii, D. Tomimoto, N. Furakawa, M. Tanaka, M. Matsushita, M. Takahashi, T. Inaba, S. Sagawa, F. Kayser, Discovery of 6-phenylpyrimido[4,5-b][1,4]oxazines as potent and selective acyl CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitors with inÂ vivo efficacy in rodents, J Med Chem, 57 (2014) 3464-3483.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Mohammad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Mayhoub</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ghafoor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Soofi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Alajlouni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Cushman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.N.</ce:given-name>
                                 <ce:surname>Seleem</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery and characterization of potent thiazoles versus methicillin- and vancomycin-resistant Staphylococcus aureus</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1609</sb:first-page>
                              <sb:last-page>1615</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0205">H. Mohammad, A.S. Mayhoub, A. Ghafoor, M. Soofi, R.A. Alajlouni, M. Cushman, M.N. Seleem, Discovery and characterization of potent thiazoles versus methicillin- and vancomycin-resistant Staphylococcus aureus, J Med Chem, 57 (2014) 1609-1615.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Kodra Jt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Andersen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Behrens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Brand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.T.</ce:given-name>
                                 <ce:surname>Christensen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Guldbrandt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.B.</ce:given-name>
                                 <ce:surname>Jeppesen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.B.</ce:given-name>
                                 <ce:surname>Knudsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Madsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Nishimura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.G.</ce:given-name>
                                 <ce:surname>Sidelmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Pedersen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.C.</ce:given-name>
                                 <ce:surname>Lynn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lau</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5387</sb:first-page>
                              <sb:last-page>5396</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0210">J.A. Kodra JT, Andersen B, Behrens C, Brand CL, Christensen IT, Guldbrandt M, Jeppesen CB, Knudsen LB, Madsen P, Nishimura E, Sams C, Sidelmann UG, Pedersen RA, Lynn FC, Lau J, Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor, J Med Chem, 51 (2008) 5387-5396.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.C.</ce:given-name>
                                 <ce:surname>Lau J</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.G.</ce:given-name>
                                 <ce:surname>Sidelmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.B.</ce:given-name>
                                 <ce:surname>Knudsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Lundt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ynddal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Brand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Pridal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kiel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Plewe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Madsen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>New beta-alanine derivatives are orally available glucagon receptor antagonists</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>50</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>113</sb:first-page>
                              <sb:last-page>128</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0215">B.C. Lau J, Sidelmann UG, Knudsen LB, Lundt B, Sams C, Ynddal L, Brand CL, Pridal L, Ling A, Kiel D, Plewe M, Shi S, Madsen P, New beta-alanine derivatives are orally available glucagon receptor antagonists, J Med Chem, 50 (2007) 113-128.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yakoub</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Jung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sattler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Damerow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Weber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kretzschmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Cankaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Piel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Rosch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Haugaard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Frolund</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Schirmeister</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Luddens</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-function evaluation of imidazopyridine derivatives selective for delta-subunit-containing gamma-aminobutyric acid type A (GABAA) receptors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1951</sb:first-page>
                              <sb:last-page>1968</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0220">K. Yakoub, S. Jung, C. Sattler, H. Damerow, J. Weber, A. Kretzschmann, A.S. Cankaya, M. Piel, F. Rosch, A.S. Haugaard, B. Frolund, T. Schirmeister, H. Luddens, Structure-Function Evaluation of Imidazopyridine Derivatives Selective for delta-Subunit-Containing gamma-Aminobutyric Acid Type A (GABAA) Receptors, J Med Chem, 61 (2018) 1951-1968.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.L.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Su</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ji</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Xiong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Geng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and optimization of a series of 1-sulfonylpyrazolo[4,3-b]pyridines as selective c-Met inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2513</sb:first-page>
                              <sb:last-page>2529</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0225">Y. Ma, G. Sun, D. Chen, X. Peng, Y.L. Chen, Y. Su, Y. Ji, J. Liang, X. Wang, L. Chen, J. Ding, B. Xiong, J. Ai, M. Geng, J. Shen, Design and optimization of a series of 1-sulfonylpyrazolo[4,3-b]pyridines as selective c-Met inhibitors, J Med Chem, 58 (2015) 2513-2529.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.V.</ce:given-name>
                                 <ce:surname>Denora N</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Pisu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Dore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Murru</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Latrofa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Trapani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Sanna</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>2-Phenyl-imidazo[1,2-a]pyridine compounds containing hydrophilic groups as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity and electrophysiological studies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6876</sb:first-page>
                              <sb:last-page>6888</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0230">L.V. Denora N, Pisu MG, Dore R, Murru L, Latrofa A, Trapani G, Sanna E, 2-Phenyl-imidazo[1,2-a]pyridine compounds containing hydrophilic groups as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity and electrophysiological studies, J Med Chem, 51 (2008) 6876-6888.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Cai L</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Zoghbi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cuevas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Baetas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.U.</ce:given-name>
                                 <ce:surname>Shetty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.M.</ce:given-name>
                                 <ce:surname>Seneca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Gladding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Temme</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Herman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.B.</ce:given-name>
                                 <ce:surname>Innis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.W.</ce:given-name>
                                 <ce:surname>Pike</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and evaluation of N-methyl and S-methyl 11C-labeled 6-methylthio-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridines as radioligands for imaging beta-amyloid plaques in Alzheimer's disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>148</sb:first-page>
                              <sb:last-page>158</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0235">L.J. Cai L, Zoghbi SS, Cuevas J, Baetas C, Hong J, Shetty HU,; Seneca NM, Brown AK, Gladding R, Temme SS, Herman MM, Innis RB, Pike VW, Synthesis and evaluation of N-methyl and S-methyl 11C-labeled 6-methylthio-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridines as radioligands for imaging beta-amyloid plaques in Alzheimer's disease, J Med Chem, 51 (2008) 148-158.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.V.</ce:given-name>
                                 <ce:surname>Trapani G</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Denora</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Trapani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Lopedota</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Latrofa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Franco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Serra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Pisu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Floris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Sanna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Biggio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Liso</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-activity relationships and effects on neuroactive steroid synthesis in a series of 2-phenylimidazo[1,2-a]pyridineacetamide peripheral benzodiazepine receptors ligands</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>48</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>292</sb:first-page>
                              <sb:last-page>305</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0240">L.V. Trapani G, Denora N, Trapani A, Lopedota A, Latrofa A, Franco M, Serra M, Pisu MG, Floris I, Sanna E, Biggio G, Liso G, Structure-activity relationships and effects on neuroactive steroid synthesis in a series of 2-phenylimidazo[1,2-a]pyridineacetamide peripheral benzodiazepine receptors ligands, J Med Chem, 48 (2005) 292-305.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Schust</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Sperl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hollis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.U.</ce:given-name>
                                 <ce:surname>Mayer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Berg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stattic: a small-molecule inhibitor of STAT3 activation and dimerization</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1235</sb:first-page>
                              <sb:last-page>1242</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0245">J. Schust, B. Sperl, A. Hollis, T.U. Mayer, T. Berg, Stattic: a small-molecule inhibitor of STAT3 activation and dimerization, Chem Biol, 13 (2006) 1235-1242.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Terry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>498</sb:first-page>
                              <sb:last-page>507</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0250">H. Chen, Z. Yang, C. Ding, L. Chu, Y. Zhang, K. Terry, H. Liu, Q. Shen, J. Zhou, Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy, Eur J Med Chem, 62 (2013) 498-507.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Xiong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wild</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Cai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Flores</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>82</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>195</sb:first-page>
                              <sb:last-page>203</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0255">H. Chen, Z. Yang, C. Ding, A. Xiong, C. Wild, L. Wang, N. Ye, G. Cai, R.M. Flores, Y. Ding, Q. Shen, J. Zhou, Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3), Eur J Med Chem, 82 (2014) 195-203.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>125</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>538</sb:first-page>
                              <sb:last-page>550</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0260">W. Zhang, T. Ma, S. Li, Y. Yang, J. Guo, W. Yu, L. Kong, Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules, Eur J Med Chem, 125 (2017) 538-550.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ji</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Mao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Qiao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel 2-Carbonylbenzo[b]thiophene 1,1-dioxide derivatives as potent inhibitors of STAT3 signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1010</sb:first-page>
                              <sb:last-page>1014</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0265">P. Ji, X. Xu, S. Ma, J. Fan, Q. Zhou, X. Mao, C. Qiao, Novel 2-Carbonylbenzo[b]thiophene 1,1-Dioxide Derivatives as Potent Inhibitors of STAT3 Signaling Pathway, ACS Med Chem Lett, 6 (2015) 1010-1014.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref51">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Zhong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Leung</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small molecule Pin1 inhibitor blocking NF-kappaB signaling in prostate cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Asian J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>275</sb:first-page>
                              <sb:last-page>279</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0270">K.J. Wu, H.J. Zhong, G. Yang, C. Wu, J.M. Huang, G. Li, D.L. Ma, C.H. Leung, Small Molecule Pin1 Inhibitor Blocking NF-kappaB Signaling in Prostate Cancer Cells, Chem Asian J, 13 (2018) 275-279.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib52">
                     <ce:label>[52]</ce:label>
                     <sb:reference id="sref52">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.C.</ce:given-name>
                                 <ce:surname>Hsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Lien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.C.</ce:given-name>
                                 <ce:surname>Kuo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.F.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Yuwen02f1 suppresses LPS-induced endotoxemia and adjuvant-induced arthritis primarily through blockade of ROS formation, NFkB and MAPK activation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>85</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>385</sb:first-page>
                              <sb:last-page>395</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0275">C.C. Hsu, J.C. Lien, C.W. Chang, C.H. Chang, S.C. Kuo, T.F. Huang, Yuwen02f1 suppresses LPS-induced endotoxemia and adjuvant-induced arthritis primarily through blockade of ROS formation, NFkB and MAPK activation, Biochem Pharmacol, 85 (2013) 385-395.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib53">
                     <ce:label>[53]</ce:label>
                     <sb:reference id="sref53">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Zhong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.D.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Leung</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>143</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1021</sb:first-page>
                              <sb:last-page>1027</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0280">K.J. Wu, H.J. Zhong, G. Li, C. Liu, H.D. Wang, D.L. Ma, C.H. Leung, Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing, Eur J Med Chem, 143 (2018) 1021-1027.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib54">
                     <ce:label>[54]</ce:label>
                     <sb:reference id="sref54">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Lyu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ji</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>An</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Nie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Xing</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Autophagy</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>999</sb:first-page>
                              <sb:last-page>1014</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0285">Q. Huang, L. Zhan, H. Cao, J. Li, Y. Lyu, X. Guo, J. Zhang, L. Ji, T. Ren, J. An, B. Liu, Y. Nie, J. Xing, Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways, Autophagy, 12 (2016) 999-1014.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib55">
                     <ce:label>[55]</ce:label>
                     <sb:reference id="sref55">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.P.</ce:given-name>
                                 <ce:surname>Nishanth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.G.</ce:given-name>
                                 <ce:surname>Jyotsna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Schlager</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Hussain</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Reddanna</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inflammatory responses of RAW 264.7 macrophages upon exposure to nanoparticles: role of ROS-NFkappaB signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nanotoxicology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>502</sb:first-page>
                              <sb:last-page>516</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0290">R.P. Nishanth, R.G. Jyotsna, J.J. Schlager, S.M. Hussain, P. Reddanna, Inflammatory responses of RAW 264.7 macrophages upon exposure to nanoparticles: role of ROS-NFkappaB signaling pathway, Nanotoxicology, 5 (2011) 502-516.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib56">
                     <ce:label>[56]</ce:label>
                     <sb:reference id="sref56">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Rhodium catalyzed direct C3-ethoxycarbonylmethylation of imidazo[1,2-a]pyridines with ethyl diazoacetate</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Tetrahedron</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>76</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0295">Q. Huang, H. Dong, B. Li, W. Hu, Y. Wang, Rhodium catalyzed direct C3-ethoxycarbonylmethylation of imidazo[1,2-a]pyridines with ethyl diazoacetate, Tetrahedron, 76 (2020).</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>